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Abstract
India is rapidly becoming established as a major player in the stem cell sector.
However, concerns have been raised about the use of unproven stem cell
therapies and the exploitation of parents for cord blood banking. This study
aims to explore the nature of stem cell activities, how key stakeholders
generate expectations around them and frame the ethical issues they raise,
and why the biomedical governance system is unable to regulate these
emerging practices. The study involved a survey, documentary analysis and
qualitative interviews with key scientists, clinicians, representatives of firms
and policymakers.
The thesis observes that, unlike international commentaries which largely
focus on embryonic stem cell treatments, in India it is adult and cord blood
stem cells which are dominant in research and clinical settings. Expectations
are configured on the basis that stem cells have the potential to: solve the
problem of organ shortage; help patients with ailments; provide affordable
health care; and establish India as a global player. The creation of
expectations is ethically problematic given the potential health risks and
economic exploitation of both native and international patients. However, the
ethically contested activities are justified by clinicians on the basis that the
Helsinki Declaration allows to use an experimental therapy; there are many
'desperate patients' demanding these treatments; and adult stem cells are
safe.
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To date, the government of India appears to be unable to prevent these
activities. Contrary to suggestions in previous literature and by some
informants that new legislation is needed to address the problem, this thesis
finds that state-led mechanisms for biomedical governance lack the ability to
implement existing oversight measures. This implementation gap is partly
because other forms of governance are not strong enough and partly because
there are high expectations at state level aimed at establishing India as a
global player in the stem cell sector.
2
Acknowledgements
This project was funded by the Wellcome Trust through the award of an
International Biomedical Ethics Studentship (WT087867MA). I am highly
thankful to the Wellcome Trust for the financial support; otherwise this
research would not have been possible.
I would like to extend my sincere gratitude to my supervisors Paul Martin,
Sujatha Raman and Pranav N. Desai (India). Throughout my PhD, they
provided encouragement, sound advice and lots of brilliant ideas.
I extended my deepest thanks to all of those informants who volunteered to
participate in this project.
Thanks to Brigitte Nerlich and Kate Weiner for their valuable suggestions and
comments at the initial stage of my PhD. Thanks also to former ISSstaffs, Gill
Farmer, Alice Phillips and Patricia Hulme for their great support and help in
the beginning year of my research journey. I would like to acknowledge the
support of Alison Haigh and Jude Jones for the day to day administrative
support throughout my PhD and making arrangement for my field work.
I would like to express my gratitude to my family and friends for their endless
love and encouragement throughout this project.
At the end I want to add a special name to this list, my wife, Ekta (Gulabo) for
her unconditional love, encouragement, emotional support throughout in
writing phase.
Note:
Sections of this thesis were presented in conferences such as 4S and EASST.In
addition, a slightly different version of Chapter 4 has been published as:
Tiwari, S. S. & Desai, P. N. (2011) Stem Cell Innovation System in India:
Emerging Scenario and Future Challenges. World Journal of Science,
Technology and Sustainable Development, 8(1), 1-23.
3
Contents
Abstract 1
Acknowledgements 3
Contents 4
Chapter 1: Introduction 9
1.1Introduction 9
1.2 Rationale for the research 15
1.3 Previous studies 16
1.4 Framework for the research 19
1.5 Research aims and questions 21
1.6 Structure of the thesis 22
Chapter 2: Literature Review 24
2.1Introduction 24
2.2 Stem cells and underlying issues 25
2.2.1 Scientific issues 25
2.2.2 Ethical issues 26
2.2.3 Legal issues 29
2.2.4 Social and economic issues 30
2.3 Sociology of biomedicine 32
2.3.1 Biomedicine as a scientific enterprise 34
2.3.2 Biomedicine as a symbolic-cultural expression 37
2.3.3 Biomedicine as an expression of social power 38
2.4 Sociology of biomedicine in India 41
2.4.1 Present status of biomedicine in India .48
2.4.2 Social science studies on stem cells in India 51
2.5 Sociology of expectations 57
4
2.6 Sociology of bioethics 66
2.6.1 Principles of bioethics 68
2.6.2 Social studies of bioethics 69
2.6.3 Autonomy and informed consent.. 71
2.6.4 International guidelines and terminally-ill patients 74
2.7 Ethical boundary-work 78
2.8 Governance 80
2.8.1 Defining governance 81
2.8.2 Analysing governance 82
2.8.3 Analysing scientific governance 88
2.8.4 Governance and stem cells 90
2.8.5 Governance and policy implementation 93
2.9 Summary and discussion 94
Chapter 3: Methods 96
3.1Introduction 96
3.2 Philosophical approach 96
3.3 Research design 98
3.4 Data collection and analysis 100
3.4.1 Survey 101
3.4.2 Documentary analysis 101
3.4.3 Qualitative interviews 105
3.4.5 Interview guide 114
3.4.6 Analysing interview data 115
3.5 Ethics 115
3.6 Conclusions 117
5
Chapter 4: Stem Cell Science in India: An Overview 118
4.1Introduction 118
4.2 Stem cell basic research 120
4.3 Stem cell clinical applications 132
4.4 Umbilical cord blood banking 138
4.5 Knowledge production 142
4.6linkages 143
4.7 Summary and discussion 147
Chapter 5: Expectations of Stem Cells in India 151
5.1lntroduction 151
5.2 Positive expectations of stem cells 154
5.2.1 Expectations of stem cell basic research 155
5.2.2 Expectations of stem cell clinical applications 165
5.2.3 Expectations of cord blood banking 174
5.2.4 Expecting India as a global player 179
5.3 Negative expectations of stem cells 182
5.4 Creating expectations through media and internet.. 184
5.5 Summary and discussion 189
Chapter 6: The Ethics of Stem Cell Research and Therapy in India 193
6.1lntroduction 193
6.2 The use of human embryo 195
6.2.1 Stem cell and IVF clinics 202
6.3 Experimental vs. standard therapy 205
6.4 Therapy or 'business' 219
6.5 The ethics of private cord blood banking 220
6
6.6 Stem cell translation and informed consent 228
6.7 Summary and discussion 234
Chapter 7: Governance of Stem Cell Research and Therapy in India 238
7.1Introduction 238
7.2 Biomedical research governance: Governance by hierarchy 240
7.2.1 Department of Health Research 241
7.2.2 Indian Council of Medical Research 241
7.2.3 Department of Biotechnology 245
7.2.4 Department of Science and Technology 246
7.2.5 Council of Scientific and Industrial Research 247
7.2.6 Central Drugs Standard Control Organization (Drugs Controller
General of India) 247
7.2.7 Summarising biomedical research governance 248
7.3 Governance of medical practices 250
7.3.1 Statutory governance: Governance by hierarchy 251
7.3.2 State-sanctioned self-regulation and professional governance:
Governance by networks 258
7.3.3 Civil society: Governance by community 261
7.4 Stem cell governance 265
7.4.1 Multiple agencies 265
7.4.2 Guidelines and a law 272
7.4.3 Public consultation 281
7.5 Summary and discussion 289
Chapter 8: Conclusions 293
8.1Introduction 293
8.2 Stem cells in India 294
7
8.3 Expectations 298
8.4 Ethics 303
8.5 Governance 309
8.6 Policy implications 316
8.7 Strengths and weaknesses of the study 321
8.8 Future research 324
References 325
Websites 385
Appendix I: Contact letter 388
Appendix II: Information sheet 390
Appendix III: Interview guide 392
8
Chapter 1: Introduction
1.1lntroduction
Stem cells are buildings blocks of life. These cells have the capacity to develop
into any kind of cells, tissues and organs, which make them an important tool
in health care and biotechnology. There is extensive investment in the field of
stem cell research in several countries in anticipation of cures for various
presently incurable diseases and contributions to understanding basic
biology. In addition, most notably, there is excitement that stem cells will be
able to boost the biotechnology and pharmaceutical industries in the future.
It is seen as a novel form of biomedicine which brings both health as well as
economic benefits.
Countries across the world have evolved their own programmes and policies
to take early advantage from stem cells (Gottweis et al., 2009; UKSCI, 2005).
The global stem cell market size for stem cell therapy is estimated to reach US
$96 billion by 2015, and as a result stem cell research is becoming increasingly
competitive (Tiwari and Desai, 2011). Research in the US, the UK, the
European Union, Asia and Asia-Pacific regions is highly supported by both
public and private players (Gottweis et al., 2009; Perrin, 2005; Sipp, 2009b,
2009c; UKSCI,2005).
In this global context, India has emerged as one of the key players in the stem
cell arena, having significant activities in stem cell basic research and therapy
(Bharadwaj and Glasner, 2009; Greenwood et al., 2006; Lander et al., 2008;
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Sharma, 2006, 2009). However, there is a widespread perception that clinical
research and therapeutic applications of stem cells in India are not governed
by international rules and regulations, or more specifically that they are not in
accordance with 'standard' Western ethical norms (Pandya, 2008; Sipp,
2009a). The various clinics and companies in India have been accused of
making false claims relating to a wide range of stem cell treatments and even,
in some cases, fake declaration of approval from governing bodies (Pandya,
2008; Sipp, 2009a). At the same time, there is considerable ambiguity and
uncertainty on the issues of regulating stem cell science and ethical standards
at the international level, a situation which has been characterised as a
'bioethical vacuum' (Salter, 2007; Sleeboom-Faulkner and Patra, 2008). This
'bioethical vacuum' at the international level is mainly associated with the use
of human embryos in research. It was visualised that some countries have
strict regulations while some have moderate ones, and in others there is no
regulation at all. For instance, the policy of the UK appears to be more liberal
than other European countries such as Germany and Italy (Gottweis et al.,
2009). The governance mechanisms at the international level in dealing with
stem cell research are therefore categorised as a 'patchwork of patchworks'
(Caulfield et al., 2009).
It has been argued that India has benefitted from this vacuum for an early
advantage in the area of stem cells in the guise of experimental therapy
(Sleeboom-Faulkner and Patra, 2008). Various clinics in India have been able
to persuade foreign as well as domestic patients to cross their respective geo-
10
political, commercial, ethical and moral borders for their 'novel' stem ce"-
based therapies (Bharadwaj and Glasner, 2009), a phenomenon alternately
described in the popular media as "stem cell tourism" (MacReady, 2009) and
in the academic literature, as "bio-crossings" (Bharadwaj and Glasner, 2009).
In any case, such "bio-crossings" are creating growing international concerns
about unproven therapies which have placed patients at health and financial
risk (MacReady, 2009; Nelson, 2008a).
The international commentary has expressed concerns mainly on the use of
embryonic stem cells by a New Delhi-based clinician, Dr Geeta Shroff (Basu,
2005; Bharadwaj and Glasner, 2009; Cohen and Cohen, 2010; Glasner, 2009;
Khu"ar, 2009; Padma, 2006; Ramesh, 2005; Salter, 2008; Srinivasan, 2006).
However, the use of adult stem cell in clinics also raises various concerns; for
example, Life Line Hospital in Chennai has claimed that an injection of stem
cells can help "improve nerve function" following spinal cord injury, yet there
is no clinical evidence that this is yet possible. L.V. Prasad Eye Institute,
Hyderabad has been working on corneal regeneration using stem cells for the
last seven years, but was recently criticised for the transplantation procedure
used by an international team of ophthalmologists (Schwab et al., 2006).
Furthermore, there is also a growing market for the banking of cord blood in
India, which is largely unregulated (Pandeya, 2009). This also raises many of
the same ethical issues, with concern about the safety and claims made for
the benefits of cord blood banking and regenerative therapies that might
arise from them, none of which are proven at present (Eaton, 2006; Kaimal et
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al., 2009). The risk of infection from cord blood transplantation is also a major
concern (Agarwal, 2006). These issues have been the subject of considerable
public debate.
In addition to concerns about the unethical use of unproven and potentially
harmful stem cell therapies, there are also problems with obtaining informed
consent and the existence of financial incentives to donate eggs and embryos
in stem cell research. There is growing demand for oocytes worldwide where
therapeutic cloning is permitted. The recent guidelines related to stem cell
research permits therapeutic cloning in India and there is a strong possibility
of a rapidly developing illegal oocytes market in the absence of legislation
(Waldby, 2006). This has been highlighted in IVF clinics which are an
important source of embryos for research. The procedure of obtaining
informed consent in India is poorly enforced (Bhatt, 2004; Glasner, 2007;
Mudur, 2001; Murthy and Subramanian, 2007; Srinivasan, 2005) and India is
viewed as an "embryo surplus nation" which supplies human gametes/hESCs
material to Western countries (Bharadwaj, 2005; Bharadwaj and Glasner,
2009; Inhorn and Birenbaum-Carmeli, 2008). These are highly lucrative for
some medical professionals and there has been resistance to regulation and
monitoring (Salter et al., 2007). In some cases couples are offered free IVF in
return for donating embryos for research (Salter and Waldby, 2007). As a
result private IVF clinics have flourished without any regulation (Widge,
2002).
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In recent years India has become a global centre for clinical trials (Maiti and
M. Raghvendra, 2007; Sirinvasan, 2009; Sunder Rajan, 2006), but this has not
been matched by the development of ethical oversight, as there is still a lack
of binding guidelines for biomedical research on human subjects. There is no
law to prevent unethical trials, and the dismal state of institutional ethics
committees is also a matter of great concern (Padma, 2005; Sunder Rajan,
2006; Tharyan and Ghersi, 2008; The Lancet, 2007).
In India, clinical trials are conducted through a regulated approach following
guidelines laid down by the International Conference on Harmonization (ICH)
and the World Health Organization (WHO) (ICMR, 2006; Maiti and M.
Raghvendra, 2007). All clinical trials are subject to the approval of an ethics
committee at an institutional level, but according to a survey conducted by
the Indian Council of Medical Research (ICMR) these committees are not
functioning well as they lack standard operation procedures and their
composition is not in line with Good Clinical Practice (Bhatt, 2004). However,
in principle, India is bound to ICH through amendments to Schedule Y of the
Drugs & Cosmetics Act 2005. To strengthen the governance of clinical trials,
India launched a Clinical Trials Registry in July 2007. However, it appears that
it is also unable to streamline the procedure of clinical trials given the growing
number of deaths of research participants during clinical trials (Cressey, 2012;
Sinha, 2012).
The governance problems that plague IVF clinics and clinical trials have a
direct link with stem cell governance, as IVF clinics are potential suppliers of
13
embryos for stem cell research and the legitimate application of stem cells in
clinics requires clinical trials (Bharadwaj and Glasner, 2009; Lander et al.,
2008; Slater et al., 2007).
Public medical research in India is funded by a number of agencies including
the Department of Biotechnology (DBT)and the ICMR.In the caseof stem cell
research both the DBTand the ICMR,along with the Drug Controller General
of India (DCGI),act as governing bodies. Both the DBT and the ICMR have
been involved in the preparation of guidelines for the regulation of stem cell
research, which play an important role in setting norms for research and
governing the ethical conduct of investigators, but they have no statutory
power to punish anyone for unethical conduct. A major issue highlighted in
academic work on stem cells in India is that no single apex body exists for the
governance of stem cell research and there have been institutional and
bureaucratic disputes over jurisdiction. It is argued that the presence of so
many agencies with an interest in this area has created confusion and
demonstrates that India has no coherent national policy, leading to a
perception that the development of stem cells in India is progressing in a
regulatory vacuum (Bharadwaj and Glasner,2009; Salter et al., 2007).
As far as the use of stem cell in clinics is concerned, it was observed that the
governance mechanisms in this area have so far proved ineffective in
preventing the rapid growth of clinical research programmes and clinics that
make unproven claims of successusing stem cells, but lack authorisation and
supervision (Jayaraman,2005). This has led to calls for more formal oversight
14
and statutory regulation for unproven stem cell-based therapies (The Times
of India, 2008).
1.2 Rationale for the research
To summarise the problems described above, the clinical development and
use of stem cell therapies in India including private cord blood banking appear
to be currently proceeding in a largely unregulated fashion. Several examples
have been cited in academic and media commentary of clinical activities
proceeding without proper review and oversight, and clinics and hospitals
offering unproven stem cell-based therapies to patients. In addition, despite
slim chances of the use of cord blood for the self, various firms are attracting
expectant parents to preserve their child's cord blood. These events are likely
to exploit patients and expectant parents, and place them at health and
financial risk.
How though do key stakeholders involved in stem cell research in India
perceive these issues? How do they respond to the various criticisms and
justify their work? Alternatively, are there significant differences within the
stem cell community in India in terms of how stem cell research and the
ethical issues it raises are framed? There is little published research on these
questions. Secondly, how has the Indian government responded to the
challenges around stem cells and the charge of experimental work proceeding
unregulated? The problem of ensuring effective regulation is compromised by
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statements from both the Health Secretary and the Director of the ICMR, who
emphasise that there should be no bureaucratic hurdles in the way of
scientific knowledge and it is the medical profession, rather than government,
who should be left to ensure ethical conduct in relation to stem cell research
(Pandya, 2008). However, signals are mixed in that the government has also
recently revised their guidelines in a way that suggests the use of stem cells
for therapy is to be discouraged. There is little work on how the complex
Indian bureaucracy of biomedical governance works in practice and why this
existing system has been unable to check ethically problematic stem cell
practices. To date no study has addressed these vital issues comprehensively,
which have global implications.
1.3 Previous studies
At a global level in the area of stem cells, developments in India sparked
attention in late 2001 when two research laboratories were selected for
National Institute of Health (US) funding to do further research work on their
existing human embryonic stem cell lines. Most of the social science studies in
this initial period focused on the regulatory framework in India dealing with
human embryonic stem cell research which existed at the time (Knowles,
2004; McLaren, 2001; Walters, 2004). Later studies have analysed India's
strengths and weaknesses in the stem cell area and its potential contribution
to a promissory global stem cell bio-economy, along with the problem of
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inadequate governance mechanisms in regulating stem cell clinicians
(Jayaraman, 2005; lander et al., 2009; Padrna, 2006; Salter et al., 2007; Salter,
2008; Sharma, 2006, 2009). Some studies have analysed the complexities
surrounding the proliferation of embryonic stem cell research and therapy,
such as various social and cultural factors and linkages between IVF clinics and
stem cell research (Bharadwaj and Glasner, 2009; Glasner, 2009; Gupta,
2011). The work of Aditya Bharadwaj and Peter Glasner could be cited as a
comprehensive study especially related to embryonic stem cells in India.
Recently, they published a book entitled, Local Cells, Global Science; The rise
oj embryonic stem cell research in India, which provides a more complex
analysis of the nature of the stem cell governance framework in India against
the background of India's distinctive configuration of politics, economy and
culture (Bharadawj and Glasner, 2009). In addition, a few studies related to
growing 'stem cell tourism' in different parts of the world have raised
concerns about unregulated stem cell clinical activities in India (Cohen and
Cohen, 2010).
Most of these studies have focused on the development of embryonic stem
cell therapy in India and associated ethical and governance concerns related
to its proliferation. In contrast, only a few studies have studied the
proliferation of therapies based on adult stem cells (Patra and Sleeboom-
Faulkner, 2010; Sleeboom-Faulkner and Patra, 2011). The proliferation of
private cord blood banking in India has also not been paid much attention in
previous studies.
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These studies have observed that India has no laws to oversee various stem
cell activities and that is why many clinicians are free to do whatever they
want; they blame the incapacity of the DBT-ICMR guidelines for unregulated
stem cell activities since these have no statutory power (Bharadwaj and
Glasner, 2009; Cohen and Cohen, 2010; Glasner, 2009; Patra and Sleeboom-
Faulkner, 2009, 2010; Sleeboom-Faulkner and Patra, 2011; Salter, 2008).
While acknowledging their valuable contribution in understanding the
complexity of the stem cell sector in India, my study argues, however, that
the observations of these studies are limited on certain accounts. For
instance, they have not investigated the different modes of governance
dealing with medical practices in India of which stem cell clinical activities are
one part. In addition, although highlighting the high expectations of stem cells
in India (Patra and Sleeboom-Faulkner, 2010), existing studies have not
analysed the basis of these expectations from the perspectives of key players
and their implications for ethics and governance.
This study will provide valuable evidence of the ethical issues raised by the
clinical development and use of stem cells in India. In order to do so, it will
map the main stem cell activities in India, and investigate how key players
who are associated with the development of stem cells frame both the need
for stem cell research (and, where relevant, therapy) and the ethical concerns
they have raised. In addition, it will help in understanding the main problems
with the existing stem cell governance framework. This will be of direct
relevance to scientists, clinicians, companies, regulators and policymakers in
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both India and other countries, given the new cross-national collaborative
partnerships emerging in this area.
1.4 Framework for the research
The proliferation of biomedicine has attracted great attention from various
disciplines of social sciences. It is very difficult to conceptualise the
development of biomedicine in a single narrative. For some, it is a great
invention of modern society which not only helps in alleviating various
suffering of human beings but also is an area which has enormous potential
to make a significant contribution in knowledge-based economy (Rose, 2006).
However, at the same time, it is also visualised in terms of a failure to address
infectious diseases such as AIDS, tuberculosis and tropical diseases with which
the majority of the world population is afflicted (Rose, 2006). The argument
here is that biomedicine has largely neglected the 'poor man's disease' (Rose,
2007). Others believe that the proliferation of biomedicine has resulted in the
commodification of human organs and tissues (Waldby and Mitchell, 2006).
Authors who have studied biomedicine using the concept of 'biopower'
suggest that biomedical development is one of the ways to exercise social
power on individuals and populations (Raman and Tutton, 2010; Rabinow and
Rose, 2006; Rose, 2001). In doing so it has extended its jurisdiction from mere
disease control to solving common life problems such as birth, menopause,
baldness etc. These kinds of developments resulted in the corporatisation of
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biomedicine, which is reflected by the heavy investment from nation-states
and the private sector in biomedical ventures (Clarket al., 2003; Rose,2006).
Over the years we have witnessed several innovations in biomedicine in the
form of genomics, pharmacogenetics, regenerative medicine,
xenotransplantation, gene therapy and the recent one in the form of stem
cells. Sociologists argue that the rhetoric of constructing expectations has
played an important role in the development of these novel forms of
biomedicine (Brown and Michael, 2003; Hedgecoe and Martin, 2003; Martin
et al., 2008a; Wainwright et al., 2008). Various studies in sociology of
expectations observe that expectations discourse helps to attract various
necessary resources and allies for any science and technological innovation.
This analytical approach is useful for analysing the construction of
expectations around a science and technological development in question
and for examining the specific mechanisms through which expectations are
configured.
Similarly, the concept of ethical boundary-work (Frith et al., 2011; Hobson-
West, 2012; Wainwright et al., 2006a) provides an opportunity to analyse in
depth how key players associated with particular ethically-contested areas of
science and technology, have constructed boundaries between
ethical/unethical or legitimate/illegitimate. In the case of growing stem cell
activities in India, this concept is useful to understand how key players
legitimise or, alternatively, critique ethically-contested activities.
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The governance of stem cell activities in India has been previously examined
by Bharadwaj and Glasner (2009), Patra and Sleeboom-Faulkner (2009, 2010),
Salter et al. (2007), Salter (2008) and Sleeboom-Faulkner and Patra (2011).
They have mainly focused on the mandates of the DBT-ICMR guidelines,
which are in place to govern stem cell research and therapy. However, they
have not looked at the overall biomedical governance dealing with research
and medical practices in India and how it works in practice. Therefore, it is
meaningful to analyse the different modes of biomedical governance under
which stem cell flourishes in India, (or which might in theory be a possible
mechanism for governance) and why they are not capable of implementing
existing oversight mechanisms. In political science, Pierre and Peters (2000)
have provided a framework to understand different modes of governance (i.e.
governance as hierarchy, governance as networks, governance as markets
and governance as communities). The framework developed by these authors
is useful for analysing the whole range of institutions and relationships which
could potentially be involved in the process of governing.
Against this backdrop of research framework, this study formulates the
following research aims and questions.
1.5 Research aims and questions
The overall aim of this study is to analyse the nature of stem cell activities in
India, how key players from science, clinical practice, private firms and
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government justify or challenge the need for specific activities and frame the
ethical issues they raise, and how arrangements to govern stem cell activities
work in practice. This study has outlined four sub-aims to fulfil the overall
aim.
1. To map the current development of stem cells in India in terms of basic
research, clinical activities and cord blood banking.
2. To analyse the configuration of expectations around stem cells by different
key players.
3. To examine how key players construct boundaries between ethically
legitimate/illegitimate activities.
4. To investigate the potential for different modes of governance around
stem cell research and its clinical practice, and their capacity in
implementing existing oversight mechanisms.
1.6 Structure of the thesis
This chapter has highlighted that the unproven clinical applications of stem
cells have raised major ethical issues including governance concerns and the
research framework within which these issues will be investigated in this
study.
Chapter 2 therefore discusses the sociology of medicine in general and India,
in particular including the theoretical framework of sociology of expectations,
ethical boundary-work and the analytical approach developed by Pierre and
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Peters (2000) in political science to understand different modes of
governance and policy implementation. In addition, this chapter also
discusses scientific governance including stem cell governance at global level
and the theoretical understandings of sociology of bioethics which is useful to
investigate various ethical issues which are raised with the application of stem
cells in clinics, such as informed consent.
The thesis is informed by the approach of Science and Technology Studies.
Data collection and analysis are discussed in Chapter 3.
The overview of various stem cell activities is highlighted in Chapter 4. The
rationale behind different activities of stem cells is examined in Chapter S.
That chapter explores the expectations discourse of key players, i.e. scientists,
clinicians, the representative of firms, and policymakers.
Chapter 6 analyses the various ethical issues associated with the development
of stem cells in India and the construction of ethical boundaries by key
players. The different modes of governance in relation to stem cell research
and therapy are examined in Chapter 7. That Chapter also analyses the
problem with the existing governance mechanism.
Chapter 8 pulls together the empirical findings of the study and attempts to
link ethics, expectations and governance including the policy implications of
this study. In addition, that Chapter also highlights the strengths and
weaknesses of the study and the avenues for future research.
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Chapter 2: literature Review
2.1lntroduction
Stem cell research is one of the major aspects of biomedical research, which
is developing on a global basis with promises to treat various debilitating
diseases (e.g. Parkinson's disease, Alzheimer's disease, retinal degeneration,
muscular dystrophy, spinal cord injuries and diabetes mellitus, etc.) for which
no effective treatment has yet been developed.
Stem cell as a novel form of biomedicine is filled with high expectations
similar to other areas such as nanotechnology, personalised medicine,
biobanking etc. However, the use of stem cells in research and therapy has
been a matter of great dispute around the world and raises significant ethical,
legal, social and economic issues; and consequently poses challenges to
govern this emerging technology.
This study as highlighted in Chapter 1 aims to explore the nature of stem cell
activities, how key stakeholders generate expectations around them and
frame the ethical issues they raise, and why the biomedical governance
system is unable to regulate these emerging practices. In order to fulfil this
aim it is necessary to have an understanding of various issues associated with
the development of stem cell. Simultaneously the sociological understanding
of biomedicine, including India, is also warranted. This chapter therefore
analyses the ethical, legal, social and economic issues associated with the
proliferation of stem cells in section 2.2. The sociology of biomedicine in
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general, and in India in particular, is discussed in sections 2.3 and 2.4
respectively. Section 2.4 also analysed the social science literature on stem
cells in India. As highlighted in Chapter 1, this thesis also aims to analyse
expectations rhetoric, ethical framing and existing governance regimes with
respect to stem cells in India. This thesis therefore discusses the analytical
approach related to expectations in section 2.5. Section 2.6 explores the
understandings of sociology of bioethics. Similarly ethical boundary-work and
governance is discussed in sections 2.7 and 2.8 respectively.
2.2 Stem cells and underlying issues
2.2.1 Scientific issues
Stem cells offer hope to understand basic biology and, most notably, in
treating various debilitating diseases and abnormal conditions of the human
body. However, there are many scientific challenges before stem cells
materialise such hopes in practice (Corrigan et al., 2006; Hyun, 2006; Liddell
and Wallace, 2005; Wilson, 2009). James Wilson1 argues that:
"Despite advances, our understanding of the biology of hESCs
and iPS cells remains thin with regard to clinical safety and
utility. Controlled incorporation of transplanted stem cells into
host tissues and organs remains a major challenge. Questions
1James Wilson, who led the gene therapy clinical trial in 1999 during which the 18-year-old
Jesse Gelsinger died, now warns stem cell scientists not to repeat that mistake. See Hayden
(2009).
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about engraftment, rejection, and toxicity abound. Steps
involved in transformation of hESCs, iPS cells, or their
derivatives into tumor cells (and strategies to ablate any
tumors that might arise) need further investigation" (Wilson,
2009: 728).
The single stem cell lines can be used for many patients in stem cell therapy
and there is risk for transmission of infection if that cell lines is infected
(Braude et al., 2005). The premature use of stem cell therapies could
potentially put patients at risk, similar to premature application of gene
therapy (Martin, 2006; Wilson, 2009).
2.2.2 Ethical issues
The ethical debate in stem cell research is mainly associatedwith the sources
of stem cells (Longstaff et al., 2009). Among the primary sources of human
stem cells, Le. the human embryo, umbilical cord, placenta, amniotic fluid,
adult tissues and organs, the extraction of stem cells from the human embryo
involves the on-going controversy about the moral status of human embryos
and challengesto other fundamental values and beliefs (Hayeset al., 2006).
In the stem cell debate, one of the major controversies is whether the early
embryos should be treated as a person. In order to derive embryonic stem
cells, embryos must be destroyed around 5-7 days after fertilisation Le. at
blastocyst stage. This raise question of whether it is right to do so (Corrigan
26
et al., 2006). The controversy surrounds around the concept of respect for
persons and it is argued that, a foetus should also be treated as a person
similar to babies, children and adults (Corrigan 2006 et al., 2006). However,
others believe that embryos have either no particular moral status or they
have an intermediate status: "they are not the moral equivalents of infants,
nor are they simply clumps of cells like any other tissue sample that can be
used and discarded at will" (Fukuyama, 2005: 195).
The other matter of ethical concern is whether to use 'spare embryos' for
research. The proponents of using embryos in stem cells argue that 'spare
embryos' from IVF clinics could be used in research. They believe that there is
nothing wrong with using those embryos which are not going to be implanted
(Dutka, 2002). This line of argument is accepted in some countries where the
creation of an embryo for the sole purpose of research is prohibited. The
creation of an embryo is regarded as immoral as it treats the embryo as a
commodity in comparison to IVF embryos. The purpose in this case lies in
having a child but, due to difficulties in implantation, this aim cannot be
fulfilled naturally. These embryos are treated as 'spare' or 'surplus' embryos.
However, the use of IVF embryos is not acceptable to many people on various
religious and moral grounds. Opponents use the Kantian argument that
persons must be treated as ends rather than as means (Darr et al., 2004). This
suggests that a person's life cannot be sacrificed to accomplish some greater
good (Darr et al., 2004).
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Apart from philosophical debates about using embryos in research, there are
apprehensions that embryos will be also used as a commodity similar to
human organs and other tissues. In Science and Technology Studies (STS),
various studies have shown the increasing linkages between biomedical
advances and the market (Andrews and Nelkin, 2001; Rose, 2007; Sunder
Rajan, 2006; Waldby and Mitchell, 2006). Human organs and tissues have
been treated as commodities on a large scale in recent decades. However, the
commercialisation of body parts is not a new phenomenon. It had already
started during the Renaissance with the growing interest in anatomy
(Andrews and Nelkin, 2001). The experiments in organ transplantation
techniques in the 1960s accelerated the phenomenon further. Organ
transplantation was based on the concept of 'a gift'. However, in reality it
works under commercial interest; more specifically, organ transplantation at
large is a blend of altruism and commerce (Scheper-Hughes, 2000; Waldby,
2002). Andrews and Nelkin stated that "body parts are extracted like a
mineral, harvested like a crop, or mined like a resource. Tissue is procured - a
term more commonly used for land, goods and prostitutes" (Andrews and
Nelkin, 2001: 5). However, it could not resolve the ever-growing demand for
organs and tissues in the wake of a more vulnerable ageing population
worldwide, which forced the development of other alternatives. In recent
years, the development of stem cell technologies is seen as one of the novel
sources to fulfil the growing demand for organs and tissues (Waldby, 2002).
This new source is different from the living donors as it is procured from the
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early human life, i.e. the embryo, and results in a new form of 'tissue
economy' (Waldby and Mitchell, 2006). lilt shifts the source of tissue from a
whole organ to a tiny collection of cells, and from an unarguably human
person to an entity whose status regarding the human community is the
subject of bitter contestation" (Waldby, 2002: 313). The 'spare' embryos,
those produced during the IVFprocess, are viewed as a good source of stem
cell technologies. However, it is also facing the same problem as organ
donors, as availability of eggs is a matter of concern and in this direction a
country like the UK has started an incentive to donate eggs for stem cell
research. This step is viewed as a departure from the previous policy and a
practice of altruistic donation (Roberts and Throsby, 2008). Drawing from
Foucault's notion of 'bio-politics' it can be argued that this 'incentive' scheme
is a new way of managing life in the name of well-being of the population
(Rose, 2001), which further leads to commodification and commercialisation
of body parts.
2.2.3 Legal issues
Legal issues in stem cell are basically related to the destruction of human
embryos in conducting research and the useof human foetal tissues. It isvery
much linked to the ethical consensus in different countries and accordingly
the legislation is formulated. The lack of ethical consensus has resulted in
different regulations across the world, which has been described as a
'patchwork of patchworks' (Caulfield et al., 2009). In the US, most of the
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states permit embryonic stem (ES) cell research that requires destruction of
human embryos, but the federal law has prohibited such types of research.
Only by 2009 did the federal government allow research on embryonic stem
cells by using public funds (Nasaw, 2009). Some states in the US prohibit
reproductive cloning but allow cloning for therapeutic purposes (Robertson,
2001; UKSCI, 2005). German law bans the embryo research and embryo
cloning within states but allows the importation of stem cell lines derived
from human embryos. Both the US and Germany were criticised for their
double standards (Wang, 2006). In the UK, through The Human Fertilisation
and Embryology Act 1990, it was made legal to conduct research on human
embryos up to 14 days after fertilisation. Reproductive cloning in the UK is
prohibited through the Human Reproductive Cloning Act 2002 (Wang, 2006).
Australia allows ES stem cells by using surplus IVF embryos but bans
therapeutic cloning. China is more focused on clinical application of stem cells
than basic research. As for therapeutic cloning, production of human
embryonic stem cell lines is legal. Different countries have different
regulations (Gottweis et al., 2009).
2.2.4 Social and economic issues
The IVF clinics have emerged as one of the major sources for 'raw materials',
Le. surplus ova, embryos and oocytes, for stem cell research (Gupta, 2011;
Waldby, 2008). There is a growing unregulated market in many countries
(both in developed as well as in developing countries) for these reproductive
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materials, which is considered to be exploitative for impoverished females.
Femaleshave become the 'reproductive labour' in the stem cell bio-economy.
The procurement of oocytes is a painful process. It requires hyper-stimulation
of the ovary followed by surgery (Dickenson, 2005). Waldby (2008: 21) argues
that the whole procedure "involves pain, abdominal inflammation, possible
renal failure and infertility, venous thrombo-embolism and cardiac
instability." However, given the financial incentives, many young women and
girls are attracted towards fertility clinics to 'harvest' their oocytes (Waldby,
2008). There is a strong possibility of economic exploitation of poor women
across countries in the era of global bio-economy, against this backdrop
(Dickenson, 2005).
Another key social issue associated with stem cell is that it will not be of
benefit to the poor as it may be highly cost-intensive. In addition, there is the
possibility that stem cell will significantly increase the average life span, which
might have several social impacts. For instance, inter-generation family
disputes and pension payments might increase considerably (Liddell and
Wallace,2005).
Despite various underlying issues highlighted above, in many countries stem
cells are being used frequently in research and clinical settings. However, a
few countries have banned the research using human embryos and its
therapeutic applications given that it is considered as an immature therapy,
except bone marrow adult stem cell transplantations. In countries like India
and China, along with bone marrow stem cell transplantations, embryonic
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stem cell, adult stem cells i.e. neural stem cell, cardiac stem cells, liver stem
cells etc. are being used in the treatment of various diseases. Patients both
domestic and internationally are flocking to these countries in the hope of
curing their disease. Stem cell-based treatment is considered as a money-
making endeavour rather than an effort to help patients.
Stem cell is a part of that biomedical enterprise which is highly complex.
Biomedicine is analysed differently across different disciplines and between
different authors. The next section has attempted to pull together various
understandings of biomedical development, which is helpful in understanding
the contextual development of stem cell.
2.3 Sociology of biomedicine
The development of biomedicine is shaped by different actors, i.e. the state,
industry, scientists, society etc. (Baronov, 2008; Bellett, 1992; Clark et al.,
2003; Conrad, 1992; Singer, 1992). It is viewed as a human social construct
which involves choices about how to spend time, energy and resources
(Bellett, 1992: 364). Biomedical science is now more under the control of
bureaucracies and private corporations than its own norms (Bellet, 1992), as
given by the fact that there are different rules and regulations in different
countries to regulate the same form of scienceworldwide.
The emergence of biomedicine was viewed differently by different sections of
society. For some, it generates great hope in curing diseasesand afflictions,
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while others warn of the dangers of treating human life as an object, for
example, by using human embryos in fertility treatments and research. Many
politicians, academicians, corporations and private investors are of the view
that it results in a new and highly lucrative bio-economy; on the other hand
there are apprehensions that this affects the development of basic sciences
because of profit-oriented services. The focus of biomedicine is more on
'elite' disease rather than 'poor' disease (Rose, 2007). In this way it serves
only the interests of the dominant class of society (Singer, 1992).
Bellett (1992: 364) has narrowed down the debate about biomedicine into
two 'voices' and stated that: a) it is characterised by having a strongly
hierarchical culture of managerial interventionists with instrumental values
and a competitive market model of society that wants to convert all research
into a centrally controlled and efficient producer of marketable products and
b) it is used as an agent of social control. Thus biomedicine has brought so
many complexities and tensions between science, market and society.
Given the complex nature of biomedicine, Baronov (2008) has attempted to
analyse its development ontologically. This study has shown that, as an
institution, biomedicine was shaped by a distinctive arrangement of scientific-
material, symbolic-cultural, and social factors. Thus the emergence of
biomedicine is manifold: (a) biomedicine as a scientific enterprise; (b)
biomedicine as a symbolic-cultural expression; and (c) biomedicine as an
expression of social power.
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2.3.1 Biomedicine as a scientific enterprise
The post-war period (1945-1975) was seen as the emergence of biomedicine.
It was claimed that, "since World War II, biology and medicine have come
together, both institutionally and intellectually, in a hybrid practice that is
neither syncretic nor synthetic" (Keating and Cambrosio, 2003: 1). During this
period, the transformation of biology and medicine took place in the
contextual development of physiology and bacteriology. This development
became an important resource for the organization, diagnosis, and treatment
of human disease and established linkages among laboratories, hospitals, and
dispensaries including public health organisations. As a result, modern,
professional medicine, Le. biomedicine, was 'invented' (Quirke and
Gaudilliere, 2008).
The 'invention' of biomedicine brought about significant changes in the
medical system, including the conduct of research and governance of
medicine. Specifically, the changes could be seen in the form of heavy
investment in research, fundamentally increased level of inquiry in biology
and medicine and a strong linkage between laboratories and clinics. The post-
war period was described as a new "way of knowing" in terms of biomedicine,
where a new system of relations developed between science-technology
(biology) and medicine (Keating and Cambrosio, 2003; Quirke and Gaudilliere,
2008).
The 1960s was viewed as a turning point for biomedicine as patient
expectations and demands for new medical procedures and drugs increased.
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This led to the development of various diagnostic instruments, along with
new ways of diagnosing diseaseand method of drug discovery. The invention
of new scientific methods (empirical and experimental) facilitated further
'advancement' and the establishment of biomedicine in society. According to
David Baronov, biomedicine has introduced radical new ways of thinking and
knowing. Firstly, it brought a seismic shift in attitudes from a traditional
reliance on "God's will" with the development of controlling power over
nature and, secondly, new epistemological developments associated with
empiricism and rationalism (Baronov, 2008). As a result, significant
advancement in medical knowledge took place.
It is argued that institutionally, biomedicine is being reorganised not only
from the top down or the bottom up but from the inside out (Clark et al.,
2003). This institutionalisation is taking place through the development of
institutional infrastructures (Le. technical, informational, organisational etc.)
through the combination of computer and information technologies (Clark et
al., 2003). Clark et al. (2003), in their study related to the proliferation of
biomedicine in the US,have observed that from 1890 to 1945 was the period
of transformation within American medicine. This period witnessed not only
the professionalisation and specialisation "of medicine and nursing, but also
the creation of allied health professions, new medico-scientific, technological,
and pharmaceutical interventions, and the elaboration of new social forms"
(Clark et al., 2003: 164). After World War II, a massive increase of investment
could be seen in both the public and the private sectors. The production of
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medical knowledge and intervention of goods and services has expanded
rapidly. Contemporary biomedicine sector in the US is a multi-billion-dollar
industry (Baronov, 2008). In the last 50 years, the US health sector has
increased from 4% to 13%of GNP,and it is projected to exceed 20% by 2040
(Clark et al., 2003). Similar kinds of development in biomedicine were seen in
Britain and France after the Second World War; however, it was not at the
level of the US (Quirke and Gaudilliere, 2008). Quirke and Gaudilliere (2008)
stated that the development of biomedicine in the post-war era resulted in
the shifting of state focus from public health concerns towards biomedical
research. However, there were differences between the mode of expansion
of biological and medical research in Britain and France;while the British built
on an older and stronger tradition of university-based research, the French
preferred a model of full-time research under the umbrella of government
agencies(Quirke and Gaudilliere, 2008: 447).
After having been established in the US,Britain and France, biomedicine has
started to expand in other parts of the globe, where it developed within
different national contexts in the background of changing relationships
between laboratories, clinics and public health establishments (Quirke and
Gaudilliere, 2008). However, Quirke and Gaudilliere (2008: 251) argued that,
"individual national patterns have had a relatively limited influence on
biomedicine. The moral and political economy of the post-war period
stimulated the rapid internationalization of biological research."
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2.3.2 Biomedicine as a symbolic-cultural expression
The notion of biomedicine as a scientific enterprise has highlighted its
universal claims that its principles and methods could be applied across
different cross cultural settings (Baronov, 2008). However, Baronov (2008)
and Lock and Gordon (1988) argue that it is very much a product of particular
social and cultural conditions.
From the perspective of biomedicine as a scientific approach, all disease
symptoms are categorised as universal in nature and applicable to all in the
same way across the society. Nonetheless, the social constructionist approach
challenges the notion of disease as culture-free (Baronov, 2008). King (1954:
quoted in Baronov, 2008) stated that, "diseases are not things in the same
sense as rocks, or trees, or rivers. Disease represents patterns or
relationships, which are not material. The problem then becomes, how real is
a pattern, what is the ontological status of a relationship?" (p.199).
Thus it can be argued that disease is not a universal phenomenon across
society and it varies with respect to time and space. This approach questions
the universal pattern of diagnosis and treatment of disease (Brown, 1995).
Payer (1988: quoted in Baronov, 2008: 243) asserted that, lithe same clinical
signs may even receive different diagnoses. Often, all one must do to acquire
a disease is to enter a country where that disease is recognized - leaving will
either cure the malady or turn it into something else."
Symbolic- cultural framework analyses biomedicine in a particular social
context and refutes the notion of biomedicine as objective, dispassionate,
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rational, and professional. It was viewed that biomedicine emerged in
Western Europe and North America and at a unique time under particular
social and cultural settings (Baronov 2008: 243). It emerged in Europe and
spread to North America. Actually biomedicine was a cultural invention of
nineteenth-century Europe, and now it has permeated across the globe
(Geest and Finkler, 2004). The post-war period has witnessed the rapid
transformation of scientists and medical professionals into business men,
resulting in power struggles between them (Baronov 2008; Light and Levine
1998; Nye 2003).
2.3.3 Biomedicine as an expression of social power
From this conceptual perspective, biomedicine is seen as "an expression of
social power that reflects structures of power and privilege within capitalist
society" (Baronov, 2008: 235). The last quarter of the twentieth century has
seen the different ways in which medicine and knowledge of illness came to
be localised upon the individual body to exercise power. Michel Foucault in
his book The Birth of the Clinic: An Archaeology of Medical Perception (1973)
described the reshaping of medicine at the start of the nineteenth century
through the interconnections of changes along a number of dimensions
(Foucault, 1973). These changes include "laws and practices of assistance,
shifts in the organization of medical professions and medical pedagogy, new
forms of record-keeping in hospitals allowing the production of various
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statistics related with morbidity and mortality, pathological anatomy and post
mortem dissection and so forth" (Rose,2007: 10).
Medicine went beyond mere treatment and curing of diseases to the
management of diseases, the administration of reproduction and the
maintenance and optimisation of the body. The maintenance of the healthy
body became a major concern for many individuals and families. This resulted
in the employment of practices such as dietetics and exercise coupled with
increasing consumption of proprietary medicine and health supplements
(Rose,2007).
The extension of medical authority in this way has been seen as
'medicalization' of social problems (Clark et al., 2003). The term is defined as
the process through which certain events or characteristics of everyday life
become medical problems and come within the jurisdiction of medicine.
Medicalization is a "process whereby more and more of everyday life has
come under medical dominion, influence and supervision" (Conrad, 1992:
210). For example, fertility, birth, pregnancy, and menopause, which are
normal and natural process of human life, are now being regarded as
conditions of illness or disease(Peerson, 1995). It is stated that medicalization
is one of the most forceful social alterations of the last half of the twentieth
century (Clark et al., 2003; Mctellan, 2007). Since 1985, striking changes in
both the organisation and practices of modern biomedicine have been put
into practice through the integration of techno-scientific innovation; Clark et
al. (2003) termed this 'biomedicalization'.
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Clark et al. (2003: 166) argue that biomedicalization is co-constituted through
five overlapping processes: (a) major political economic shifts; (b) a new focus
on health and risk and surveillance biomedicine; (c) the technoscientization of
biomedicine; (d) transformation of the production, distribution, and
consumption of biomedical knowledge; and (e) transformations of bodies and
identities.
Biomedicalization is marked by the concentrated corporate power in the form
of privatisation of research, university/industry collaborations and
commodification of research. Medicine has become technomedicine, highly
dependent on sophisticated diagnostic and therapeutic equipment (Clark et
al., 2003; Rose, 2007). The expansion in biomedicine has resulted in a
complex division of labour among specialists. Medical professionals have lost
their monopoly of diagnosis and therapeutic calculation. They are/have
become forced to depend upon pathological tests. Evidence-based medicine
is said to have constrained the clinical judgement of the practising physician.
The use of standardised, corporately framed diagnostic and prescribing
procedures became essential for medicine and medical professionals.
Medicine has been reshaped by its intense capitalisation. Intellectual property
became a major factor for research in biotech companies and universities.
Illness and health have become major fields for corporate activity. Thus, the
human body has been opened up for technical innovation and economic
exploitation (Rose, 2007).
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Peerson (1995) argues that the individual body has become objectified in
terms of localisation and configuration of disease. 'The clinical gaze' has
become the important tool for measurement of human anatomy and
physiological processes, both qualitatively as we" as quantitatively.
Biomedicine ignores the patient's subjectivity, Le. her/his perception of illness
and treatment is overlooked. There is more reliance on various medical tests
(Peerson, 1995). The intensification of knowledge in biomedicine has resulted
in a new power relationship between medicine and the human body. In the
process of acquiring knowledge, medicine has gained importance and power
over the human body (Peerson, 1995). It is evident by the fact of using the
human body as 'a guinea pig' in the name of clinical trials, especially in the
case of developing countries such as India (The Lancet, 2007).
The development of biomedicine in India is an interesting case to study since
India is known as a place of various rich traditional systems of medicine,
despite biomedicine being firmly established in contemporary India.
2.4 Sociology of biomedicine in India
In the beginning of the first millennium AD, there were three principal
systems of medicine: a) Ayurveda, b) Greek, and c) Chinese. The basic
principle of these systems of medicine is based on the relationship between
man and nature. However, their explanations of the human body and disease
are different in different medical systems. Of the three systems of medicine,
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Ayurveda is viewed as a unique medicine system with a holistic approach
both in terms of foundational ideas and therapeutic measures (Subbarayappa,
2001).
Ayurveda is considered as the principal system of medicine in India. However,
the Siddha, the Unani and the folk medicines are also seen as a part of the
Indian System of Medicine (ISM). Sometimes, even homeopathy is included to
the list of ISM (Banerji, 1981; Khan, 2006; Subbarayappa, 2001); and later in
the first half of the twentieth century biomedicine, i.e. a Western system of
medicine, began to interact with ISM (Khan, 2006).
The co-existence of different multiple systems of medicine is viewed as a
medical 'pluralism' (Minocha, 1980). However, it is argued that in the case of
India there is need to go beyond the liberal pluralist predispositions and that
one should consider the issues of power, domination and hegemony
associated with the development of biomedicine in India (Frankenberg, 1981;
Khan, 2006).
The history of Western medicine in India can be traced back to the early
sixteenth century, when the first medical hospital was established by the
Portuguese in Goa. Later, the British also established their first hospital in the
mid-seventeenth century and a medical college in the mid-nineteenth century
(Desai, 2007).
It is largely perceived that Western medicine in India evolved to address the
medical needs of the military rather than local needs, and medical thought
was dominated by environmental paradigm (Arnold, 2000; Desai, 2007). The
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identification of the cholera bacterium (Koch 1843-1910), the discovery of the
mode of malaria transmission (Ronald Ross 1857-1932), and the outbreak of
the bubonic plague shifted the environmental paradigm towards germ theory
in the late nineteenth century. Western medicine began to address various
tropical diseases like anthrax, malaria, cholera and tuberculosis through
medical services and research (Desai, 2007).
In India, however, these services and research were only confined to the
"colonial enclaves" - the army, prisons, hospitals, civil stations, etc (Khan
2006: 2789). The development of biomedicine is perceived as a hegemonic
weapon. Despite many revolutionary breakthroughs such as germ theory, the
medical advancements did not reach the general medical professionals
(whether European or Indian) (Arnold, 1996; Desai, 2007; Khan, 2006). Khan
(2006) argued that, notwithstanding being a state-sponsored medical system,
Western medicine never reached beyond metropolitan elites. The rest of the
country had to rely solely on the indigenous system.
The situation changed a little by the late 1920s and 1930s as the idea of India
getting independence had become fairly predominant (Khan, 1996). During
the decades of the 1920s and 1930s the main nationalist body, the Indian
National Congress (INC), became a strong force in the national politics. INC
had performed well in the 1924 municipalities and district boards' election. In
the 1937 provincial legislature's election, INC had attained a complete
majority (Khan, 2006). In 1939 the legislative assembly of United Provinces
(UP) has passed "The United Provinces Indian Medicine Bill, 1938". The goal
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of the bill was to "modernize" the Indian system of medicine with the help of
Western medicine. As a result, Western medicine became a top priority in the
nationalist agenda. However, some sections of the society had perceived this
bill as an attempt to ignore the indigenous system of medicine, i.e. Ayurveda
and Unani (Khan,2006).
After independence in the background of the Bhore Committee report (1946),
the government of India expressed her firm commitment to establish
Western medicine in the country (Srinivasan, 1995). While advocating the
modern system of medicine once first prime minister of India, Jawaharlal
Nehru said that:
"The science of medicine would not be divided up into
compartments but would be built upon solid foundations of
past and present experience tested by modern scientific
methods. The proper approach, therefore, should be that any
system of medicine to be followed or encouraged must be
modern and up-to-date and should take advantage of all the
accumulated knowledge we possess"(Khan, 2006: 2,790).
Here the argument was to have a "modern" and "up-to-date medicine"
system and to get government support; indigenous systems had to be
"modern" and "up-to-date". It is pertinent to highlight that it was the
Western medicine system which acted as the scale of measurement to test
the modernity of the indigenous medicine system (Khan, 2006). Drawing on
the notion of critical studies of science, medicine, knowledge and
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development discourses, Khan (2006: 2,790) argued that lithe whole logic of
the 'uniform policy' based on 'modern scientific methods' was quite
discriminatory to the indigenous systems, and it inevitably meant giving a
dominant position to the system of allopath in policy formulation."
This approach was quite similar to the colonial government as they always
insisted on scientific evidence on the matter of recognition to indigenous
medicine (Jeffery, 1977; Khan, 2006). More explicitly in the name of scientific
advances, indigenous medicine was always undermined.
It is worth mentioning that, during the same period (1920s-1940s)when INC
was advocating Western medicine, the popular leader of the INCMahatma
Gandhi firmly stood for promoting the indigenous system of medicine
(Srinivasan, 1995). However, at large, Gandhi was critical towards any type of
medicine, especially biomedicine; Khan (2006: 2,793) argued that "his critique
of biomedicine is much sharper and at a much higher grade" than the
Ayurveda and Unani systems of medicine. Gandhi criticised the system of
modern medicine or biomedicine in his book Hind Swaraj by stating that it
increases more dependency on the doctors and undermines self-control; it
weakens the mind. As he said:
"I overeat, I have indigestion. I go to a doctor, he gives me
medicine, Iam cured. Iovereat again, I take his pills again. Had
I not taken the pills in the first instance, Iwould have suffered
the punishments deserved by me and I would not have
overeaten again. The doctor intervened and helped me to
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indulge myself. My body thereby certainly felt more at ease;
but my mind became weakened. A continuance of a course of
medicine must, therefore, result in loss of control over the
mind" (Gandhi, 1938: 43).
Gandhi was also against the killing of animals for the medical research, as he
stated that " ... it is not necessary to take so many lives for the sake of our
bodies" (Gandhi, 1938: 43). This argument of the most popular leader of India
is very much important with respect to embryonic stem cell research in India
where an attempt is being carried out to use human embryos for the sake of
medical advancement (Basu, 2005).
Khan (2006) argued that the voice of dissent against Western medicine within
the nationalist discourse was based on the fear that, in the name of scientific
medicine, the hegemony of modern medicine will be established. The
advocators of indigenous medicine were concerned for the better treatment
of Indian medicine. The opposition to Western medicine, however, was never
effective.
In independent India, science became an essential part of India's
development, under the leadership of the first Prime Minister of India,
Jawaharlal Nehru (Rao, 2008). He was a great supporter of biomedicine.
Independent India has seen the establishment of several agencies to carry out
medical research based on the model of biomedicine. The re-designation of
the Indian Research Fund Association (IRFAL soon after independence, into
the Indian Council of Medical Research (ICMR) in 1949 could be seen as a first
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step in this direction. The IRFA was constituted in 1911 at the Plague
Laboratory in Bombay under the chairmanship of Sir Harcourt Butler (Desai,
2007). Over the years, the ICMR played a major role in the development of
modern medicine in India, including stem cells, being a principal advisory
body to the Ministry of Health and FamilyWelfare.
It would be worth highlighting here that the Western medicine in India has a
colonial root and its introduction in India was viewed as one of the efforts to
strengthen colonial power similar to the development of railways, telegraphy,
roads and bridges (Krishna, 2001; Kumar, 1995, 1997). It could not be simply
seen as a diffusion of modern science from the central to the periphery
(Baber, 2001); rather, biomedicine had also brought its underlying
'hegemonic' and 'exploitative' character in India, which was prevalent in the
West (Arnold, 1993). However, there are some views that biomedicine in
India did not achieve hegemony during the colonial period, though it was a
dominant system of medicine (Kapila, 2010).
To sum up, it can be argued that the Western medicine during the British
period only served a privileged section of the society. The question therefore,
one may ask, what is the current situation of biomedicine in India, especially
after the end of colonial rule? Is it still confined to the elite and privileged
section of the society or has it become medicine for the common man? The
answer to this question is directly linked to the stem cell proliferation.
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2.4.1 Present status of biomedicine in India
Similar to the colonial period, the independent India also used science for its
political dominance and justification for the Indian state (Nandy, 1988).
Science was strongly driven by the Indian state in the beginning years of
independence. Though the role of the state is still dominating in the
promotion and proliferation of science in India, private players have also
started making a significant contribution, especially after economic
liberalisation since 1991.
The initial years, till the 1970s, were viewed as a happy period for science
with the assumption that the future "belonged to those who made friends
with science" (Visvanathan and Parmar, 2002: 2,714). Later it was realised
that science is used as an instrument of dictatorship, especially during the
period of emergency (1975-1977) when, in the name of population control,
forced sterilisations were carried out. Similarly, due to various developmental
projects, millions of people were displaced (Visvanathan and Parmar, 2002).
These kinds of examples recall Ashis Nandy's argument, Le. "in the name of
science and development one can today demand enormous sacrifices from,
and inflict immense sufferings on, the ordinary citizen" (Nandy, 1988: 1).
The biomedicine in India is also the part of the state-driven science project.
The development of biomedicine is highly complex given the distinguished
political economy of India. As a nation-state, India is characterised as an
uneven innovator where more than one India exists (Bound, 2007). For
instance, India is both an economic leader, where the annual growth rate is
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impressive (average 7% even during global recession), and a country which
has the world's largest population and number of people surviving on less
than a dollar per day (Shastri, 2007). Nearly 70% of the Indian population live
in its villages where the large sections of the population are deprived of basic
health care facilities (The Asian Age, 2011). At the same time, in some urban
areas there are world-class health care facilities, largely provided by the
private sector, though these are only accessible to about one-third of the
Indian population (Sengupta and Nundy, 2005). The health care system in
India is full of contradictions; on the one hand there are state-of-the art
medical facilities for the rich, and on the other hand access to basic health
care for the poor is a distant dream. Similarly, modern medicine attracts great
attention from the government of India, whereas the various issues of public
health are largely neglected (Amrith, 2007). India fails to control infectious
diseases such as tuberculosis, Japanese Encephalitis, diarrhoea and mosquito-
borne diseases such as malaria and dengue fever. The government of India is
comparatively more interested in areas such as genomics, nanotechnology,
GM crops and stem cell research rather than public health.
The modern medicine is viewed as one of the causes of poverty in India. It is
argued that the increasing costs of medical expenses push 40 million of the
population to below the poverty line each year. At the moment, Indians are
paying 80% of medical expenses from their own pocket (The Hindu, 2012).
India has been unable to develop state-of-the art public hospitals which can
provide affordable health care to millions, free of charge. The majority of
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public sector hospitals are in the worst condition. There is always a shortage
of medicine and unavailability of diagnostics tests in these hospitals. People
are forced to go to private sector hospitals, despite allegations that private
service providers of health care execute unnecessary pathological tests and
surgical procedures (Sengupta and Nandy, 2005).
The public spending in the health sector as a proportion of GDP is only 1%,
which is less than its neighbouring countries such as Sri Lanka (1.8%), China
(2.3%) and Thailand (3.3), and far behind in comparison to the US and the UK
(Planning Commission, 2012; The Financial Express, 2012). On the other hand
the private spending on health is 4.2% of GDP (Nagarajan, 2010). There is a
great reliance on private service providers, which accounts for nearly 80% of
medical services in India. The recent report of the Planning Commission of
India on health has expressed concern over the greater reliance on private
service providers as it is beyond reach of the poor people. This report
reflected that the public health care system in India has not only a shortage of
adequate funding but also there is a problem with the existing health care
governance system. It was stated in the report that the health care system
has several structural problems. For example, there is a lack of integration
between disease control and other programmes in the social sector, and the
regulatory system related to drugs and medical practices is weak (Planning
Commission, 2012).
Against this backdrop of political-economy of India in general and
biomedicine in particular, stem cell research and its clinical activities
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proliferate in India. In the next section, I critically examine how social
scientists have begun to explore these developments.
2.4.2 Social science studies on stem cells in India
The proliferation of stem cell research in India has attracted attention at
national and international level since the beginning of 2000s, as highlighted in
Chapter 1. Given the controversies related to the use of human embryos in
stem cell research worldwide, most of these studies have focused on
similarities and differences in the regulatory framework adopted by different
countries with embryonic stem cell research, with India as one of the case
studies (Knowles, 2004; McLaren, 2001; Walters, 2004). The first major social
scientific study looking specifically at stem cells in India was conducted by
Brian Salter and his colleagues in 2007. They observed that India was yet to
formulate strategies related to intellectual property rights, venture capitals,
public-private partnership, and regulatory issues, with respect to the use of
human embryos in stem cell research. Further, they highlighted problems and
inadequacies in the governance regime dealing with IVF clinics which are a
main source of raw materials for stem cell research as well as with the
regulation of clinical trials. Since both IVF clinics and clinical trials have been
linked with stem cell development, they argued that these aspects need to be
addressed by the regulatory authority. They suggested that India needs to
have appropriate governance mechanisms in three areas: a) the supply of
oocytes and the use of human embryo in research; b) the conduct of human
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embryonic stem cell research; and c) the clinical experimentation with stem
cells. Brian Salter and his colleagues also highlighted the unapproved and
unproven stem cell clinical practice of a controversial clinician, Dr Geeta
Shroff. Overall, Salter et al. (2007) focused on the scientific strengths of India
in general and stem cells in particular along with the limits of governance
regimes existing at the time with respect to stem cells. They depicted that
Indian stem cell research, including clinical practices in the country is
proliferating in a governance vacuum since India has non-binding guidelines
which have no statutory power.
However, they did not pay attention to the specificities of institutional
arrangements in stem cell science in India. For instance, what is the main
focus of various public and private players in stem cells such as research
laboratory, firms, and hospitals? Second, it appears that this study was based
on secondary sources, as they do not mention any field work in India. A later
study conducted by Bryn lander and her colleagues in 2008 attempted to fill
this gap (lander et al., 2008). They mapped the current state of stem cell
research in India at the time and highlighted the various activities in stem
cells at different research institutes, companies, hospitals and clinics. Lander
et al. (2008) have argued that India hasthe capability to harnessthe potential
of stem cells to address various chronic diseases from which a growing
number of the population suffer, and observed that India can make a
significant contribution to the emerging stem cell knowledge economy. The
study also highlighted the lack of a robust stem cell regulatory framework in
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India and expressed concern that there is considerable potential of
exploitation of patients against the background of inflated expectations
surrounding stem cells. However, finally, they concluded that, similar to
impressive progress in information technologies and biotechnology, India
could be an important contributor in stem cells, especially in its clinical
applications. The study was based on interviews with key players working at
research institutes, private companies, universities, hospitals and clinics
including policymakers, bioethicists, intellectual property experts and science
journalists. The interview study was supplemented with relevant policy
documents, academic literature and bibliometrics analysis.
The findings of Lander et al. (2008) were important in the sense of
understanding the overall status of stem cell research in India. However, they
were also limited in certain respects. For example, though their research
highlights the possible exploitation of patients in the context of high
expectations associatedwith stem cells and poor regulations, it was unable to
provide a more nuanced understanding of the rhetoric surrounding
expectations and its ethical implications.
Both studies described above largely attempted to explore the overall status
of stem cell research in India and highlighted the problem with the existing
regulatory regime. They did not analyse in depth the interconnections
between socio-cultural and economic factors and the proliferation of stem
cell related research and therapy in India. This interconnection was examined
by Bharadwaj and Glasner (2009). They conducted an ethnography study in
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New Delhi and Mumbai to understand the rise of embryonic stem cell
research in India and attempted to investigate how social and culture factors
shape the proliferation of embryonic stem cell research and practice in India
(Bharadwaj and Glasner, 2009). Their study showed a strong linkage between
IVF clinics and embryonic stem cell research and they argued that the
proliferation of embryonic stem cells in India is inextricably intertwined with
IVF clinics, infertile couples, patients and a lax regulatory framework. The
study was largely based on interviews with the same controversial clinician,
Dr Geeta Shroff (whose claims regarding stem cell therapy became the
subject of media coverage), and IVF experts, patients, donors and
policymakers. In this study, the clinical services offered by Dr Shroff were
portrayed both as a 'miracle', as in helping patients in their sufferings, as well
as 'maverick', as her treatment modality is neither peer reviewed nor
approved by regulatory authority. Though Bharadwaj and Glasner (2009)
blame the powerlessness of existing stem cell guidelines and poor regulatory
framework related to IVF clinics and clinical trials for unregulated
proliferation of stem cell treatments in India, at the same time they argue
that India is challenging Western dominance not only economically but both
ethically and politically, since many foreign patients are travelling to India for
an ethically-contested therapy which is not approved in the West. The
phenomenon of overseas travel for stem cell therapy is termed 'stem cell
tourism' and many studies have raised concerns about this growing
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phenomenon in India, especially the unproven use of embryonic stem cells
(Cohen and Cohen, 2010; Murdoch and Scott, 2010; Sipp, 2011).
Most of the studies highlighted above have focused on the therapeutic
application of embryonic stem cells; they did not pay much attention to
investigating the adult stem cell-based treatments in India. Only recently have
Patra and Sleeboom-Faulkner (2009, 2010, 2011) analysed the proliferation of
adult stem cells in clinical settings. Their work was based on an ethnography
study, including participant observations, case studies and semi-structured
interviews with stem cell researchers, clinicians and hospitals (both public and
private), firms, policymakers, patients and their family members in locations
such as New Delhi, Mumbai, Kolkata, Bangaloreand Cuttack. Their main focus
of research was to investigate how patients are being 'recruited' for an
experimental therapy through a phenomenon termed 'bionetworking'. They
conceptualise bionetworking as a network of key individuals from research
and health organisations to 'recruit' patients strategically for unproven stem
cell therapy. For instance, the majority of the patients are 'recruited' through
false testimonials of 'cured' patients. Patra and Sleeboom-Faulkner (2009,
2010, 2011) stated that this bionetworking exploits the lax regulatory system
for financial gain and put patients at health and financial risks.Similar to other
studies, they also argued that unproven stem cell treatments proliferate in
India because of the ineffective DBT-ICMRstem cell guidelines, as these
guidelines have no statutory power to punish anyone in the case of
tra nsgression.
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It is worth highlighting here that in both studies (Bharadwaj and Glasner,
2009; Patra and Sleeboom-Faulkner, 2009, 2010, 2011) data was collected by
a native speaker unlike Lander et al. (2008). The richness of these studies
(Bharadwaj and Glasner, 2009; Patra and Sleeboom-Faulkner, 2009, 2010,
2011) in terms of more in depth sociological analysis of stem cell
developments in India compared to Lander et al. (2008) suggests that native
competency plays a crucial role in qualitative research. Ganga and Scott
(2006), while studying international migration in Nottingham (UK) and Paris
(France)2 have observed that, to a large extent, social proximity (similar
ethnic, national, religious, linguistic and cultural heritage) between
researchers and participants assists in data collection through interviews. This
suggests the significance of native language skills and native understanding of
the surrounding politics and culture in data collection, especially through
qualitative interviews.
The existing studies on stem cell research in India have made a valuable
contribution to understanding the proliferation of stem cell research and
therapies in India. However, these studies have important limitations. First,
though they highlight that patients are being attracted through the creation
of hope and hype, and there is a high expectation of stem cells, these studies
have not analysed the basis of hope and hype, or more specifically the
generation of expectations. Second, these studies have not paid attention to
2 Ganga and Scott (2006) have analysed lithe case of an Italian researcher interviewing Italian
migrants in Nottingham (UK) and a British researcher interviewing British migrant in Paris
(France)".
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analysing the ethical implications of expectations and how various key players
justify or challenge stem cell activities in India. Furthermore, they do not
analyse the ethical issues in great detail associated with those stem cell
clinical services which are being offered by many clinicians such as Dr Shroff.
More specifically, how do different actors comprehend these and other
recent stem cell practices? Third, none of the studies described above have
investigated the different modes of governance dealing with medical
practices in India, of which stem cells are one part. Focusing on the limits of a
specific set OBT-ICMR guidelines introduced to regulate stem cells, they
neglect the relationship between stem cell medical and the wider governance
regimes which are in place to govern general medical practitioners.
In Chapter 1, the growing activities around stem cells are highlighted and one
of the aims of this thesis is to analyse the expectations discourse of key
players in the background of various activities of stem cells. This can be
studied through an analytical approach provided by the social studies of
expectations. The next section critically analyses this approach in greater
detail.
2.5 Sociology of expectations
In recent years, scholars in STS have begun to examine the significance and
dynamics of expectations in the development of a particular science and
technology regime (Brown and Michael, 2003). The sociology of expectations
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shows- how visions of the future are used to mobilise resources and in the
formation of socia-technical networks. Expectation studies in science and
technology provide a valuable framework to study the rise and fall of a
particular science and technology area and help in analysing its successand
failure.
In sociology of expectations studies, since the late 1990s various studies in
different areas of science and technology have been conducted with varied
aims and objectives, most notably in the areas such as xenotransplantation
and stem cells (Brown and Michael, 2003), pharmacogenetics (Hedgecoe and
Martin, 2003), biobanking (Tutton, 2007), haematopoietic stem cell research
(Martin et al., 2008a), cord blood banking (Brown and Kraft, 2006)
regenerative medicine (Wainwright et al., 2008), and anti-aging medicine
(Mykytyn, 2010). Most of these studies have investigated the articulation of
hopes, visions and promises in shaping of the particular research areas or
technology. For instance, the study of Brown and Kraft relating to the banking
of cord blood stem cells elucidated that extensive advertisements directly to
the expectant parents as a future investment for their child have helped in
the establishment and proliferation of private cord blood banking firms over
the years (Brown and Kraft, 2006).
Scholarship in sociology of expectations has argued that a strong vision in
terms of potential capability of a particular technology is necessary to draw
attention of the public, funders and policymakers for social and financial
support and a favourable policy regime (Borup et al., 2006; Brown, 2003;
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Martin et al., 2008b; Petersen, 2009). Furthermore, a 'future' is deliberately
created to marshal resources and the support of different actors for the
development of a particular techno-scientific venture and the direction of
research especially for emerging technologies where actual products or
services are yet to be manifested (Brown and Michael, 2003).
However, the 'creation of future' is not a simple or linear process; it is highly
contested, since varied promises lead to contested claims and counterclaims
with regard to potential of a given area of science and technology, both in
technical and social aspects. During the whole exercise of creating a positive
future, some claims get accepted while some get rejected. Brown and his
colleagues in their study of Contested Futures seek to "understand how it is
that some futures come to prevail others, why once seemingly certain futures
happened to fail, how other futures are marginalised as a consequence of the
dominant metaphors and motifs used in everyday life, and the consequences
of particular framing of the future" (Brown et al., 2000: 4). The futures are
mainly contested in terms of their time-frames (Le. when will the desired
futures be secured?) and varied interests of key actors. In addition, possible
risks and uncertainties associated with a given technology also lead to
contested futures. For instance, the translation of research findings from lab
to clinic have always been a contentious issue in the area of biomedical
research in relation to potential capability, safety and possible risks
associated with a given technology. In the past, the case of gene therapy and
stem cells presently can be a good example of contested futures (Martin,
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2006; Wilson, 2009). Here, expectations playa vital role in diluting various
contentious issues and in the alignment of various actors towards 'shared
futures' (Martin et al., 2008a).
Analysing the 'translation' of haematopoietic stem cells (HSCs),Paul Martin
and his colleagues develop the idea of 'communities of promise', which
provides a useful framework to study how different actors are assembled in
the background of high expectations for a particular technological
development. This study illuminates how a particular 'imagination' has the
capability to not only pull heterogeneous actors to work together but also it
can attract new players in given science and technology ventures. For
example, in the initial stages of HSCs'development, mainly scientists and
clinicians were involved but later, with the identification of the C034 marker,
other players such as firms also enrolled themselves in HSCs'development as
C034-based HSC-separation promised to treat various haematological
disorders (Martin et al., 2008a).
The studies have shown that expectations discourse is not only limited to
attracting various resources and the alignment of various actors, in the form
of 'hope' rhetoric, but it also helps in the generation of capital, even when
there is no actual product. The proliferation of cord blood banking, especially
those which are private in nature, appears to be a good example for the
same. It is observed that "the creation of commercial cord blood
banks...marks the capitalization of human tissues within a future-oriented
'regime of hope' (Martin et al., 2008b: 127). This development is viewed as a
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shift from 'regime of truth' (proven evidence and established practice) to
'regime of hope' in present bio-economy, where hope itself becomes a
marketable product, termed 'capitalization of hope' (Martin et al., 2008b).
The interesting thing about this 'regime of hope', which has been observed by
Paul Martin and his colleagues, is that, it is not geographically confined and it
has a tendency to capture different countries and locations, which is
conceptualised as a new 'geography of promises' (Martin et al., 2008b).
Arguably, "this geography illustrates the spatiality of a regime of hope
focused initially on the US and the UK, but with Asia and the near East closely
following" (Martin et al., 2008b: 134). For instance, private blood banking had
been established during the 1990s in the West (Brown and Kraft, 2008;
Martin et al., 2008b) and has spread in countries such as in India in the
beginning of the 2000s (Singh, 2009; The Hindu, 2001).
The majority of studies in the sociology of expectations discussed above have
concentrated on Western settings and do not pay attention to the nature of
expectations in different cross-cultural settings. In addition, these studies
limit their analysis of expectation discourse at the level of specific actors, viz.
only scientists, clinicians and entrepreneurs, and overlook the role of nation-
states and governments in expectations rhetoric. Only a few studies have
compared the nature of vision and hype in different cross-cultural settings,
most notably the comparative study of Biocapital in the US and India (Sunder
Rajan, 2006), which attempted to investigate the varied nature of
expectations in these two countries. In the US it is largely the corporate sector
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that engaged in the articulation of vision and hype while in the caseof India it
is the state itself, for the major part, playing a leading role in the creation of
expectations. In India, the majority of biotechnology R&D is supported
through government funded laboratories; therefore, it is quite natural for the
Indian state to actively participate in expectations discourse. However, the
study of Sunder Rajan illuminates a fundamental difference between the
vision and hype of the USand India. The vision and hype in the former case is
embedded in 'salvation' rhetoric, i.e. a particular biomedical research has the
capability to 'save life'; while in the latter case it is dominated by 'nationalist'
discourse where there is a desire to be a global player. Sunder Rajan (2006:
126) further argues that, in contrast to the US,"the speculative capitalism in
India is far less developed in relation to manufacturing capitalism, which
suggeststhat salesand profit, rather than the conjuration of futures, are likely
to be the driving dynamic of the Indian biotech and pharmaceutical
industries." More clearly this argument reflects that futures vision circulates
in the generation of capitalism (speculative) in the US. Drawing on the
observation of Paul Martin and his colleagues in the case of proliferation of
cord blood banking (Martin et al., 2008b), it can be argued that the 'regime of
truth' is dominant in India compared to the 'regime of hope'. However, the
concept of 'geography of promises' reflects that this regime has now started
to change. Similarly, Sunder Rajan (2006) also illustrated that, in the desire to
go global, India has started to lean towards the speculative/hope regime,
which is a more market-oriented approach. The above discussion informs us
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that visionary promises need to be analysed at the nation-state level as well.
Vision and hype as a 'nationalist discourse' might have serious implications
for ethics and governance, as in the case of Indian stem cells it was often
argued that, the Indian stem cells rush ahead in the background of weakened
regulations (Padma, 2006).
The studies highlighted above largely investigate the role of positive
expectations in the shaping of new technologies; for instance, how hope,
hype, and promises are used as rhetoric to draw the attention of various
necessary allies and marshal resources. In contrast to positive expectations,
recently the role of pessimistic discourse has been analysed as another
approach to sustain resources and to interact with various actors (Tutton,
2011). Richard Tutton highlights that "in addition to projecting optimistic
scenarios, firms advance much more pessimistic images of futures that they
wish to avoid: possible failures, disappointments and financial losses" (Tutton,
2011: 411). Examining the pessimistic projections in company filings to the US
Securities and Exchange Commission, he observes that, along with positive
visions and hopes, the narratives such as fears and uncertainties are playing
an important role in future-making endeavours (Tutton, 2011). Similar to this
study, while establishing the link between sociology of metaphors and
sociology of expectations using avian flu as a case study, Nerlich and Halliday
(2007) have argued that negative expectations can also play a performative
role to draw attention and to mobilise actions and resources in certain
directions. The study of Nerlich and Halliday conceptualises negative
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expectations in terms of 'fear' and they attempted to highlight that negative
expectations in the form of 'fear' force actors to take preventive actions
against avian flu in the UK (Nerlich and Halliday, 2007). Therefore, it can be
inferred that not only positive but negative expectations have a decisive role
in shaping the direction and outcome of science and technology ventures.
Irrespective of whether the future is conceptualised in positive or negative
terms and whether or not a particular vision materialises in practice, the key
point is that narratives of expectations help to legitimize and 'sell'
investments in the technology in question (Brown, 2003; Sunder Rajan,2006;
Tutton, 2011). The legal protection of 'forward looking statements' made by
companies in the USreflects how visions are important for the contemporary
biocapital regime. The Private Securities Litigation Reform Act 1995 of the US
illustrated that lithe issuers of such statements (usually corporate investors
relations departments) are not liable in case of the failure to fulfil a promise
or predictions made within the statement" (Sunder Rajan, 2006: 132). Given
this protection to visionary statements, biotech companies sell their visions as
actual tangible products (Sunder Rajan,2006; Tutton, 2011).
While the literature on the sociology of expectations contains a number of
important insights, from the standpoint of questions relating to the ethics of
stem cell research, it is limited by its methodological orientation. So, the
majority of studies focused on investigating questions such as: a) how is the
future created in the present through various visionary statements?; b) who
are the main actors involved in promising ventures?; c) how do different
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actors in a given sector construct the future as per their institutional
settings?; d) how are consumers configured in the mis-selling of particular
visions? (Martin et al., 2008b). Indeed, it is implied that there is nothing
particularly problematic in the 'business of expectations'. Expectations are
seen as one of the essential components for a 'successful innovation' as
expectations speak about the capacity of a technology in solving many
existing problems (Mensink and Birrer, 2010). Mensink and Birrer (2010: 37)
stated that, "lf we were to only act when we are completely sure, there would
be no innovation." A few studies in this field even highlight the role of
bioethics in the creation and preservation of expectations (Hedgecoe and
Martin, 2003; Hedgecoe, 2004; Hedgecoe, 2010). In sum, the majority of
social studies of expectations confined themselves only at the level of
analysing the role of expectations (the positive as well as the pessimistic
approach) in the development of a technology (Brown, et al., 2000;
Hedgecoe, 2004; Tutton, 2011). The growing literature in this area, does not
address the ethical and social implications if a particular set of expectations
fails to achieve the promised results. Yet, high expectations may result in the
proliferation of immature and unproven applications of technologies and can
have serious impacts on patients (Petersen, 2009, 2011). Moreover, in a
situation when there is a legal protection to inflated promises in countries
such as the US, the situation becomes more complicated. It can be argued
therefore that there is a need to study the ethical and social implications of
heightened expectations as well, which is largely overlooked in the social
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studies of expectations (Petersen, 2009). In addition, if a state were involved
in expectation rhetoric then it might affect implementation of existing
regulations. This aspect is also not paid attention in the sociology of
expectations.
In addition to analyse the expectations rhetoric of key players who are
associated with the development of stem cells, the aim is also to investigate
the construction of ethical boundaries of different key players and the raised
ethical issues in the background of growing activities of stem cells and
expectations attached with these activities. It would worth to examine
previous work related to sociology of bioethics.
2.6 Sociology of bioethics
Bioethics emerged in the late 1960s to study the ethical problems in medical
research and biomedical sciences. It evolved from the field of medical ethics
when established principles failed to answer some of the emerging
philosophical questions associated with the advancement of biomedical
sciences (Bhardwaj and Macer, 2003; Sherwin, 2011). In recent years it has
come to be viewed as a mechanism to protect vulnerable populations from
exploitation in the course of being research subjects and to resolve wider
social conflicts and ethical dilemmas which arise with new developments in
the area of medicine (Salter and Jones,2002).
66
Van Rensselaer Potter is credited with coining the term 'Bioethics' in 1971 in
his book, Bioethics: Bridge to the Future (Reich, 1994). Potter characterised
bioethics as "a new discipline that combines biological knowledge with a
knowledge of human value systems ... I chose bio- to represent biological
knowledge, the science of living systems; and I chose -ethics to represent
knowledge of human value systems" (Potter 1975: 2297-2299; cf. 1971: 2
cited in Reich, 1994). The emergence and establishment of bioethics was
coupled with the development of biomedicine and biotechnology. After the
Second World War, significant changes in the conduct of research and
governance of medicine took place with the increasing involvement of human
subjects in medical research. This led to the formation of the Nuremberg
Code3 (1947) and the 1964 Helsinki Declaration to protect human participants
in biomedical research following the abuses of the Nazi death camps. Further,
the development of recombinant DNA technology in the early 1970s opened
up the possibility of 'genetic manipulation' of plants and animals, including
human beings. These developments raised major ethical and social issues. To
address these issues, a series of discussions and academic programmes was
started; as a result of these efforts, by the late 1970s bioethics had become
firmly established as a discipline in the West (Engelhardt et al., 2009). Much
Anglo-American bioethics is based on certain basic principles developed by
3 The Nuremberg Code was formulated in Nuremberg, Germany after the judgment in a trial
where 23 scientists and clinicians where accused of the killing and murder of human
participants during the medical experiments in the concentration camps (Shuster, 1998).
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Tom Beauchamp and James Childress in their book, Principles of Biomedical
Ethics (2001), first published in 1979 (Petersen, 2011); so-called principlism.
2.6.1 Principles of bioethics
Within principlism there are four basic principles which can be used to help
make moral decisions in health care practice: a) Autonomy; b) Beneficence; c)
Nonmaleficence and d) Justice (Beauchamp and Childress, 2001). These
principles primarily aim to protect patients from possible exploitation during
biomedical research such as clinical trials and therapeutic interventions.
Autonomy is based on the principle of 'respect for persons' and emphasises
that patients/individuals should make their decision without any interference
from outside while encountering any biomedical research or therapeutic
interventions. Beneficence argues for the overall benefit of a patient by
improving her/his quality or length of life. Nonmaleficence advocates that
there should be no harm to a patient; and finally Justice addresses the equal
distribution of health care services. Although these principles are viewed as
essential guides to protect human subjects in biomedical research, there are
various critiques on the grounds that they ignore important social, religious
and cultural considerations while applying these principles and are dominated
by a Western-centric approach, especially of the US (Petersen, 2011; Ryan,
2004). In addition, these principles themselves are subject to internal conflicts
(Sutrop, 2011). For instance, there is always a confrontation on "whether
respect for the autonomy of patients should have priority over professional
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beneficence" (Wolpe, 1988: 45); more specifically, whether a patient knows
better than a physician what is good for her/him.
Various studies within multiculturalism, feminism, disability rights, and
sociology have highlighted the limitations of bioethics principles by offering
more rigorous sociological studies of bioethics (Azetsop and Rennie,2010; Fox
and Swazey, 1984; Petersen, 2011; Ryan,2004; Sherwin, 2008; Turner, 2003).
In particular it has been argued that there is a gap between bioethical
principles and 'lived experience' in clinical settings (Hegoecoe, 2004). In
addition, it has been suggested that the principles of bioethics mainly deal
with the decision-making process and doctor-patient relationship and they
largely overlook the ethical implications of specific technologies (Petersen,
2011).
2.6.2 Social studies of bioethics
The main argument made by scholars working on the sociology of bioethics is
that for bioethicists there is a need to understand the social contexts in which
a particular ethical issueemerged.
The principle of autonomy has been given foremost importance amongst the
four principles of bioethics in the majority of bioethical discourse and it is
seen as one of the most important tools to protect human subjects and
patients (Azetsop and Rennie, 2010; Corrigan, 2003; Helsinki Declaration,
2008). This principle advocates that individuals should have control over the
decision-making process,as to whether to participate as a research subject or
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allow any therapeutic interventions (Helsinki Declaration, 2008). Beauchamp
and Childress state that " ... the core idea of personal autonomy is an
extension of political self-rule to self-governance by the individual: personal
rule of the self while remaining free from both controlling interferences by
others and personal limitations such as inadequate understanding, that
prevent meaningful choice" (Beauchamp and Childress 1989: 68, quoted in
Corrigan, 2003: 770).
This highly individual centric approach has been a matter of criticism
worldwide since it ignores certain cultural, social and institutional
environments which might have influence on the decision-making process of
a particular individual (Corrigan, 2003; Kara, 2007). Azetsop and Rennie
(2010) highlighted that various cultures, such as the Jewish, Confucian and
African, perceived human beings not only as individuals but also the part of
society to which it belongs. In Tonga, a South Pacific island, there was an
opposition to a genetic database of the population on the basisthat it hasnot
taken the consent of the extended family (Burton, 2002; Corrigan, 2003).
Similarly, in India, family and the largely patriarchal nature of the society have
influenced medical decision making (Kumar, et al., 2012). Apart from socio-
cultural factors, the economic status and the level of literacy also have an
impact on the decision-making process, which is also not given proper
attention while ensuring the principle of autonomy (Bhan et al., 2006; Dein
and Bhui, 2005; Kumar, et al., 2012). It is argued that in India poor people
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take part in clinical trials with ritual informed consent in order to avail free
treatment (Srinivasan, 2009).
2.6.3 Autonomy and informed consent
'Respect for autonomy' is meant to be ensured through the mechanism of
'informed consent', which was established as a key principle in biomedical
research and therapy after the Nuremberg Trials in 1946, popularly known as
the Nuremberg Code. Subsequently, informed consent was given prime
importance through international guidelines formulated by organisations such
as the World Medical Association (Helsinki Declaration 1964) and the Council
for International Organisations of Medical Sciences (ClaMS) (Boulton and
Parker, 2007). Informed consent is conceptualised as;
"consent that is voluntarily given (or refused) in response to a
prior, explicit disclosure, detailing the nature, risks, costs,
benefits and side-effects of a proposed course of action
(perhaps with a specification of the risks, costs, benefits and
side effects of alternative courses of action, or of taking no
action at ali). Informed consent is something much more
specific than 'simple' consent in that it involves specific
obligations to inform patients and research subjects about the
nature, risks and side effects of a proposed course of action"
(Manson, 2007: 300).
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Informed consent initially started with the emphasis on research ethics but
later also extended to clinical ethics (Manson and O'Neill, 2007). However,
both in the caseof research aswell as in clinical settings, it has been observed
that the individual centric approach is problematic not only in developing
countries such as India and China,where an individual is highly dependent on
her/his family to make free and informed choices, but also in Western
countries such as the USand the UK,where an individual appears to be more
independent in terms of her/his decision-making process (Corrigan, 2003;
Dein and Bhui, 2005). It has been argued that various social aspects and
largely paternalistic and autocratic clinical settings have a profound influence
on the procedure of informed consent, by and large, everywhere. Dein and
Bhui (2005) have argued that, for ethnic minority groups in the UK, the
individual centric approach of informed consent is not meaningful since, even
after living in the UKfor many years, they still adhere to their own culture and
traditions where other family members have an impact on their decision. In
addition, an individual centric approach is problematic in certain research
areas such as genetics and genomics, where information provided by a
particular individual may have an impact on other family members (Boulton
and Parker, 2007). In the UK, events in the past decade have called into
question the assumption that informed consent is embedded in Western
medical practice. For example, the Alder Hey 'scandal' of organ retention in
the UK was seen to reflect the paternalistic and autocratic nature of the
medical community, where organs or tissues of dead children were retained
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without the informed consent of parents (Dyer, 2000; Leith, 2007).
Furthermore, the widely-publicised death of JesseGelsinger during a gene
therapy clinical trial in the US suggests that there is a need to go beyond
'informed consent' as an ethical mechanism in biomedical research and to
recognise that even fully 'informed consent' does not always guarantee to
protect patients from possible harm (Savulescu,2000; Wilson, 2009).
The procedure of informed consent also needs to be seen in the background
of high expectations associated with biomedical research and therapy. The
study of Larry Churchill and his colleagues with respect to gene therapy
illuminates that inflated promises of potential therapy can have an impact on
the functioning of informed consent (Churchill et al., 1998). In the current era
of biocapital, there is an immense pressure on researchers for funding and
'breakthroughs' and this leads to exaggerated claims and high expectations. It
attracts patients for an immature therapy, especially those who are terminal
and desperate. The gene therapy in the past and the growing phenomenon of
'stem cell tourism' are good examples for the same (Petersen and Seear,
2011). Biomedicine, which is an integral part of biotechnology venture, often
proliferates on the basis of 'hope' and 'high expectation' and it is not
surprising to see the dilution of informed consent against this backdrop
(Churchill et al., 1998).
It is often highlighted that the level of literacy can have a profound impact on
the procedure of informed consent, especially in those developing countries,
where the level of education is comparatively low compared to developed
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countries (Bhutta, 2004; Marshall et al., 2006). Whilst studying the informed
consent procedure in India, it is observed that the low level of literacy often
affected the functioning of informed consent as, for most of the research
subjects or patients, it is very hard to understand information sheets (Bhan et
al., 2006; Jhanwar and Bisnoi, 2010; Nirmalan et al., 2004). However, it is not
the case for only illiterates; in a recent study in the UK confined to cancer
trials, a similar problem was observed. It was found that the language of the
information sheet was over-complicated, poorly structured and too technical,
and participants find that it is difficult to understand (Armstrong et al., 2012).
The above discussion reflects that the functioning of informed consent is
subject to various social and cultural factors. This is the reason behind the
formulation of the International Ethical Guidelines for Biomedical Research
Involving Human ResearchSubjects in 1993 by the Council for International
Organisations of Medical Sciences (CIOMS) and the World Health
Organisation (WHO). It highlighted the limitations of the Declaration of
Helsinki in developing countries and argued to consider particular cultural
values and multiple health care systems while applying universal ethical
standards.
2.6.4 International guidelines and terminally-ill patients
International guidelines, whether it is the Helsinki Declaration or CIOMS
guidelines, mainly aim to protect human research subjects. Given the
mandates of these guidelines, especially with regard to
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experimental/unproven treatments, it appears that, for terminally-ill patients
who have exhausted all treatment options, these guidelines are unable to
provide enough safeguards against possible exploitatlon. For instance, the
ClaMS guidelines stated that "persons who have serious, potentially disabling
or life-threatening diseasesare highly vulnerable. Physicianssometimes treat
such patients with drugs or other therapies not yet licensed for general
availability because studies designed to establish their safety and efficacy
have not been completed. This is compatible with the Declaration of Helsinki,
which states in Paragraph 32: "In the treatment of a patient, where
proven ...therapeutic methods do not exist or have been ineffective, the
physician, with informed consent from the patient, must be free to use
unproven or new...therapeutic measures, if in the physician's judgement it
offers hope of saving life, re-establishing health or alleviating suffering.' Such
treatment, commonly called 'compassionate use', is not properly regarded as
research, but it can contribute to on-going research into the safety and
efficacy of the interventions used" (ClaMS, 2008: 65-66). Though these
guidelines put emphasis on informed consent before doing so, nevertheless,
given the complexity in the proper functioning of informed consent, there is
no guarantee that a particular patient will be not exploited (Bhutta, 2004).
Moreover, the 'compassionate use' seems to be complicated, given that no
single mechanism could be developed worldwide. In the European Union
significant variations have been observed regarding the regulatory
mechanism dealing with 'compassionate use'. For example, in four countries
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(Hungary, Ireland, Sweden and the UK) there are no formal regulatory
systems, yet in other countries there are legislations, which are not uniform
and are varied both in content and comprehensiveness (Whitfield et al.,
2010).
It resonates from the above discussion that there is a discrepancy at world
level to address the disease conditions for which there are no treatment
options available. This suggests that the international community largely fails
to develop a uniform mechanism to address the use of unproven therapies on
terminally-ill patients. However, many countries have state-sanctioned
professional regulations, such as the General Medical Council (GMC) UK and
the Medical Council of India (MCI), which have enough statutory power to
punish a clinician, if the profession feels that the intervention of particular
medical practice is unjustified.
In addition to certain limitations of these international ethical guidelines,
many countries are reluctant to implement these guidelines on certain
grounds. Recently, in October 2008, the US Food and Drugs Administration
(FDA) made the decision to abandon the Declaration of Helsinki for
international clinical trials and it has ruled that, instead of the Helsinki
Declaration, the International Conference on Harmonisation of Good Clinical
Practice (GCP)will act as a regulatory standard for the clinical trials conducted
outside the US (Goodyear, 2009; Kimmelman et al., 2009). The rationales
behind this step are: a) the Helsinki Declaration is subject to frequent
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revision, which creates confusion:" and b) any future modification might be
inconsistent with the USlaws and regulations. It should be worth highlighting
here that the US FDA was working on the idea to refuse the Helsinki
Declaration since 2001 after the revised version of the Declaration in 2000
which put more restrictions on placebo-control trials in developing countries
(Kimmelman, et al., 2009). This restriction is viewed as an impediment to
prove the efficacy of a new drug (Wolinsky, 2006). However, the step of the
US FDA has met with criticisms as unwillingness to fully implement the
Helsinki Declaration offers less protection to research participants and more
protection to the pharmaceutical mdustrv",
Similar to the USFDA,the European Commission hasalso rejected the revised
versions of 2000 and 2004 of the Helsinki Declaration and has adhered to the
1996 version of the Declaration, which is comparatively less stringent
(Wolinsky, 2006).
It appears that international communities are largely unwilling to adhere to a
stringent ethical document in the background of financial and industrial
interest and 'scientific' arguments, especially in dealing with clinical trials in
developing countries. This reflects that ethics is negotiated on several counts
4 The Declaration of Helsinki to date has been revised eight times after its formulation in
1964.
5 Requirements in the latest version of the Declaration of Helsinki but are absent in GCPare:
a) Investigators to disclose funding, sponsors, and other potential conflicts of interest to both
research ethics committees and study participants; b) Study design to be disclosed publicly
(e.g. in clinical trial registries); c) Research, notably that in developing countries, to benefit
and be responsive to health needs of populations in which it is done; d) Restricted use of
placebo controls in approval process for new drugs and in research done in developing
countries; e) Post-trial access to treatment; f) Authors to report results accurately, and
publish or make public negative findings (Kimmelman et al., 2009: 14).
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in a particular context. The sociological point of view informs us about the
concept of ethical-boundary work (Frith et al., 2011; Hobson-West, 2012;
Wainwright et al., 2006a).
2.7 Ethical boundary-work
The idea of ethical boundary-work is developed from Thomas Gieryn's
concept of boundary-work (Gieryn, 1983). The concept of boundary-work
focuses on the construction of boundary between science and non-science,
which is defined as the "attribution of selected characteristics to the
institution of science (Le. to its practitioners, methods, stock of knowledge,
values and work organization) for purposes of constructing a social boundary
that distinguishes some intellectual activity as non-science" (Gieryn, 1983:
782). Recently, this concept has been used to analyse the construction of a
host of boundaries between 'ethical'/'unethical' or 'Iegitimate'/,illegitimate'
practices in areas related to biomedicine such as stem cells and infertility
clinics and animal research field (Frith et al., 2011; Hobson-West, 2012;
Wainwright et al., 2006a).
Originally the concept of ethical boundary-work was proposed by Steven
Wainwright and his colleagues to "explore how scientists draw the
boundaries of ethical scientific activity" (Wainwright et al., 2006a: 735). The
ethical boundary-work argues that non-science, in the form of ethics, is an
integral part of science to maintain its image, unlike Gieryn's boundary-work,
which focuses on the demarcation of science from non-science. Furthermore,
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ethical boundary-work "differentiates between scientists, enhances the
authority of 'non-science' (e.g. regulatory bodies) and de-privileges science"
(Wainwright et al., 2006a: 735). However, Hobson-West (2012) questions that
the use of language 'de-privileges science' as it echoes that science and ethics
are fixed domains and are engaged in some kind of battle for authority. She
argues that reference to 'non-science' (society or regulation) is "more likely to
be just one point on the route towards the overall positioning of scientists
and biomedical research as legitimate" (Hobson-West, 2012: 12-13). By
quoting Gieryn,6 she attempted to highlight that, similar to science, the
boundaries of ethics might be also flexible and seemingly both are 'co-
constructed' (Hobson-West, 2012).
The US FDA decision to abandon the Helsinki Declaration for overseas clinical
trials and the adaptation of a comparatively less stringent ethical document
for the same could be seen as an example of flexible boundaries of ethics.
This step of the US FDA also illustrates that ethics is subject to 'scientific' and
commercial interest. It can be argued, therefore, that science and ethics are
flexible and 'co-constructed' in the background of commercial interest.
It would be interesting to investigate in this preceding context, how various
players in India are constructed ethics or legitimate their activities. This is one
of the main focuses of Chapter 6. The Chapter 1 highlights that unproven
clinical activities of stem cell have raised not only ethical concerns but also
governance concerns. This informs us to investigate the existing biomedical
6 '''Science' is no single thing: its boundaries are drawn and redrawn in flexible, historically
changing and some-times ambiguous ways" (Gieryn, 1983: 781).
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governance framework in India and to analyse why it fails to regulate those
stem cell activities which are not proven. The next section of this chapter
discusses different conceptual framework of governance including the
approach of scientific governance and existing stem cell governance regime in
different countries.
2.8 Governance
Science has travelled a long distance from Mertonian norms to Mode 2
knowledge. Arguably, science has transformed from public good to financial
good (Jacob, 2009). It has become a business enterprise and attracted great
interest from governments and industries across the world, given its
enormous power in nation building. During 2007, for example, the USspent
US $377 billion and China invested US $102 billion on research and
development in science (Hasan et al., 2012). In the 2009-2010 union budget,
India has increased its R&D budget by 17% (US $5.8 billion) (Jayaraman,
2009). Over the years science promises to solve various problems of society
related to health, hunger and livelihood. However, the development of
science and technology has also raised several ethical, legal and social issues;
for instance, the BSEcrisis in the UK, commercialisation of GM crops in India
as well as Europe, and on-going concerns about nuclear power in different
parts of the world, including India. The debate around stem cell research can
be seen in this wider context in which various issues associated with these
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scientific developments have forced different nation-states to accommodate
societal concerns. How this interaction between government and society in
the broadest sense (to include a variety of organised stakeholders from
industry, the professions and civil society) should be conceptualised is an
important question for investigating the way in which the domain of stem cell
research and therapy in India is governed.
2.8.1 Defining governance
The term 'governance' is used in a variety of ways and has a variety of
meanings. Governance is conceptualised in a wide range of disciplines such as
sociology, political science, public policy and international relations, which is
one of the reasons behind the different notions of governance which is
influenced by the particular disciplinarv approach. Governance is seen as a set
of relationships between government and its citizens which can be variable
from a state-centric approach to a societal-centric approach (Howlett et al.,
2009). Kooiman (1993) perceived governance as an interaction between
government and society. He refers to governance as "arrangements in which
public as well as private actors aim at solving problems or create societal
opportunities, and aim at the care for the societal institutions within which
these governing activities take place"(Kooiman, 2000: 139). Rhodes (1997: 15)
conceptualises governance as a new process of governing which "refers to
self-organising, inter-organisational networks characterised by
interdependence, resource exchange, rules of the game and significant
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autonomy from the state." For Richards and Smith (2002: 2), "governance is a
descriptive label that is used to highlight the changing nature of the policy
process in recent decades. In particular, it sensitized us to the ever-increasing
variety of terrains and actors involved in the making of public policy. Thus, it
demands that we consider all the actors and locations beyond the 'core
executive' involved in the policy making process."
Various international organisations such as the World Bank and United
Nations Development Programme (UNDP) conceptualise governance in
different ways. The World Bank perceives governance as an exercise to
manage a country's social and economic resources for development; on the
other hand the UNDP relates governance to sustainable human development
(Kitthananan, 2006). These varieties of meanings of governance compel us to
analyse governance in great details. The following section discusses some
approaches of governance including scientific governance.
2.B.2 Analysing governance
2.B.2.1 The propositions
Gerry Stoker has set out five propositions for better understanding of the
governance theory. According to Stoker (1998) these five propositions are: a)
Governance refers to a set of institutions and actors that are drawn from but
also beyond government. This proposition challenges the highly government
centric approach. It informs about the involvement of private and voluntary
institutions in service delivery and the decision making process;
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b) Governance identifies the blurring of boundaries and responsibilities for
tackling social and economic issues. This proposition blurs the boundaries
between state and other private actors. It shifts the responsibility from the
state to different stakeholders. The problem underlying this proposition is
that it becomes very difficult to fix any responsibility on either state or other
actors in the case of failure of any policy decision; c) Governance identifies
the power dependence involved in the relationship between institutions
involved in collective action. The idea here is that, in the governance
mechanism, where multiple institutions are involved, no single organisation
can easily command, though one institution can playa dominant role. This
proposition resonates that governance is an interactive process, based on
collective action. However, it is argued that dependence on others often
results in a lack of co-ordination; d) Governance is about autonomous self-
governing networks of actors. The formation of self-governing networks is
one of the fundamental features of governance. It is perceived as more
effective than government imposed regulation. It not only influences the
policy of the government but also takes over the business of government.
However, the dominance of certain elite actors and the problem related with
accountability poses a limitation to this proposition. The critics argue that
self-governing networks work for their own interest rather than for society at
large. The intervention of government therefore becomes inevitable to steer
and guide the networks; e) Governance recognises the capacity to get things
done, which does not rest on the power of government to command or use
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its authority. This proposition sees government as able to use new tools and
techniques to steer and guide the activities of different groups.
2.8.2.2 The 'old' governance and 'new' governance approach
These two perspectives of governance were highlighted by Peters (2000). The
'old' governance focused on the capacity of the government to govern the
economy and society while the 'new' governance focused on either the self-
steering capacity of societies or the interaction between state and society at
various levels (Peters, 2000; Raman, 2002). These two approaches can be
characterised as a state-centric approach and a society-centric approach,
respectively (Kitthananan, 2006).
2.8.2.3 Governance as structure and as process
Beyond this perspective of 'old' and 'new' governance, Pierre and Peters
(2000) have postulated the governance as structure and as process. They have
discussed four structural arrangements of governance: a) Governance as
hierarchies; b) Governance as markets; c) Governance as networks; and d)
Governance as communities.
2.8.2.3.1 Governance as structure
a) Governance as hierarchies
This structure of governance is based on the assumptions that "governance
conducted by and through vertically integrated state structures is an idealized
model of democratic government and the public bureaucracy" (Pierre and
Peters, 2000: 15). It is a top-down approach. Here the idea is that state
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governs society through the mechanism of command and control by imposing
law and regulation and never gives up its legal right to other institutions. In
the backdrop of increasing globalisation and liberalisation, however, critics
argued that this form of state-led governance is no longer relevant (Pierre and
Peters, 2000). It is contended that translation organisations such as the EU
and WTO influenced the policy decision of nation-states (Pierre and Peters,
2000). However, Pierre and Peters (2000) emphasised that these institutions
actually serve the interests of the nation-states and are dominated by their
interests. Therefore, various transnational institutions are actually indirectly
dominated by the interests of states. Furthermore, "governance through
hierarchies still plays an important role in a surprisingly large number of
national and institutional contexts" (Pierre and Peters, 2000: 18). For
instance, in Britain, central government still has political control over local
authorities in the form of audits. Similarly in Germany, regional and local
authority has control over public services. However, this power is at the
discretion of the government and can be resumed at any time (Pierre and
Peters, 2000). In India, though, local bodies; Panchayats in rural areas and
Municipalities in urban areas are recognised by the 73rd and 74th
constitutional amendments; it is argued that enough powers are not devolved
to these local authorities by the national government (Steytler, 2005).
b) Governance as markets
In this governance framework, the market is seen to be a dominant factor and
the most efficient way of governing resource allocation. It is believed that the
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market-led governance is free from politics and hence can empower citizens
in the same way as consumers. In the case of public services, similar to the
market situation, they provide for citizens to choose services directly and
there is no dependency on elected or government officials for the same.
However, this form of governance is dominated by self-interest of actors and
it is seen as a problematic. Pierre and Peters (2000) argued that this form of
governance is problematic "because of the atomistic and anonymous nature
of the market and its actors" (p. 19).
c) Governance as networks
This form of governance is basedon the network of a wide variety of actors in
a given policy sector. It is contended that, "policy networks facilitate
coordination of public and private interests and resources and, in that
respect, enhance efficiency in the implementation of public policy" (Pierre
and Peters, 2000: 20). However, policy networks of actors are more aligned
towards self-interest rather than the collective interest of society. In addition,
these policy networks have influence on the state policies which can be
viewed as anti-democratic. One of the main drawbacks of this form of
governance is to maintain proper co-ordination between the state and policy
networks. The common interests of varied actors tend to challenge the
domination of the state and the state feels that its policy initiatives are
obstructed by policy networks. In sum, it can be argued that policy networks
play an important role in policy implementation.
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d) Governance as communities
Here the idea is that communities can deal with their common problems with
a minimum intervention from the state. It is argued that the care of children
and elderly people can be organised in a more efficient manner by the
communities themselves. The supporters of this form of governance believe
that the bureaucratic structure is too complicated to deal with these types of
issues. Pierre and Peters (2000: 21) argued that "communitarian governance
builds on a consensual image of the community and the positive involvement
of its members in collective matters. The state is believed to be too big and
too bureaucratic to deal with these issues". However, this form of governance
is also limited on account that individuals are not always ready to sacrifice
their personal interest for the common good at community level.
2.8.2.3.2 Governance as process
The above discussion of different ways of governance has shown the
structural arrangements of governance. Governance as structure (hierarchies,
markets, networks and communities) is based on the assumption that, for a
'right' form of governance, there is need to manage structural arrangement.
In contrast, governance as process emphasises outcomes rather than
structural and institutional arrangements. The governance as a process
perspective is concerned more about interactions among structures rather
than structures themselves. Governance is conceived as a process of steering
and coordination of a given sector where states dominate. However, this
approach does not discard institutional arrangements entirely as it is
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important to decide the roles of the state. This perspective of governance
argues that "states are still indeed capable of (steering' society; only now its
authority is less based on legal powers and more due to its control over
critical resources" (Pierre and Peter, 2000: 23).
Out of a variety of notions of governance, for Pierre and Peters, the hierarchy
mode of governance is still dominant. While discussing the different ways to
think about governance, Pierre and Peters (2000: 25) argue that "the role of
state is not decreasing as we head into the third millennium but rather its role
is transforming, from a role based in constitutional powers towards a role
based in coordination and fusion of public and private resources". Against this
backdrop of state-led governance, the next section has attempted to
investigate whether in the governance of science as we" as the state
dominates.
2.8.3 Analysing scientific governance
In STS discourse, governance is conceptualised as both a top-down and a
bottom-up approach, as reflected from various studies. Irwin (2008) argued
that governance is not simply a matter of a nation-state and a defined set of
bureaucratic institutions; rather it encompasses a wide range of actors, which
includes scientific organisations, consumers, industry, markets, and pressure
groups. It was viewed as a step away from the traditional government
approach (a top-down legislative approach to regulate the activities of people
and institutions) to governance (a bottom-up approach which encompasses
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more participation of different stakeholders in the decision-making process).
More specifically, 'governance' is the replacement of traditional 'powers over'
with contextual 'powers to' (Lyall and Tait, 2005: 3). It is a step in which the
divergent public views are translated into a policy-making process. According
to Gottweis (2005) the concept of governance minimises the dominant-state
role in society.
It does not mean, however, that the 'traditional' form of governments or
governmental institutions has no more relevance in governing science. This
relevance still exists and is playing a crucial role in the policy-making process
across nation states. 'Traditional' governments continue to playa vital role in
the development of science and technology (Gottweis, 2005). Salter and
Jones's conceptualisation echoes the dominant role of state in governance,
especially of scientific governance, as they argued that, "Governance is the
general process of accountability used by governments to monitor and shape
those areas of economic and social activity for which they are responsible.
Regulation is a specific form of governance that is characterised by standard
setting, monitoring and, where necessary, corrective intervention of defined
areas of activity" (Salter and Jones, 2002: 810). Some scholars believe that
science still requires a hierarchical mode of governance, i.e. "conventional
command and control style regulation" (Lyall et al., 2009: 2). The
controversial technological developments such as stem cells, GM crops, and
nuclear power and many more which have raised profound ethical, social and
safety issues might be the reason to advocate state-led governance. It has
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been observed that most of the science policies worldwide rely on legislation
(Lyall et al., 2009). The stem cells science is a good example for the same,
which is governed by legislation in most countries.
2.8.4 Governance and stem cells
Stem cells as a promising scientific venture have attracted considerable
attention at government level worldwide. However, the same science is dealt
with differently in different countries, which informs us that, in the
governance process, the state still plays a leading role and a particular
governance mechanism is subject to a particular political system. It can be
better understood by Sheila Jasanoff's comparison of biotechnology debates
in the UK, Germany and the US. In her concept of 'National Styles of
Regulation', she stated that, "Regulation, it emerged, displayed distinctively
national characteristics, leading to observable differences in the timing,
priorities, forms, and stringency of interventions. Scientific evidence was
shown to carry different policy environments, its interpretation conditioned
by home grown traditions of legal and political reasoning and habits of
deference or scepticism toward expert authority" (Jasanoff, 2005: 17). The
'National Styles of Regulation' informs us that governance of science varies
acrossdifferent political systems.
In the case of stem cell governance this variation is significantly observed.
There is a considerable ambiguity and uncertainty on the issues of
governance of stem cells. The international and regional jurisdiction policies
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and practices are highly varied along with public opinion. The diverse religious
and cultural norms shape the stem cell policies globally (Caulfield et al., 2009).
The legal governance framework varies from strict to moderate and finally no
regulation at all (Table 1).
Table 1. A small sample of how regulations governing human ES cell
research differ from country to country:
country Imported Deriving new human Deriving new
lines ES cell lines from lines through
excess IVF embryos nuclear transfer
Italy Allow Prohibit Prohibit
Germany Allow Prohibit Prohibit
United Kingdom Allow Allow Allow
Ireland Prohibit Prohibit Prohibit
Denmark Allow Allow Prohibit
Canada Allow Allow Prohibit
Source: Caulfield et al. (2009)
For example, the restrictions on stem cell research in Germany are much
more stringent than in the US (Gottweis, 2002). These policy variations exist
not only across nation-state level but within the jurisdiction of a single nation-
state. For example, in the USdifferent states have different rules for gametes,
embryos and the derivation of new Human Embryonic Stem cell lines, and
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their uses. This disparate approach on the same issue is termed a 'patchwork
of patchworks' (Caulfield et al., 2009). The legal variations across different
countries lead to the exploitation of patients by a phenomenon, characterised
as 'stern cell tourism' where patients seek unproven therapies across the
border countries where there is a lack of proper legislation to govern stem
cell research and therapy (Caulfield et al., 2009; Ryan et al., 2010). This
demands a harmonisation of policy across the world, at least at the level of
research standards and clinics. The initiative of the International Society for
Stem Cell Research, International Stem Cell Banking and European Human
Embryonic Stem Cell Registry has been seen as an effort to harmonise policies
across countries (Caulfield et al., 2009). However, these efforts are so far not
effective, given the politicisation of stem cell science globally. Brian Salter
argued that, in the case of stem cell science, "a range of cultural values
support, oppose, or are indifferent to its progress, and these have to be
politically negotiated by states and institutions with an interest in promoting
it" (Salter, 2007: 278).
It is clear from the above discussion that stem cell governance across the
world is greatly influenced by particular social and cultural factors. This
suggests that despite the dominance of state-led governance other forms of
governance are playing an important role in policy formulation. Against this
backdrop it would be interesting to see as per thesis aims-what is the existing
mechanism of stem cell governance in India and more importantly why it fail
to regulate experimental stem cell based treatments?
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2.8.5 Governance and policy implementation
Pierre and Peters (2000), while analysing the different modes of governance,
have attempted to understand the capacity of government to steer society
i.e. the competence of government to formulate policy and its
implementation. It is reflected from their state-centric approach of
governance that the policy implementation is highly dependent on other
modes of governance. They argued that policy networks and civil society play
an important role in the implementation of public policy. They either help or
obstruct the implementation process which is subject to their co-ordination
with the state and their own interest.
Makinde (200S) has observed that the involvement of different stakeholders
in the policy-making process is one of the essential components for successful
policy implementation. In addition, various social, cultural and economic
factors also affect the implementation of policies. It is argued that when these
factors do not take into account at the level of policy formulation, it often
results in implementation gap (Makinde, 200S). It appears that, to address
the implementation gap, public consultation has been become major thrust in
many countries while formulating policies, especially for controversial issues
in scienceand technology (Marchant and Askland, 2003).
In recent years, we have witnessed public consultation on sensitive issues
(e.g. GM crops, stem cell) to accommodate various societal concerns in
developing governance framework in developed as well as developing
countries (Irwin, 2006; Padma, 2010; Shankar, 2011; The Economist, 2010).
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However, the credibility of public consultation is often questioned on the
issue such as the wider participation of the general public and the procedure
of public consultation itself (BBC,2003; Durodie, 2003; Gill, 2010; Gray, 2010;
Irwin, 2006).
2.9 Summary and discussion
The aim of this Chapter was to examine various issues associated with the
proliferation of stem cell biomedicine which reflects that there are many
unresolved ethical, legal, social and economic issues attached with its
development. The other aims were to discussthe sociology of biomedicine in
general and India in particular in order to understand the contextual
development of stem cells in India. The various understandings of
biomedicine reflect that biomedicine is used largely as a commercial
enterprise and exercising power on citizens. The discussion related to Indian
biomedicine shows that primarily it serves the wealthy and influence
population of the society and various important public health issues which
affects the large section of the society are largely ignored by the government
of India. The growing activities of stem cell in India are also a part of this
biomedical venture and therefore it can be argued that stem cell also carries
the similar characteristic of biomedicine which has been discussed in this
Chapter. To examine the current development of stem cell including
expectations discourse, ethical construction and existing governance regime
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this Chapter has discussed analytical approach of sociology of expectations,
sociology of bioethics including ethical boundary-work and different
approaches to understand governance framework. The data chapters 4-7 is
analysed using these frameworks.
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Chapter 3: Methods
3.1lntroduction
The aim of this thesis is to explore the issues related to ethics and governance
with the proliferation of stem cell in India from the perspective of key
stakeholders using an interpretive approach. The study seeks to analyse the
nature of stem cell activities in India, how key players from science, clinical
practice, private firms and government justify or challenge the need for
specific activities and frame the ethical issues they raise, and how
arrangements to govern stem cell activities work in practice. The study
involved a survey, documentary analysis and qualitative interviews with key
actors, including scientists, clinicians, representatives of firms and
policymakers. Following the discussion of key literature pertinent to this study
in Chapter 2, this chapter describes the philosophical standpoint of the
research and the methods which have been adopted in the designing and
execution of this study. More specifically, this chapter attempts to justify the
rationale underpinning the choice of a qualitative research strategy and
methods.
3.2 Philosophical approach
The theoretical approach adopted in this study was informed by various STS
literatures as described in Chapter 2 and beyond. Based on recent trends, the
96
ontological position in STS could be considered as constructivism, which
means that reality is the outcome of social processes. The underlying
assumption in STS is that "science and technology are thoroughly social
activities" (Sismondo, 2010: 10). Within STS, there is a greater thrust to
investigate the constitution of scientific knowledge and technological
artefacts. Science is seen as an active and socially-situated process, and
scholars argue that it should be studied as such (Sismondo, 2010).
Epistemologically, this informs us that knowledge is not value-free, rather
socially constituted; therefore, the phenomenon under consideration should
focus on questions such as 'what counts as knowledge?' and 'how are facts
constructed?' (Bijker, 1993; Sismondo, 2010;). Bryman (2008: 13) notes that
"an epistemological issue concerns the question of what is (or should be)
regarded as acceptable knowledge in a discipline." The underlying assumption
of STS suggests that epistemologically (the nature of knowledge) it is more
close to interpretivism, which emphasises analysing the subjective meaning of
social action. This approach demands the analysis of "the perceptions and
actions of social actors" (Bryman, 2008: 18) which are essential to
understanding any social reality.
However, critics argue that there is a danger in adopting a constructivist
approach (highly human-centric perspective) entirely, as it ignores the
materiality of the social world (Murphy and Dingwall, 2003). It can be argued,
therefore, that the construction of reality is subject to the external
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environment, which needs to be taken into account while applying this
approach.
3.3 Research design
This project is informed by the philosophy of qualitative research. The reason
behind using qualitative research is that it provides an opportunity to study
experiences and views of participants or stakeholders in a chosen study.
Qualitative research emphasises the interpretation of meaning in a given
social world. It is based on the assumption that meaning is socially
constructed. There is no single reality; rather, there are multiple
interpretations of reality which are flexible and change over time. Qualitative
research provides a framework to understand this reality in a particular social
context in a given time (Merriam et al., 2002). Qualitative research is not only
helpful in exploring experiences and views of different stakeholders but it is
also useful in analysing the inconsistency and conflicts of views of various
stakeholders (Jaye, 2002). It is especially suited for finding the answers to
questions such as how, why and in what way (Hancock, 2002). The qualitative
research method helps in understanding the world. Hancock (2002) argues
that it provides an opportunity to know a) why people behave the way they
do; b) how opinions and attitudes are formed; c) how people are affected by
the events that go on around them; d) how and why cultures have developed
in the way they have; and e) the differences between social groups.
98
Against the back drop of this conceptual framework, this research seeks to
investigate the views of different key players associated with stem cell
development in India. Using qualitative research methods provides more
flexibility than quantitative research in this type of research where the main
aim is to explore experiences and views of different key players. This study
puts more emphasis on words rather than numbers (Miles and Huberman,
1984). However, simultaneously this study acknowledges that choice of any
methodology "should depend on the nature of what we are trying to
describe, on the likely accuracy of our descriptions, on our purposes, and on
the resources available to us; not on ideological commitment to one
methodological paradigm or another" (Hammersley, 1992: 163).
In the background of both epistemological and ontological consideration of
STScombined with the nature of study under investigation, a qualitative
research strategy, therefore, was most suitable for the data collection.
The basic interpretive approach was applied to explore ethical and
governance issues,especially the framing and/or understandings of ethics and
problems with the existing system of governance from stakeholders'
perspective and the expectations rhetoric of different key players with
respect to stem cells.The reason is that the interpretive approach provides an
opportunity to explore lithe complex world of lived experience from the point
of view of those who live it" (Schwandt, 1994: 118).This approach is helpful in
understanding how participants construct the meaning of a phenomenon or a
situation. Merriam et al. (2002) argue that basic qualitative study helps lito
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discover and understand a phenomenon, a process, the perspectives and
worldviews of the people involved, or a combination of these" (p.6). This
approach is based on the assumptions that constructions and interpretations
are subject to change over time and qualitative researchers seek to
understand various interpretations in particular time and contexts (Hancock,
2002; Merriam et al., 2002). Data for this research approach are collected
through interviews, observations or documentary analysis (Merriam et al.,
2002).
3.4 Data collection and analysis
For this study, the empirical data were collected and analysed using a survey,
documents and semi-structured interviews. The choice of methods was
pragmatic in terms of their suitability to address the research aims and
questions of the thesis. A survey was conducted to map the stem cell
activities in India. The documents were used to investigate existing policy and
regulatory regime related to stem cells in India and also to analyse how
different key players framed their expectations regarding this line of research
as well as the emerging ethical and governance issues related to the
proliferation of stem cell therapy in clinics. In addition to various documents,
semi-structured interviews were also conducted to have a more nuanced
understanding of stakeholders' perspectives for the same.
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3.4.1 Survey
A survey was conducted to map the current basic research, clinical activities
and cord blood banking. It was helpful to analyse the various activities which
are being undertaken by a range of public and private organisations, including
hospitals, clinics, universities and private companies. In addition this survey
was useful to identify individuals to interview. The survey was web-based and
involved detailed internet searches of all leading Indian medical research
centres, laboratories, hospitals, clinics and stem cell companies. The data
obtained from this survey provided an overview related to the focus of the
basic research, type of service offered, stem cell used, disease target, and
principal investigator.
3.4.2 Documentary analysis
In qualitative research some of the commonly used documents are diaries,
letters, autobiographies, media outputs, visual forms (such as photographs)
and official documents derived from both the state and the private
organisations (Bryman, 2008). According to Altheide (1996), a document can
be any symbolic representation that can be retrieved or recorded for analysis.
Documents are viewed as an invaluable source of data in qualitative research
to reveal underlying social reality (Bryman, 2008; Hoepfl, 1997; Scott, 1990).
However, the available documents are subject to scrutiny on the basisof four
criteria (Scott, 1990: 6): a) Authenticity (Is the evidence genuine and of
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unquestionable origin?); b) Credibility (Is the evidence free from error and
distortion?); c) Representativeness (Is the evidence typical of its kind, and, if
not, is the extent of its untypicality known?) and d) Meaning (Is the evidence
clear and comprehensible?).
3.4.2.1 Collection of documents
This thesis has used media outputs and official documents of various
government and private organisations. Documents are viewed as an
important "source to understand culture - or the process and the array of
objects, symbols, and meaning that make up social reality shared by members
of a society" (Altheide, 1996: 2). As far as media outputs are concerned,
various national and international newspapers were used including science
magazines, television programmes and the internet. The media have been
influential in shaping public attitudes of new emerging technologies,
especially the promises of technologies to address various issues related but
not limited to the environment and health and illness.
For conducting media analysis there is no standard method described; it is
subject to the researcher's interest and relevance (Altheide, 1999). Although
documents have an independent existence, their meaning and significance
depend on researchers' perceptions and questions (Altheide, 1999), and this
makes sampling a prominent issue. The choice of sources, publications and
time-period is crucial as it can have an effect on data generation.
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3.4.2.2 Sampling
For this study, documents since 2001 were chosen, since 2001 was the year
when India's two research centres were selected by the National Institute of
Health (USA)for embryonic stem cell funding, among ten institutions world-
wide (Bharadwaj and Glasner, 2009: 60). Most importantly, the government
of India started taking the initiative for the development of stem cell research
in the year 2001 when, for the first time, the Department of Biotechnology
issued draft guidelines to govern stem cell research in the country (Salter et
al.,2007).
Collection of media documents was done with the help of setting up a Google
Alert with a search term 'stem cell research in India'. This helped me to
monitor day-ta-day newspaper articles, web pages and blogs, and to track
newspaper articles as it was easy to look at various newspapers daily only for
the news specifically related to stem cell in India. In addition to Google Alert,
the widely-used on-line media database Nexis was also used for more
comprehensive news items. With the help of both Nexis and Google Alert a
corpus of 480 news articles was produced. All new articles were downloaded
in rich text format into Microsoft Word for further in depth study. The articles
were read and re-read to look for overlap in coverage of newspapers and
more importantly, to find out the most suitable news items for the purpose of
the study. Finally 73 news articles were selected for in-depth analysis, most
notably the news items published in India's leading newspapers, The Times 0/
India, The Hindu, The Indian Express and science magazines Biospectrum
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India, Express Healthcare and Express Pharma. These were analysed in more
detail along with news coverage of some key international daily and news
agenciessuch as The Washington Post.
In addition to newspaper articles, this study also analysed policy and legal
documents published by various government agencies, which are related to
stem cell basic research and its clinical practices; for instance, guidelines
formulated by the Indian Council of Medical Research (ICMR), the
Department of Biotechnology (DBT)and the Drug Controller General of India
(DCGI)and various legislations dealing with clinical practices in India including
the Medical Council of India (MCI) Act. The documents from private
organisations such as stem cell firms, which were available on-line, were also
examined. All documents were available on-line; therefore, it was very easyto
use this method in the study.
3.4.2.3 Analysing documents
The documents, especially newspaper articles, were useful in gaining
information regarding various activities of stem cells including locations and
key players. This was not only helpful for Chapters 4-7 but also for the
selection of interviewees. I have used the data from newspapers mainly to
analyse how various media reports portrayed the proliferation of stem cell in
India, especially in terms of expectations of stem cells. This study has not
done widely popular discourse analysis in qualitative research for the same
reason since the aim was not to do so. The policy documents published by the
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government of India were helpful to understand the existing biomedical
governance system in general and stem cell in particular.
Although this thesis and many other studies have used documents for data
generation, and it was worthwhile as far as my purpose of study, using
documents as a standalone method is not so popular in qualitative research.
It is argued that, if using documents solely, a researcher is placed at some
distance from real people (Miller and Alvarado, 200S). Instead, it is argued
that documents can be used in combination with other methods to increase
the comprehensiveness and legitimacy of any single study as the strengths of
one method can compensate for the weaknesses of another method (Patton,
2002). For Patton (2002), combining both interviews and documents is
therefore worthwhile as it can help to overcome potential weaknesses of the
methods on their own; the researcher may get distorted data from the
interview due to personal prejudice, while available documents might not be
complete or accurate or authentic (Bryman, 2008; Patton, 2002).
3.4.3 Qualitative interviews
The interview is one of the most widely-used methods in qualitative research
(Britten, 1995; Bryman, 2004). Qualitative interviews are viewed "as an
opportunity to explore how informants themselves define the experiences
and practices that are the object of the research" (Murphy and Dingwall,
2003: 82). It is argued that interviews (as interactionism) provide a
trustworthy understanding into people's experiences (Silverman, 1993).
lOS
Interviews are a way to gather facts about reality, whether that reality exists
internally in the interviewees' mind or externally in the world (Murphy and
Dingwall, 2003).
Despite popular use of qualitative research interviews in examining the social
reality, it is argued that there is no surety that informants will reveal true
information and the data from interviews might be socially and contextually
constrained (Dingwall and Murphy, 1998). This notion depicts that
representation of truth is questionable in qualitative interviews and hence the
data from interviews should not be examined under the framework of true
and false; rather, it should be viewed as informants' perspective on a
particular phenomenon (Dingwall, 1997).
Several types of qualitative research interviews are described, which include
structured, semi-structured and unstructured (Esterberg, 2002). Qualitative
researchers mostly prefer the use of a semi-structured interview (sometimes
called in-depth interview) because of its flexible nature (Barbour, 2008) as it
allows interviewees to express their opinions and ideas in their own words
(Esterberg, 2002). The semi-structured interview follow an open and informal
interview style (Hardon et al., 2004). It is neither a free conversation nor
highly structured. It focuses on certain themes rather than on exact questions
(Kvale, 1983). The flexible and interactive nature of semi-structure interviews
paves the way to obtain 'insider accounts' (Hammersley and Atkinson, 2007:
97) of a given social phenomenon from the respondents' perspective.
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The semi-structured interview therefore is justified to achieve the aims of this
study.
3.4.3.1 Sampling
In qualitative research, sampling is viewed as a very complex issue (Coyne,
1997). Johnson and Waterfield (2004) stated that the sampling strategy in
qualitative research does not look to accomplish statistical
representativeness; rather, it strives for diversity within the study population.
According to them, "the sample must be sufficient to generate depth rather
than breadth and may comprise a small number of participants or just one"
(Johnson and Waterfield, 2004: 124). Sample size depends upon the research
questions and aims of the study and the type of data to be collected. Curtis et
al. (2000) argued that is why often purposive sampling is employed rather
than probability sampling. However, Murphy and Dingwall (2003: 105) argued
that, "using nonprobability sampling methods in qualitative research is best
seen as a pragmatic compromise between breadth and depth." Therefore it
can be argued that in qualitative research there should be a balance between
depth and breadth of sample size.
This study has employed purposive sampling. The analysis of documents was
very helpful to select informants. In addition, prior contact with some of the
key players during a meeting was very useful for sampling (Devers and
Frankel, 2000). The potential respondents are selected from four different
groups: a) scientists - involved in basic research; b) clinicians - engaged in
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clinical research and medical practice using stem cell; c) firms - involved in
basic research, product development and cord blood banking; and d)
regulators, government agencies, members of ethics committees and
National Apex Committee for Stem Cell Research and Therapy.
3.4.3.1.1 Scientists
Scientists who are involved in stem cell basic research and cord blood banking
were approached for interview. Interviews with scientists aimed to
investigate the current status of stem cell basic and clinical research and their
expectations of stem cells, as well as their views on the ethical and regulatory
problems relating to stem cells in India and the problems of maintaining and
enforcing ethical standards.
Given the nature of this research and its aims, purposive sampling was
desirable. With the help of survey and media analysis, most of the
respondents were selected. Around 15 scientists were contacted via email for
interview. Of these, five scientists expressed an interest to take part in the
research project. It is worth highlighting that I had prior contact with two
scientists, during my M. Phil when I did an on-line survey for the dissertation.
3.4.3.1.2 Clinicians
In India, as described in Chapter 1, there are significant numbers of hospitals
and clinicians offering stem cell based treatments. Given the prominent
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ethical and governance issues related to various stem cell based therapies, I
was comparatively more interested to interview as many clinicians as
possible. Again, newspaper coverage has helped me to select clinicians. In
India, as in many other countries, medical services are being offered by both
the public and the private sectors. The approach was, therefore, to make
contact with clinicians serving in both public and private sectors. An e-mail
was sent to 35 clinicians; of these, 11 clinicians responded and showed
willingness to take part in the study.
3.4.3.1.3 Firnns
Many firms are active in stem cell research and cord blood banking. Before
starting my field work, I was not very sure whether this group of people
would respond to my e-mail as my effort to enrol them in an on-line survey
for my M. Phil in India was largely unsuccessful.However, the participation in
UKNSCN/UKTIIndian stem cell mission seminar in london (15th March 2010)
helped me to establish prior contact with representatives of stem cell firms.
The full credit goes to one of my supervisors, as he suggested to attend this
meeting; it provided me with valuable information about various firms in
India and simultaneously I was able to get personal contacts with
representatives of firms. I would like to stress here that only by attending this
meeting did it become possible to arrange interviews with this largely
unapproachable group. In total, 12 firms were approached through e-mail; of
these seven firms were responded to take part in this study.
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3.4.3.1.4 Regulators/policymakers/members 0/ ethics committees/NAC-
SCRT
With the help of official documents, I selected a few people to contact for the
interview. Again, a prior meeting with a regulator during a one-day workshop
in India has helped me to approach this group of people. I selected ten people
to contact via e-mail; of these three agreed to take part in the research
project. One policymaker/regulator got in touch with the help of another
respondent. In this case, therefore, 'snowball sampling' was used.
3.4.3.2 Justifying sampling
In total, I conducted 27 interviews. It appears to be a relatively small number.
However, all these interviews were conducted with key persons. For instance,
although I conducted interviews only with five scientists, all these are leading
scientists in the area of stem cells. One of the scientists has received NIH
funding for his existing embryonic stem cell lines. Similarly, another scientist
has an international reputation. The embryonic stem cell lines, which are
derived from her, have passed the eligibility criteria from the UK stem cell
bank and are now available for researchers to conduct further research.
Similarly, in the case of firms, I have conducted interviews with those firms
which have invested a significant amount in stem cell R&D and are recognised
as leading firms in the stem sector of India. The majority of the firms which
were interviewed were invited by the UK National Stem Cell Network (UKSCN)
110
and the UK Trade and Investment (UKTI) in 2010 in the UK to foster possible
international research collaboration and business in the area of stem cells.
This suggests the importance of these firms. One of the firms is also the
beneficiary of NIH funding to work further on embryonic stem cell lines. In the
case of policymakers, although I conducted interviews with only four,
including one ex-policymaker, all of them are key informants since they are in
charge of either the stem cell division in the OBT or in the ICMR or are a
member of the newly-constituted National Apex Committee for Stem Cell
Research and Therapy. Similarly, an ex-policymaker is a key person in
biomedical policy areas who has been involved in the biomedical
policymaking process in India for 30 years. Clinicians who were interviewed
are also known as leading medical practitioners in India and are often quoted
in media reports related to stem cell coverage. Some of them are associated
with the state-of-the art hospitals of the country.
Although I conducted interviews with important key persons, I could not
arrange an interview with Dr Geeta Shroff, a clinician who is always quoted in
various academic writings and media reports, and with the officials of the
Medical Council of India (MCI) and the Drug Controller General of India
(DCGI). Dr Shroff refused my invitation by saying that she has no time, and
officials of both the MCI and the DCGI did not respond to my mail. In the case
of the MCI, the reason was that, at the time of my field work, the MCI was in
crisis as its president was arrested on corruption charges. However, my data
collection has not been affected because of the availability of significant
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studies related to Dr Shroff's work (seeChapter 1) and the role of the MCIand
the DCGI.In addition, through interviews with other policymakers I was able
to get valuable information about the MCI and the DCGI.
3.4.3.3 Conducting interviews
Informants were contacted bye-mail with a brief introduction of the project
(see Appendix I and Appendix II). The interviews were conducted in India
during the period June 2010-January 2011 and again during September-
October 2011. All interviews were carried out face-to-face in respondents'
offices and for which I had to travel a lot given the huge geographical area of
India. In general, each interview was around 40-50 minutes; however, in some
cases it was more than one hour and in one case it was only 15 minutes. The
conduct of interviews with clinicians was more challenging as most of them
fixed an appointment at their clinics and during this time patients were also in
the queue. In the midst of our conversation some clinicians tended to talk
with their patients and support staff. The flow of the interview got
interrupted as a result. I believe that conducting an interview in this
environment has affected my data collection. Sometimes I felt guilty that
patients were waiting for their number for several hours while I entered
clinicians' offices to conduct my interview.
Most of the interviews were recorded using a digital recorder with the
permission of interviewees. It has been argued that, in qualitative research,
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the way of saying matters as much as what people say. The taping of the
interview allows for more in-depth analysis of what people say (Bryman,
2004). However, three interviewees refused permission to record the
conversation. In that case I noted down their response.
The interview guide before going into the field was very helpful in conducting
interviews. However, I faced some difficulties in conducting interviews
especially because of weather and traffic. In addition, I encountered
difficulties in fixing appointments with policymakers.
My local supervisor in India is based in New Delhi (Northern region) who is
affiliated to Jawaharlal Nehru University. It was quite natural therefore for me
to go New Delhi and report to him. I reached New Delhi in the last week of
May in 2010. May is the hottest month in India in the Northern region. The
average temperature in this month is usually around 32-40°C and it was not
the ideal time for conducting interviews in New Delhi. However, I started
contacting my informants who were based in New Delhi through e-mail. Initial
days were very disappointing as, for my first interview; I had to wait for one
.month. The reason was that most informants were on holidays during the
summer time. This suggests that timings of starting field work play an
important role in data collection. Then I decided to contact those informants
who were based in the Southern region of India, i.e. Chennai, Bangalore, etc.
(most of the stem cell activities are in this region). The response was
overwhelming and, within eleven days, I conducted eight interviews in
Chennai and Bangalore. However, conducting interviews in various cities in
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India is always very challenging becauseof traffic. Within a city I had to spend
2-3 hours in traffic to reach respondents' office. In Mumbai, becauseof heavy
traffic I missedmy appointment with a clinician. And for another appointment
I had to wait for one week.
To fix an appointment with policymakers was very difficult as no-one
responded to my mail. My local supervisor had helped me in getting hold of a
policymaker by inviting her for a one-day workshop at Jawaharlal Nehru
University. I took this opportunity to talk to her personally about my project
and fixed an appointment. For other policymakers I had to make a telephone
call to arrange an interview.
3.4.5 Interview guide
Interviews were conducted using the philosophy of the semi-structured
interview, which allows freedom for the informants to express their views on
the topic under investigation. The interview guide was developed before
going into the field for the data collection; it includes the key themes and
questions (see Appendix III). Questions were mainly prepared according to
the actors, i.e. scientists, clinicians, the representatives of firms, and
policymakers; however, certain general questions were also asked to every
actor. Questions were refined throughout the data collection process.
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3.4.6 Analysing interview data
The analyses of interview data started first with the transcription, Le. the
written translation of a recorded interview. All interviews were transcribed by
me. Although it was a laborious and time-consuming task, this exercise helped
in bringing me closer to the data in terms of identifying key themes and in-
depth analysisof various narratives of research participants (Bryman, 2008). I
conducted interviews and transcriptions simultaneously as there was some
time between interviews. The initial transcriptions were very helpful in
refining questionnaires further. For emergent themes, transcripts were
analysed by content and then coding was carried out (Strauss, 1987; Weber,
1990). Emerging themes were named and the data obtained from different
stakeholders were collated and included in each of the themes. The analysis
of interview data is presented in Chapters 4-7.
This study has taken into account the ethical issues associated with the
conduction of qualitative research.
3.5 Ethics
Ethical issues in qualitative research are one of the most important aspects
(Orb et al., 2001) which cannot be ignored as they directly related to the
integrity of the research work (Bryman, 2004). There is an imperative to
ensure the anonymity, privacy, confidentiality and informed consent with
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respect to the participants in the research process (British Sociological
Association 2002; Daymon and Holloway, 2002).
This project was designed as per the University of Nottingham's ethical
guidelines and, after approval from the university, field work interviews were
conducted in India. The relevant ethical issues which were taken into account
are described below.
Empirical data were collected using face-to-face interviews and recorded
using a digital voice recorder with the permission of the interviewee. As per
the current research code of conduct guidelines, the interviews will be
retained for seven years. Research participants were asked for written
consent for the recording to take place. The permission was also taken to use
their quotations taken from their answers for the reproduction in my thesis
and any subsequent papers derived from my thesis.
The topic of my research was ethically sensitive given that its aim was to
explore the ethical and governance issues with the help of participants'
perspective. In an ethically sensitive area, there is a greater emphasis to take
care of research participants who are particularly vulnerable in terms of age,
mental or physical health etc (Bryman, 2008). In my case, there was no such
issue as I did not conduct interviews with any vulnerable groups. My
informants were leading scientists, clinicians, representatives of firms, and
policymakers. However, given the increasing unethical clinical activities in
stem cells, there was a possibility of self-incrimination of respondents
(Cowburn, 2005) if, during interview, they had told of certain unethical
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routine procedures they performed. Hence, those types of questions which
could potentially incriminate the informants were avoided.
In addition, participants were assured that their responses would be kept
confidential and also their identifications were anonymised. Their reference in
the data chapter was highlighted as per the occupational role which they play,
such as scientists, clinicians etc. Participants were informed of their right to
withdraw from the study at any time without giving explanation.
3.6 Conclusions
This chapter has described the methods and philosophy which were used in
the execution of the study. The chapter has attempted to explain the
rationality for choosing the methods to fulfil the aims of the study. In doing
so, the chapter has highlighted the merits and limitations of the adopted
methods. The data gathered through using a survey, documentary analysis
and qualitative interview are analysed in Chapters 4-7.
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Chapter 4: Stem Cell Science in India: An Overview
4.1lntroduction
This chapter analyses the status of stem cell research and therapy in India.
This chapter is based on a survey, media articles, science magazines, existing
academic literatures, hospitals'/institutes'/firms' websites and the reports
from the different departments of the government of India. The data from
the interview with different stakeholders enriched this chapter with up-to-
date development in recent years.
The proliferation of stem cell research and therapy in India can be traced back
to the beginning of the 1980s. After performing its first successful allogenic
bone marrow transplantation (a type of stem cell transplantation) on 20
March 1983 (Chakraborty et aI., 2009), India geared towards the development
of biotechnology, leading to the establishment of the Department of
Biotechnology (DBT) in early 1986 (Natesh and Bhan, 2009; Salter et aI.,
2007). However, other scholars such as Bharadwaj and Glasner have viewed
that the rise of India in stem cell research can be best traced to the middle of
the twentieth century, when science had been assigned to technological
innovation (Bharadwaj and Glasner, 2009). Whatever the circumstances or
reasons, the various studies depict that India is emerging as a global player in
the field of stem cell research and therapy (Bharadwaj and Glasner, 2009;
Glasner, 2009; Sharma, 2006, 2009; Sleeboom-Faulkner and Patra, 2008),
given that its two research laboratories were selected for the US National
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Institute of Health {NIH} funding for the existing stem cell lines, from which
they derived in 2001.
The NIH funding could be seen as one of the important factors for
accelerating stem cell research in India. In 2000, in the area of stem cells,
there were very few authored papers by the Indian scientific community, but
by the beginning of 2007, there were nearly 100 authoring papers
(Chakraborty et al., 2009; Tiwari and Desai, 2011). Indian scientists published
412 papers related to stem cell research during the period 2006-2010. Out of
these, there were 142 internationally collaborated papers with the
researchers from countries such as the US, Japan, France, Canada and the UK
(Tiwari and Desai, 2011). India is placed amongst the top 10 countries of the
world in term of publication (McMahan et al., 2010; Tiwari and Desai, 2011).
In this preceding context, this chapter attempts to explore the nature of stem
cell activities in India. In doing so, section 4.2 analyses the development of
stem cell basic research. In India, there are significant numbers of hospitals
and clinics engaged in stem cell based treatments. Section 4.3 therefore
explores the therapeutic applications of stem cells. In recent years, umbilical
cord blood banking has flourished significantly in India. The activities and
nature of cord blood banking are examined in section 4.4. In addition to these
activities, some academic institutions are involved in knowledge production
through various short and long term courses, training programmes and
research at doctoral level. The status of knowledge production is discussed in
section 4.5. For a successful innovation, linkages of various sorts among
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different players in a particular sector are viewed as one of the key
components (Tiwari and Desai, 2011). It was argued that, for a translational
research field, like stem cells, a high degree of linkages between basic and
clinical research is the need of the hour (lander et al., 200S). Section 4.6
investigates the different kinds of linkages in the Indian stem cell sector; and,
finally, the last section deals with the summary and discussion.
4.2 Stem cell basic research
In India, basic research in stem cells is being carried out largely by the
government funded research laboratories. These research laboratories are
supported by the different government agencies such as the Department of
Biotechnology (DBT), the Council for Scientific and Industrial Research (CSIR),
the Indian Council of Medical Research (ICMR), the Department of Science &
Technology (DST) etc.
Among them, DBT is playing a major role and every subsequent year it has
expanded its support to more research programmes by increasing funding.
From the Sth five year plan (1992-1997) to the n" five year plan (2007-2012),
the DBT's budget has been increased by 16 times (from US $44 million to US
$3.6 billion), of which stem cells share 30% of the total budget. Currently, DBT
is supporting around 55 programmes in different aspects of stem cell research
(Patra and Sleeboom-Faulkner, 2010).
120
In India, the focus is mainly on the adult stem cells. Different institutions are
engaged in different areas of adult stem cell research. In comparison to adult
stem cells, even after the 'favourable' environment compared to the West, a
few research laboratories are focusing in the area of embryonic stem cells
(Tiwari and Desai, 2011). Some of the research laboratories are also engaged
in research on umbilical cord blood cells. The major programmes in stem cells
include differentiation of pancreatic progenitor cells to insulin secreting cell,
isolation of multi-potential adult progenitor cells from bone marrow and their
clonal expansion, use of banana lectins for stem cell preservation,
hematopoietic stem cell (HSq for haplo-identical HSCtransplantation, use of
limbal stem cells for ocular surface disorders, isolation and characterization of
mesenchymal and liver stem cells, cardiac stem cells, in vitro differentiation of
human embryonic stem cells to neural and non-neural lineages, etc. (Patra
and Sleeboom-Faulkner, 2010).
Some of the centres in India have developed state-of-the-art technology in
the field of stem cells. For example, Centre for Stem Cell Research (CSCR),
Vellore has succeeded in the creation of induced pluripotent stem (iPS) cells.
In media commentary, this is portrayed as a path breaking research, where
adult stem cells are reprogrammed to behave like embryonic stem cells. India
is the fifth country after Japan, the US, China and the UK, which has
developed this technology (Menon, 2009; Tiwari and Desai, 2011). The main
goal of CSCRis to develop stem cell based therapies and to understand basic
mechanism of human disease. It has set up four aims for the stem cell based
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research and therapy', namely: a) to have a scientific faculty involved in basic
research that will have translational potential, mostly with adult stem cells at
present; b) to develop a training programme for students and scientists who
will contribute to the manpower required for this field in the country; c) to
develop cellular and animal models of diseasesto test hypotheses generated
from our understanding of stem cell biology, and d) to do clinical trials with
stem cells produced under current good manufacturing practice (GMP)
conditions (Tiwari and Desai, 2011). The CSCR is more interested in
translation research with the help of the Christian Medical College (CMC),
Vellore.
India has recently established the Institute for Stem Cell Biology and
Regenerative Medicine (inStem), with the investment of US $50 million in
Bangalore. It is viewed as a major boost for stem cell R&D in India
(Sachitanand, 2009).The major focus of inStem is basic research. However, it
will work in close collaboration with the clinician of CMC,Vellore. A scientist
at inStem informs:
"Currently we have only basic research here and we interact
with the clinicians at CMC,Vellore, where a lot of translation
work is going on. inStem basically aims to conduct basic
research on problems of clinical importance" (Scientist, 3).
7 http://www.cscr.in/. [Accessed April 30, 2011).
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The narration of the scientist reflects that the government of India is making
effort to bring scientists and clinicians on a common platform to work
together.
The National Centre for Biological Sciences (NCBS), Bangalore is conducting
research in embryonic as well as adult stem cells. Its three human embryonic
stem cell (hESC) lines had fulfilled the eligibility criteria for funding from NIH,
USA, in 2001. However, these cell -llnes are still not available for the
researcher to conduct further research (Tiwari and Desai, 2011). The main
focus of the work here is to study the role of neurotransmitters, more
specifically the role of serotonin in depression, stress and psychosis as
informed by the scientist during field visit (Scientist, 2).
A multidisciplinary research institute, Jawaharlal Nehru Centre for Advance
Scientific Research (JNCASR), which is also in Bangalore, has derived two
human embryonic stem cell (hESC) lines from the discarded embryo. These
cell lines are available through UK stem cell bank to carry out further
research. The Bangalore Assisted Conception Centre (BACC), Bangalore and
the NCBSwere also a part of this collaborative project (Inamdar et al., 2009).
The JNCASR website highlights that "this project will be part of the
International Stem Cell Initiative 2 (ISCI) project to identify the common
genetic changes that occur in hES lines on prolonged culture. This will be the
first time that India is represented on an ISCIproject'". Similar to JNCASR,the
scientists at the National Brain Research Centre (NBRC), Manesar are also
8 http://www.jncasr.ac.in/newsview.php?id=Sl. [Accessed April30, 2011].
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conducting research in the area of embryonic stem cells (Sharma, 2006).
However, they are more active in neural adult stem cells.
For diabetes, the National Centre for Cell Sciences (NCCS), Pune is involved in
animal and preclinical analyses of bone marrow stem cell injections for
pancreatic regeneration. The scientists of the NCCS are in the process of
establishing a team of clinicians, scientists, and patients to act as a platform
for the trial related to diabetes (Lander et al., 2008; Tiwari and Desai, 2011).
The Centre for Cellular and Molecular Biology (CCMB), one of the constituent
national laboratories of CSIR,based in Hyderabad, has established a stem cell
facility centre in association with DST and the Nizam's Institutes of Medical
Sciences (NIMS), Hyderabad. The facility centre aims to work in both the basic
and applied research. For applied research, NIMS will provide patients to
CCMB (The Financial Express, 2009; Tiwari and Desai, 2011).
Scientists at the stem cell laboratory of the National Institute of Immunology
(Nil) New Delhi are working on bone marrow derived adult stem cells. A
scientist at Nil stated that:
"I am working on bone marrow derived stem cells i.e.
mesenchymal and hematopoietic stem cells. I am also
interested in differentiating them [mesenchymal and
hematopoietic stem cells] into other kinds of tissues"
(Scientist, 1).
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The Central Leather Research Institute (CLRI), Chennai, which is one of the
leading centres in leather technology, has been focusing on the engineering
tissue by seeding scaffolds with stem cells. The main aim of CLRI is to conduct
basic research and with the collaboration of private sectors further develop
their research findings (Lander et al., 2008).
In contrast to public research laboratories, hospitals in India are engaged in
both the basic as well as clinical research. The majority of the hospitals are
offering direct therapy to the patients, more specifically the private hospitals;
however, a few public hospitals are also engaged in the therapeutic
applications of stem cells.
Public hospitals are mostly involved in basic/clinical research in stem cells.
The All India Institute of Medical Sciences (AIIMS), New Delhi, which is India's
premier research intensive public hospital, set up a Stem Cell Facility for this
purpose in 2005. During a field work visit, a clinician at this centre informed
that:
"The stem cell facility at AIIMS was established for the
purpose of doing basic and clinical research and we are
trying to see its [stem cell] role in degenerative areas like
cardiac, neurological, epithelial surface, eye and skin"
(Clinician, 7).
AIIMS is also engaged in the research on umbilical cord blood banking. It has
developed an in-house umbilical cord blood bank for the same reason (The
Hindu, 2009).
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Similar to the AIIMS, the other hospitals/medical institutes such as the Post
Graduate Institute of Medical Sciences (PGI), Chandigarh, the Sri
Venkateswara Institute of Medical Sciences (SVIMS), Tirupati and the Sanjay
Gandhi Post Graduate Institute of Medical Sciences (SGPGI), Lucknow are
conducting basic and clinical research in the different areas of stem cells. A
clinician at PGI, Chandigarh stated that:
"We are doing a few clinical trials using bone marrow
mononuclear cells in several disease conditions such as heart
attack, stroke, spinal cord injury and diabetes. In addition to
these, we do lot of basic research related to stem cells"
(Clinician,4).
In addition to these, a not-far-profit hospital, the L.V. Prasad Eye Institute
(LVPEI), Hyderabad is also active in research and development for the stem
cell based therapy. LVPEI is conducting both basic and clinical research in the
area of stem cells, specifically in limbal stem cells.
Sankara Nethralaya, an eye hospital based in Chennai, is conducting research
in the area of corneal and retinal stem cells. Recently, it has develop synthetic
gel to grow stem cells cornea and also obtained an international patent for
this technology (The Times of India, 2010). It can be seen as an indicator of
growing scientific strength in the field of stem cells, along with publications.
In contrast to research laboratories and hospitals, a few firms are doing basic
research along with clinical research. The Reliance Life Science Pvt. Ltd (RLS),
Mumbai is conducting research in embryonic and adult, as well as cord blood
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stem cells. RLS is actively involved in developing the stem cell technology in
India, as per information provided by the company's representative during
the field visit (Firm's representative, 6). RLS is developing a wide range of
novel research-led, autologous and allogenic cell therapies and tissue
engineered products. Under the Regenerative Medicine initiative, RLShas set
up several groups to work in the areas of embryonic stem cells, ocular stem
cells, haematopoietic stem cells and skin and tissue engineering. It is
interested in developing stem cell based therapies in the areas of cardiac
disorders, neural degeneration, spinal cord injury, metabolic disorders like
diabetes, ophthalmic diseases, hematological diseases, oncological diseases,
burns and wound management, diabetic and venous ulcers, skin pigmentation
disorders, orthopaedic and cartilage disorders.
RLS is conducting clinical trials for diseases conditions such as stable vitiligo,
Parkinson's disease, non-healing diabetic ulcers, spinal cord injury and
autologous stem cell conjuctival graft using stem cells. Recently, RL5 has
developed a few stem cell products: a) ReliNethra to cure corneal blindness;
b) ReliHeal - G (biopolymeric hydrogel wound management product), which
claims to be useful in early wound healing and c) CardioRel for heart attack
(Bisserbe, 2010; Tiwari and Desai, 2011).
RLShas started the ReliCord™ programme for umbilical cord blood banking.
There are two types of services being offered under this programme: a)
ReliCord '5' Sibling Donor Program, and b) ReliCord 'A' Allogenic, voluntary
donor program. It has recently launched the Relicord 1M' program for cord
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blood banking service, which stores umbilical cord derived from mesenchymal
stem cells (Tiwari and Desai, 2011).
RLSdoes not offer any stem cell services directly to the patients. It conducts
basic research for the development of stem cell based products. In addition, it
is also involved in clinical trials and for which it has collaboration with
different hospitals. The long term plan of RLS is to commercialise stem cell
based therapies through hospitals across the country (Tiwari and Desai,
2011).
The Stempeutics Research Pvt. Ltd is another important firm in India primarily
engaged in developing stem cell based products. It has invested US $ 7.5
million in the clinical research of stem cell and planning to invest more money
in near future". Stempeutics is a group company of the Manipal Education and
Medical group in India which is basically based in Bangalore. However, it has
also set up its subsidiaries in Manipal (India) and Kuala Lumpur (Malaysia).
The Stempeutics stem cell facility centre in Malaysia has been given the
Bionexus Status by the Malaysian Biotechnology Corporation. BioNexus Status
provides certain exclusive rights to the companies as stated within the
BioNexus Bill of Guarantees. For instance : a) freedom of ownership; b)
freedom to source funds globally; c) eligibility to receive assistance for
international accreditation and standards, and d) a strong intellectual
property regime. In Malaysia, the Stempeutics also has got approval from
9 http://archive.biospectrumasia.com/Content/llOS090TH94Sl.asp [Accessed May 02,
2011).
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National Pharmaceutical Control Bureau, which allows Stempeutics to go in
nearly 20 other countries which are under the purview of the Organisation of
Islamic Conference without conducting any further clinical trials
(Biospectrum, 2011, Tiwari and Desai, 2011).
Stempeutics mainly focuses on adult stem cell research, although they are
also interested in embryonic stem cell research but it is a long-term goal only,
according to a representative of Stempeutics who said that:
"We do research on embryonic stem cell on a small scale
considering the potential for embryonic stem cells in the
future but it is not our short-term or mid-term goal; this is our
long-term goal. As for our short-term and mid-term goals we
are focusing on adult stem cells" (Firm's representative, 4).
In adult stem cells, Stempeutics is basically involved in mesenchymal stem
cells (MSCs) derived from sources such as bone marrow, adipose tissue,
Wharton's jelly and dental pulp. Presently, the main focus of Stempeutics is on
MSCs derived from bone marrow, which is now at the stage of clinical trials.
The MSCs derived from other sources like, Wharton's jelly, adipose tissue and
dental pulp are confined at the level of laboratory only (Tiwari and Desai,
2011). The above representative of Stempeutics informed that:
"We are conducting four clinical trials, two in India and two
in Malaysia; all are from bone marrow derived MSCs, so we
have crossed the basic research and pre-clinical levels and
we are at the human clinical trial stage, whereas the other
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projects, that is MSCs from Wharton's jelly, adipose tissue
and dental pulp, are at the research level" (Firm's
representative,4).
The clinical trials are basically for the four disease conditions such as: a)
Mayocardial Infarction; b) Critical Limb Ischemia; c) Cerebral Stroke, and d)
Osteoarthritis. The clinical trials related to Myocardial infarction and Critical
Limb Ischemia are being conducted in India and the rest (related to Cerebral
Stroke and Osteoarthritis) in Malaysia (Firm's representative, 4). The trial in
India, for Critical limb Ischemia (CLI), which was started in 2009, is considered
India's first true stem cell trial approved by the regulatory authority
(Jayaraman, 2009). It completed the initial phase 1/11clinical trial in April 2010
and will soon launched a product named 'Stempeucel-CLI' (Tiwari and Desai,
2011).
Furthermore, Stempeutics recently obtained approval for the phase II clinical
trial for chronic obstructive, liver cirrhosis, pulmonary disease, osteoarthritis
and diabetes mellitus from the Drug Controller General of India (Tiwari and
Desai, 2011).10
Stempeutics has filed thirteen patent applications in India and six PCT
applications. It has recently received a patent in India on "An in vitro human
embryonic model and a method thereof' for the potential application in
toxicological studies and drug screening. Stempeutics is in the process of
10 http://www.stempeutics.com [Accessed April22, 2012].
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launching its products in the European and North American markets (Tiwari
and Desai, 2011).
The Nichi-In Centre for Regenerative Medicine (NCRM) is also seen as one of
the leading firms in the stem cell sector in India. It is an Indo-Japanese joint-
venture firm mainly focusing on autologous adult stem cells; more specifically
limbal, haematopotic, mesenchymal liver and corneal endothelial precursors
stem cells. It has collaboration with various public and private institutes in
Japan. The institute in Japan helps NCRM in stem cell basic research. It has
linkages with different hospitals in the country for research and clinical
application of stem cells (Tiwari and Desai, 2011). A representative of the
NCRM explained his activities:
"We are providing basic research and cell processing services
to the hospitals. We provide an autologous bone marrow stem
cell isolation service to the hospitals; we don't deal with fetal
cells, we don't deal with embryonic stem cells, we don't use
animal material or anything, also we don't use allogenic
material" (Firm's representative, 2).
However, the work of NCRM as a stem cell service provider was a matter of
criticism in 2008 because of its nexus with the Life Line Hospital, Chennai,
which offers unproven therapy to the patients (Pandya, 2008). It seems that
after this criticism NCRM suspended its services to the Life Line Hospitals as
per the information provided on the company website, viz. "our services were
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provided to this institute (Life Line Hospital) until 29th Feb 2008".11 This type of
nexus is termed 'bionetworking', which is conceptualised as a network of
plurality of actors in biotechnological ventures. It facilitates the selling of stem
cell services as an experimental therapy (Patra and Sleeboom-Faulkner, 2009;
Sleeboom-Faulkner and Patra, 2011).
The Advanced Neuro-Science Allies (ANSA), a stem cell research and
development company based in Bangalore, also focuses on adult stem cells
similar to the above-mentioned firms. Their main thrust is on mesenchymal
adult stem cells. ANSA has done some clinical trials at a small level for the
disease conditions like multiple sclerosis, Parkinson's disease, cerebral palsy
and traumatic brain injury as per information provided by the co-founder of
the company (Firm's representative, 7). Currently, researchers at ANSA are
working on diabetes type 1. ANSA's long-term plan is to produce stem cell
products and services at an affordable cost so that poor people in India can
get benefit from the stem cell technology.
4.3 Stem cell clinical applications
In India, significant numbers of public and private hospitals are involved in the
clinical applications of stem cells. They are offering various kinds of stem cell
based therapies to the patients for a wide range of incurable diseases using
adult stem cells. Only, The Nu Tech Mediworld is offering embryonic stem cell
11 http://www.ncrm.org/media/pm12jun07.htm [Accessed May 10, 2011].
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treatments. Stem cell based treatments have attracted a significant number
of local and international patients towards various hospitals the so-called
'stem cell tourists' (Cohen and Cohen, 2010). The projected market of stem
cell therapy in India is worth US $8 billion by 2015 (The Indian Express, 2012).
However, the therapeutic applications of stem cells in India have raised
several ethical issues in the absence of regulatory approval and clinical
evidence.
AIIMS has done a few stem cell transplantations for some disease conditions
over the years. The first use of stem cell in 35 cardiac patients by the clinicians
at AIIMS was reported in the media and science magazines in 2005. The stem
cell injection was given to these patients between February 2003 and January
2005 (Biospectrum, 2005). However, these stem cell transplantations were
criticised on ethical and safety grounds since AIIMS failed to provide any
proof of the ethical clearness and the experimental and clinical study prior to
applying this therapy to the patients (Pandya, 2008). For example, the Deputy
Director-General of the ICMR Dr Vasantha Muthuswamy had argued at that
time, "We are only a block away from AIIMS and we did not know this was
happening there. If the nation's premier medical institute did not ask our
permission for such therapy, how can we blame private clinics for what they
do?" (Jayaraman, 2005). There was also a report that AIIMS did not fully
inform the patients about the pros and cons of stem cell treatments.
Following the widespread criticisms, AIIMS made an announcement about the
abandonment of this kind of treatment. It appears that AIIMS is now moving
133
in this area cautiously as it has recently dropped two stem cell trials related to
muscular dystrophy and motor neuron disease because of poor patient
response (Krishnan, 2009).
LVPEIhas treated 750 patients as told by the director of the Institute during a
field work visit (Clinician, 8). It is worth to highlight here that many patients
were treated free of charge (Lander et al., 2008; Tiwari and Desai, 2011;
Vemuganti and Sangwan, 2010). However, in 2006, the stem cell
transplantations procedure at LVPEIcame under scrutiny when a team of
international ophthalmologists criticised the existing stem transplantation
procedures, where human and/or animal materials were being used for the
limbal stem cell growth (Schwab et al., 2006). These ophthalmologists had
reviewed all the clinical trials worldwide between the period July 1, 1996 and
June 30, 2005, including LVPEIclinical trials. The use of bioengineered ocular
surface tissue in transplantation procedures was basically examined during
this review. It was observed that the "current investigational protocols rely on
the use of animal and/or donor human tissue products and thus carry the
potential to induce xenogenic microchimerism in recipients or disease
transmission through contamination with bacteria, viruses, or other infectious
agents, such as those responsible for transmissible spongiform
encephalopathy" (Schwab et al., 2006: 1,734). In response to this report, a
clinician at LVPEIhad admitted the 'potential risk'; however, he denied any
adverse effects of stem cell transplantations in his patients (Gulf Times, 2007).
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The most 'notorious' hospital in India is The Nu Tech Mediworld, which has
attracted great attention at national and international platforms for its
unproven embryonic stem cell treatments. This is a private stem cell clinic run
by an obstetrician Dr Geeta Shroff in New Delhi. She claims to have treated
more than 800 patients from 35 different countries using embryonic stem cell
for the ailments such as Parkinson's disease, eye disorders, diabetes, cardiac
problems and spinal injuries. Dr Shroff also stressed that none of her patients
have shown any side effects. She has filed a patent, claiming that "terminal
disease and other disorders or conditions that may be treated or ameliorated
according to the present invention include, without limitation, cancer, liver
and kidney disorders, nervous system disorders, skin disorders, autoimmune
disorders, genetic disorders, eye disorders, musculoskeletal disorders, fertility
and reproductive disorders and cardiovascular disorder" (Tiwari and Desai,
2011; WO 2007141657 20071213). In her patent application, around 80
diseases are listed which might be treated by this new medical technology
(Sipp, 2011; Tiwari and Desai, 2011). It is worth to mention here that, she
never published her findings in peer-reviewed journals. However, she has
filed a patent (Cohen and Cohen, 2010; Khullar, 2009; Tiwari and Desai, 2011).
In a recent meeting at the 2nd Annual World Stem Cells & Regenerative
Medicine Congress Asia 2010 in South Korea, Dr Shroff explained her method
of treatment and the clinical results of 108 patients suffering from spinal cord
using human embryonic stem cell (Dash, 2011; Pandeya, 2010). However, in
the absence of any peer review, stem cell experts across the world are
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sceptical about the claims made by her (Cohen and Cohen, 2010; Khullar,
2009). In December 2010, there were reports in the media that Drug
Controller General of India (DCGI) had asked Dr Shroff to explain her claims to
have successfully treated patients and to show whether she has an approval
from any regulatory body (Pandeya, 2010). Similar action was also taken from
the government of India in 2006 when an inquiry was set up against Dr
Shroff's stem cell treatments. There was promise from the Ministry of Health
that strict action would be taken once the inquiry report came out. However,
Dr Shroff still continues with her work (Cohen and Cohen, 2010; The Hindu,
2006).
The Chaitanya Stem Cell Centre is part of Chaitanya Hospital, located in Pune.
As per the information on the hospital website, it claims to treat more than
92 patients using patients' own bone marrow stem cells with a success rate of
70%. This centre offers therapy for a wide range of diseases including spinal
cord injury, diabetes, stroke, autism, liver diseases and motor neuron
diseases. The hospital offers different 'medical tourism packages' for different
diseases". Its' website reflects that, this hospital is using stem cell as a
standard mode of treatment. However, during a field work visit, the hospital
management stated that it is still an experimental therapy (Clinician, 9). It can
therefore be argued that, through false claims, this hospital is exploiting the
patients. The website is fully loaded with patients' experience, which is a kind
of 'informal advertisement' and is violating the medical code of ethics as per
12 http://www.chaitanyastemcell.com/index.php [Accessed May 04,2011).
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the Medical Council of India. The Chaitanya Stem Cell Centre is also involved
in a stem cell clinical trial in collaboration with Reliance Life Sciences,
Murnbaf '.
A hospital in India is offering stem cell therapies in combination with India's
traditional medicine Ayurveda, named Crystal Hospitals ltd. This hospital is
based in Mumbai. Its website highlights that 500 patients have been treated
with the combination of stem cells and Ayurveda. The hospital has a slogan
for stem cell based therapy, Le. "Ayurveda" of Allopathy. Apart from making
claim for treating most of the untreatable diseases,it also promises to reduce
age by 10 to 20 years and enhancement of beauty by the stem cells. Crystal
Hospitals Ltd has collaboration with Ree laboratories Pvt. ltd, another
biotechnology company engaged in stem cell banking and treatment. Ree
laboratories provides stem cells to Crystal Hospitals for the treatments (Sipp,
2011).
Sir Ganga RamHospital, a private hospital based in New Delhi, is involved in
stem cell research and therapy. It was reported that nearly 60 patients were
treated at this hospital usingstem cells by the beginning of 2011 (Jha,2011).
The Fortis Hospital in Delhi offers stem cell treatments for arthritis, bone
regeneration, cartilage regeneration, non-healing wounds and chronic pain. In
the beginning of the New Year 2011, Fortis Hospital drew the attention of the
media after the treatment of an Iraqi national using stem cell injection.
13 http://ctrLnic.in/Clinicaltrials/pubview2.php [Accessed May 04,2011].
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However, the ICMR raised concern over the unproven therapy offered by the
Fortis Hospital since it is still an experimental therapy and has not been
authorised in India (Chatterjee, 2011).
The Life line International, Chennai, The Medanta Medicity, Gurgaon, Apollo
Hospitals, Narayana Hrudayalaya, Jain Institute of Vascular Sciences (JIVAS),
BGS Global Hospital in Bangalore, The Sion Hospital in Mumbai and PGI
Chandigarh, among others, are also offering stem cell therapy for various
disease conditions, basically using adult stem cells.
A few banking firms also jumped in the clinical applications of stem cells. For
example, International Stem Cell Services Ltd (ISSL) is basically a stem cell
banking company located in Bangalore. In recent years, it started offering
various stem cell based treatments for the disease conditions such as
Buerger's disease (critical limb ischemia), chronic liver and kidney failure,
osteoarthritis, muscular dystrophy, myocardial infarction and spinal cord
injury. ISSLhas also conducted clinical trials for some of the above-mentioned
disease conditions as per information provided by the representative of firms
during field work (Firm's representative, 5).
4.4 Umbilical cord blood banking
There are significant numbers of multinational firms in India who are involved
in cord blood banking. Most of them are offering private banking where they
charge US $1,500- US$2,000 to the expecting parents to preserve their child's
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cord blood. Given the high birth rate in India the projected market of private
cord blood banking is worth of million dollars.
life Cell International in India is one of the leading cord blood banking firms; it
started functioning in the year 2004 in collaboration with CRYO-CEll
International Inc. and is based in Chennai. The company has invested US $4
million. It has about SO centres in different parts of India. lifeCeli has so far
collected over 25,000 cord blood units. However, the representative of the
company during an interview felt that, given the population of India, this
collection is very low (Firm's representative, 3). It charges close to US $1,500
for preserving each unit of cord blood component for a period of 21 years.
The transplant centre of the company is set up at Sri Ramchandra Medical
College, Chennai. It has accreditation from the American Association of Blood
Banks (AABB). life Cell has tied up with Hindustan lever limited for cord
blood banking for its employees. The employees pay half the amount and the
rest is paid by the company. Life Cell has similar collaboration with Starcom
and India Inc. (Ilic, 2006).
StemOne Biologicals Pvt. ltd was first established in 2005 as Cord Life Biotech
Pvt. ltd. It is basically involved in private cord blood banking. In recent years,
it has expanded in the area of stem cell based research and therapies as well.
StemOne Biologicals has collaboration with the NCRM for cryopreservation. It
has collected around 1,500 cord blood units.
Cryobanks International India is a joint venture between Cryobanks
International USA and RJ Corp India, based in Gurgaon near Delhi. It was
139
established in 2006. Cryobanks International India offers services for the
private as well as the public cord blood banking. It has also shown interest in
the development of stem cell therapies for cardiac disease and diabetes. Its
website shows that it has collected 15,000 samples of cord blood stem cells.14
CordLife Sciences India Pvt. Ltd is located in Kolkata. It was launched in 2006.
It is part of the Cord life group, which is considered to be Australasia's largest
network of private cord blood banks. Apart from India, it is also operating in
China, Hong Kong, Singapore, Philippines and Indonesia. It has a storage
capacity of up to 150,000 cord blood units.
Cryo-Save India was established in 2009. It is based in Bangalore. It is a
subsidiary of Cryo-Save, Netherlands. Cryo-Save is working in 40 countries. In
India, it has collected around 7,000 samples of the cord blood in urban areas.
Given the opportunity of more business in rural areas, it is in the process of
expanding its business in the rural areas of different parts of India. At the
beginning, it targeted rural areas of Northern and Western parts of India
(Vijay, 2011).
The Jeevan Blood Bank and Research Centre is located in Chennai. It is a not-
for-profit blood bank established in 1995. It started its stem cell umbilical
cord blood unit in 2010 as per the information provided during the field visit
(Firm's representative, 1). The nature of this bank is both public and private.
However, the majority is 'public' in nature. It has so far collected 500 samples
14 http://www.cryobanksindia.com/cryobanks-india.html[Accessed May OS,2011].
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of cord blood donated by the general public. Jeevan is interested to expand
its inventory size but there is a problem of funding, as one of its scientists
stated that:
"we are working towards an inventory size of 30,000 because
only with that kind of size do we have a hope that we might
be able to issue cells to people who require them; but our
major problem is that we have not had adequate funding,
rather I would not say adequate funding but we have no
funding, in terms of help from the government whether at the
state or central level" (Firm's representative, 1).
The Regenerative Medical Services (RMS) Pvt. ltd was started in 2007. It is
basically a cell therapy division of Satyan Interchem Pvt. ltd. Satyan
Interchem Pvt. ltd. is a pharmaceutical and specialty chemicals supply
company located in Mumbai. The subsidiary of RMS, Babycell India, is
involved in cord blood banking. RMS has collaboration with Sewan Cellontech,
South Korea for the transfer of technology.
StemCyteTherepeutics India (SCIPTl) is a joint venture between StemCyte Inc.
(USA), Apollo Hospital Enterprises ltd and Cadila Pharmaceuticals ltd,
headquarters located in Ahemdabad. It was established in 2007. The company
is interested to build a cord blood inventory of the ethnically diverse Indian
population with the storage capacity of 25,000 cord blood samples. SCIPTL is
also interested to conduct some clinical trials related to stem cells based
therapies.
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Nanog India Pvt. Ltd is a Pune based cord blood company. It is a subsidiary of
Nanog International, Italy. Nanog India has alliance with the Stemone
Biologicals for laboratory facilities in India.
Pacific Stem Cells, Hyderabad; Tran-Scell Biologics Pvt. ltd, Hyderabad;
Histostem; Karnataka Stem Cell, Bangalore; Advanced Cell Therapeutics,
Mumbai; and IQRA Biotech Services, Lucknow are some of the emerging
players in the business of cord blood banking in India.
4.5 Knowledge production
The universities are emerged as the main centre of knowledge production in
India. They are producing knowledge in two ways, firstly through basic
research and secondly by starting courses related to stem cell (Tiwari and
Desai, 2011). The school of life sciences at Jawaharlal Nehru University (JNU),
New Delhi has started basic research on multipotent adult progenitor stem
cell as informed by a Prof of the school during field visit (Scientist, 4).
Similarly, The University of Delhi in collaboration with the Indian Institute of
Nuclear Medicine and Allied Sciences, New Delhi is conducting research to
study the basic mechanisms of stem cell function (Lander et ai, 2008). At the
University of Hyderabad, scientists are engaged in neural stem cell research
(Tiwari and Desai, 2011). The Special Centre for Molecular Medicine,
Jawaharlal Nehru University, has started teaching on 'Stem cell research and
its application in human health' in its pre-PhD course (Tiwari and Desai, 2011).
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Similarly Guru Gobind Singh Indraprastha University, New Delhi, in the
curriculum for the Masters of Technology degree has included the topic 'Stem
cells in health care' (Greenwood et al., 2006; Tiwari and Desai, 2011). The
Department of Zoology at the University of Madras, Chennai, has started a
one-year PG Diploma programmes in 'Molecular cell biology and stem cell
technology' (Tiwari and Desai, 2011).
Some firms have established linkages with universities for the production of
knowledge. For instance, Nichi-In Centre for Regenerative Medicine, Chennai
has started the doctorate programme on stem cells in collaboration with
Acharya Nagarjuna University, Guntur. The university gives recognition of the
doctorate programme of this firm. Similarly, Life-Cell has established the Trl
Cell' stem cell centre to understand haematological diseases using stem cells.
In addition to universities and firms several medical colleges are also engaged
in knowledge production of stem cells such as AIIMS, New Delhi, PGI,
Chandigarh, SGPGI, Lucknow, CMC, Vellore, SVIMS, Tirupati, etc. (Tiwari and
Desai, 2011).
4.6 Linkages
The government of India has taken some steps to establish linkages between
basic and clinical research. The mandate behind the establishment of inStem
is very much in this direction. inStem will work in collaboration with the
clinicians of CMC, Vellore. inStem has already started some collaborative
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research programmes with overseas institutes such as the Institute for
Integrated Cell Material Sciences, the University of Kyoto, Japan. The National
Centre for Biological Sciences (NCBS) is a part this collaborative research
programme. In addition, inStem has also signed a Memorandum of
Understanding with the US-based, California Institute for Regenerative
Medicine to start a collaborative research project (Tiwari and Desai, 2011). It
is interested in promoting a public-private partnership with the help of
another newly established institute, the Centre for Cellular and Molecular
Platform Technologies (C-CMAP), Bangalore in order to bring bench side
research to bed side.
The DBT has launched the city cluster programme. The main aim of this
programme is to share information and to explore collaboration between the
basic researchers and the clinicians. Delhi, Bangalore, Vellore, Pune and
Hyderabad are included in the city cluster programme. The city cluster
programme facilitates linkages between public and private players. For
instance, the stem cell city cluster programme at Bangalore consists of the
Indian Institute of Sciences (liSe), NCBS,Manipal Hospital, CMC, Vellore and a
local company (Tiwari and Desai, 2011).
The different hospitals, firms and research laboratories have established
linkages with different national and international organisations. They have
linkages with various research laboratories and stem cell firms (Tiwari and
Desai, 2011).
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For the basic research, LVPEI has recently started a collaborative project with
the University of Sheffield, UK. This collaborative project aims to develop
biocompatible materials for stem cell transplantation. The biocompatible
materials are being developed by the researchers of Sheffield University and
their clinical evaluation is being conducted at LVPEI. It is hoped that, if
successful, these synthetic materials will be safer and more affordable than
the human amniotic membrane which is currently being used for the growth
of lirnbal stem cells. This project is being funded, under the scheme "R&D for
Affordable Health Care in India". The scheme was launched in July 2010 by
the DBT in collaboration with the Wellcome Trust, UK to support R&D projects
for the development of innovative health care products at affordable costs.
Fortis Healthcare (India) Ltd has collaborated with California-based
TotipotentRX Cell Therapy Pvt. Ltd for the stem cell clinical trials, at selected
Fortis hospitals. The main focus is on stem cell clinical research for disorders
such as diabetes, cancer, cardiovascular disease, and neurological ischemia
(The Economic Times, 2011).
CCMB is engaged in a collaborative cardiac stem cell transplantation project
with NIMS, The Madurai Kamaraj University and The Wellcome Trust Sanger
Institute UK (Tiwari and Desai, 2011).
There seems to be strong linkages between various hospitals and firms in
India. RLS has collaboration with AIIMS, New Delhi, and Aditya Jyot Eye
Hospital, Mumbai, for clinical trials. For cardiac stem cells it is working with Sir
Hurkisondas Nurrotumdas Hospital, Mumbai by establishing a stem cell
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research laboratory. RLSprovides its services to hospitals for the extraction of
stem cells from bone marrow (Dutta, 2006, Tiwari and Desai, 2011).
RLS is also working with different government research laboratories such as
NCCS,Pune and NCBS, Bangalore. NCCS,Pune has provided storage facility to
embryonic stem cell lines of RLS. Similarly, NCBS, Bangalore has also
collaborated with RLSfor stem cell facilities (Tiwari and Desai, 2011).
Stempeutics has established its linkages with different hospitals and research
institutes. It is not directly involved in any kind of stem cell based therapies
similar to RLS; rather it offers various stem cell based services to its
collaborating groups. Stempeutics has signed a MoU with India's leading
pharmaceutical company, Cipla for marketing of its stem cell products (Tiwari
and Desai, 2011). Under this collaboration Cipla is investing up to US $ 10
million in Stempeutics for research and development of stem cell products. In
return Cipla will get marketing rights.
Similar to other players NCRM has collaborated in both basic research and
therapeutic application of stem cells with different hospitals and research
centres. NCRM provides services such as stem cell isolation and NK cells
expansion for stem cell based treatments to hospitals based on MoU. The
responsibility of NCRM is limited to this stage only. Hospitals further conduct
clinical assessment, harvesting and application of stem cells (Tiwari and Desai,
2011).
ISSLhas a MoU for banking and therapy with St Theresa Hospital, Bangalore
Apollo-BSR Hospital, Bhilai, Tirupti Nursing Home, Bangalore and Sita Bhateja
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Multispecialty, Bangalore. It appears that St Theresa Hospital is its main stem
cell therapy centre."
4.7 Summary and discussion
It seems that, in India, a lot of activities are going on in the area of stem cells
both at the research aswell as translational level. In addition, a few academic
institutions also started courses on stem cells to understand the basic stem
cell science. The government of India is highly supportive of stem cell based
research, shown by the increasing budget and different programmes over the
years. Recently, new research institutes exclusive for stem cells have been
established with government support. The initiatives have been taken to
promote collaboration between the basic researchers and clinicians. The
leading institutes are working in close associations with each other through
city cluster programmes. In addition, the various centres have been able to
develop networks in the US, the UK, Japan, Korea etc. and started
collaborative research programmes. This could be viewed as a good indicator
for the linkages among different actors in the emerging stem cell sector and
will perhaps help in the flow of knowledge. Someefforts have also been taken
by the government of India to bring both the public and the private players to
a common platform which might be helpful in stem cell transplantation.
15 http://www.internationalstemceliservices.net/stem-cell-therapy.html[Accessed June 21,
2011].
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In India, the majority of the research institutes are focusing on adult stem cell
research. Only a few scientists are conducting research on embryonic stem
cell. It appears that India is unable to develop those 'state-of-the-art'
technical skills which are required in embryonic stem cell research. It is
pertinent to highlight that, the embryonic stem cell lines, which received NIH
funding in 2001, are still not available for researchers. There were reports in
the media that the cell lines of NCBShave petered out (The Economic Times,
2007). However, the scientists at JNASCRare able to develop and characterise
a few stem cell lines, which are available through the UK stem cell banks.
Similar to research institutes, most of the firms of Indian origin are also
involved in adult stem cell research. RLS in the beginning started research in
embryonic stem cell but it seems that it is now focusing only on adult stem
cells and cord blood banking. Firms in India are interested in the development
of stem cell based products. However, some of them are indirectly involved in
the therapeutic applications of stem cells in the form of providing services to
various hospitals and clinicians. This has been a controversial issue which is
seen as a nexus for unproven stem cell treatments.
In India, the majority of foreign origin stem cell firms are engaged in private
cord blood banking. The future market of the private cord blood banking is
worth millions of dollars, having 25 million births per year in India. It seems
that, for this potential market, multinational firms are attracted towards
India.
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Hospitals in India are offering stem cell therapy for a wide range of diseases.
The majority of the hospitals are using the patients' own stem cells derived
from bone marrow, Le. adult stem cells. Only a few hospitals, such as The
Nutech Mediworld, are said to treat patients using embryonic stem cells.
Some of the hospitals are also treating patients with stem cells from cord
blood. However, the overall clinical development and private cord blood
banking in India have raised major ethical concerns with respect to patients'
safety and their economic exploitation in the absence of peer-reviewed and
legitimate clinical trials. Only in the year 2009 did the regulatory authority
approve the first 'true clinical trials' in the country; before that several claims
were made by different hospitals and individual practitioners to treat/cure
patients using stem cells. The clinic based at New Delhi started stem cell
treatments at the very beginning of the 2000s using embryonic stem cells and
still continues in the venture without having any clinical evidence or
publication in any peer-reviewed journals.
The unproven clinical applications of stem cells are directly linked to the
existing governance framework and raise an important question as to how
various unethical clinical activities flourish in India. This suggeststo analysing
the raised ethical and governance issues. However, before analysing these
issuessome other important questions need to be addressed in order to have
more nuanced understandings of stem cell proliferation in India. In this area
the government of India has invested a substantial amount in basic research.
Private players have also made a significant contribution in stem cells. The
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significant investment coupled with increasing activities in this area compels
us to investigate why the Indian government and various private players have
so much interest in stem cells. The clinical activities of stem cell also raises
question on similar line that how has it become possible for Indian clinicians
to attract several patients for an experimental therapy. It would be
meaningful therefore to analyse the expectations of different players with
respect to this emerging area.
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Chapter 5: Expectations of Stem Cells in India
S.llntroduction
The discussion in the previous chapter has shown that significant activities are
taking place in the area of stem cells in India. Both the public and private
sectors have made noteworthy investments in the stem cell venture. New
institutes and several new programmes in stem cells have been started in
recent years.
Stem cells in India are part of its ambitious biotechnology programme which
was described as the next big thing after the software revolution (Bharadwaj
and Glasner, 2009). The development of stem cells in India could be seen as a
part of its exercise to capture the global biotech market. Various key players
and media reports highlighted the potential of stem cells to find answers to
some of the pressing questions in biomedical research as well as to cure
various debilitating diseases for which there are no treatment options
available (Sharma, 2006; Sharma, 2009; The Hindu, 2010; United News of
India, 2009). However, there are a number of concerns with respect to
unproven stem cell therapeutic applications that are being offered by some of
the clinicians and hospitals in India (Biospectrum, 2011; Pandya, 2007). In
addition, activities in private cord blood banking have also increased
substantially in recent years raising legitimate concerns about its future
promises, especially for self-use' i.e. autologous (Kaimal et al., 2009).
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In India, therefore, it can be argued that, on the one hand, there are great
hopes associated with stem cells; on the other hand, there are fears as well.
This chapter of the thesis aims to examine how the different key players in
the stem cell sector, such as scientists, clinicians, representative of firms and
policymakers, articulate hopes and fears associated with the proliferation of
stem cells. This will be examined through the theoretical framework provided
by the sociology of expectations (Borup et al., 2006; Brown and Michael,
2003; Hedgecoe and Martin, 2003). This chapter, however, is not limited only
to analysing the 'dynamics of expectations', it will also focus on how the
future of stem cells is being created in India by different key players and
through media and the internet. It has been observed in various social studies
of expectations that, in the innovation process, especially for an emerging
area of science and technology, the 'creation of futures' is essential to
mobilise necessary resources. The chapter will try to investigate on what basis
various key players are attempting to mobilise resources for stem cell
innovation.
This analysis largely focuses on discussing real-time present expectations of
stem cells in India rather than its temporal pattern (Brown et al., 2006) since
the Indian stem cell sector is in its early stages of innovation. The discussion in
this regard will prepare the ground to analyse explicitly the ethical and
governance issues in the next chapters of the thesis, which are, I argue,
inextricably intertwined with the real-time current expectations of stem cells.
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The growing numbers of studies in the sociology of expectations have mainly
discussed, as highlighted in Chapter 2, the role of hope, hype or we can say
positive expectations as a performative force, while they largely ignored the
role of pessimism, fear or negative expectations in shaping a particular area of
science and technology. However, expectations studies acknowledged that
fears and risks have a significant influence in technological development
(Borup et al., 2006). In a few studies, it was recently analysed that a
pessimistic approach or fear can also have the capacity to mobilise the future
into the present (Nerlich and Halliday, 2007; Tutton, 2011). I will therefore
examine both positive and negative expectations of stem cells in India. Stem
cells promise different potential applications ranging from basic research to
translational research, including cord blood banking and accordingly different
key players might have different expectations (Sunder Rajan, 2006). This
chapter investigates whether expectations varied as per different potential
applications of stem cells and also tries to analyse whether there are any
similarities or differences in expectations discourse between and within the
different key players and how these are being institutionalised in different
communities of promise, and how expectations vary between different
groups.
In doing so, based on interview data and media coverage including the
promotional websites of different firms, clinicians and hospitals, I analyse
positive expectations of stem cells in section 5.2 as per their different
potential applications, and also discuss the expectations of different key
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players. Similarly, negative expectations are discussed in section 5.3. The role
of media and internet in creating expectations is highlighted in section 5.4. In
addition, each section also examines how different key players construct
India's strength at the global level, and finally the last section deals with
summary and discussion.
5.2 Positive expectations of stem cells
There are high expectations of stem cells across the world (Boseley, 2011;
Keller, 2005; Kitzinger and Williams, 2005; Wainwright et al., 200Gb). In a
report jointly published by The American Association for the Advancement of
Science (AAAS) and the Institute for Civil Society, it was argued that:
"Human stem cell research holds enormous potential for
contributing to our understanding of fundamental biology.
Although it is not possible to predict the outcomes of basic
research, such studies will offer the real possibility for
treatments and ultimately for cures for many diseases for
which adequate therapies do not exist" (Chapman et al., 1999:
iv).
Similarly in a document published by the Government Office for Science, UK,
it was expected that, "stem cells have the greatest potential in the field of
regenerative medicine, and could see widespread application by the early-mid
2020s" (Government Office for Science, 2010: 18). In this document, it was
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also emphasised that there is a great potential for stem cells to transform
medicine (Government Office for Science, 2010). As we have seen in the
previous chapter, India is also geared up to take potential advantage of stem
cells, which is quite similar to the development of the US and the UK. This
section aims to discuss the positive expectations of stem cells related to
different potentials of stem cells in basic research, clinical applications and
cord blood banking, and attempts to analyse on what basis different key
players in India are creating a future for stem cells. It will help in a more
nuanced understanding of expectations of stem cells in India.
5.2.1 Expectations of stem cell basic research
Many scientists and policymakers are optimistic about stem cells in terms of
their use in basic research. It would be interesting to analyse how they
portray future prospects of stem cell basic research. The DBT-ICMRguidelines
for stem cell research and therapy 2007 also recognise the importance of
stem cells for understanding basic biology, which in turn is expected to
contribute to understanding how to deal with various debilitating diseases.In
2006, and again in 2009, the principal scientist of the DBT, who is mainly
involved in the policy-making process of stem cells in India, published two
papers in peer-reviewed journals. These papers, though mainly discussingthe
overall status of stem cell research in India, also reflected the high
expectations of stem cells in the country at government level (Sharma, 2006,
2009). The DBT is currently supporting a large number of stem cell
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programmes in basic research, which was highlighted in the previous chapter.
During the field work visit, it was observed that scientists in India are very
excited about stem cells and they feel that stem cells will be useful in solving
the various problems of medical science and will help in regenerating
damaged cells, tissues and organs. A scientist illustrated that:
"any organs damaged by a natural wear and tear process or by
some toxic effect of some drugs or by infection, the organs
need to be replaced fully or partly because their function is
either completely gone or is partly affected, or there are certain
caseswhere there is a genetic disorder in the patient because a
certain kind of protein is not able to be produced by that
individual. In the case of X-linked recessive disorder, say
haemophilia, a particular type of protein is not produced in an
individual. In those cases regenerative medicine perhaps helps
to take care of the patients with the help of bone marrow
derived stem cells"(Scientist, 1, emphasis added).
Further, he argued that stem cells have the ability to solve the problem of
organ shortage, which is considered to be very crucial these days at a global
level.
"If you can create or make an artificial organ outside the body
with the help of stem cells then the shortage problem will not
come into the picture" (Scientist, 1).
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The expectations of scientist 1, in terms of solving the problem of organ
shortage using stem cells, could be seen as an effort to mobilise resources,
since there is an on-going campaign about a crisis in the supply of organs for
transplantation worldwide. For instance, in the US,reportedly 95,000 patients
were on the waiting list in the year 2006 (Abouna, 2008). Similarly, in Europe,
10,000 people were on a transplant waiting list in 200816• In the UK alone,
7,980 persons were on the active national waiting list in the year 2009-10
(Farrel et al., 2011). Campaigners highlight the number of deaths in the US
and EUarising from this (Abouna, 2008).
The shortage of organs is also one of the reasons behind illegal global
trafficking of human organs worldwide. India, amongst many countries, has
emerged as one of the preferred places for illegal human organ trade
(Scheper-Hughes, 2000), having a large number of poor and vulnerable
people. In 2008, a report was published in Time magazine, which established
the linkages between desperate foreign patients and black marketing of
organs in India (Robinson, 2008).
Against this backdrop, expectations regarding the impact of stem cell
research on the burgeoning organ shortage crisis help legitimize and generate
resource/funding for this line of research. For stem cells, scientist 1 is creating
an expectation on the same lines. On a similar line, scientist 2 also
endeavours to set an agenda for raising funds by saying that:
16http://www .eppgroup.eu/press/showpr.a sp?prcontroldoctypeid=1&prcontrolid= 7317 &prc
ontentid=12766&prcontentlg=en [Accessed June 12, 2012).
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"[His] research might help to understand the ways embryonic
stem cell combats stress. Embryonic stem cell seems to be
better than other cell types in understanding the stress. The
embryonic stem cells synthesize a fair amount of serotonin
and some of our research suggests that it helps a cell to
survive stress ... not clinically might be any immediate help
but as if we understand better ... might be some options"
(Scientist, 2).
He can 'understand better' only when there would be a favourable
environment for basic research in the form of better laboratory facilities and
other necessaryresources for conducting state-of-the-art research. Increasing
budgets for the development of biotechnology and stem cells in particular in
recent years suggest that expectations of their future impact on the
treatment of debilitating diseasesare playing a key role.
However, it is often the case that, "many expectations are widely optimistic
and over-estimate the speed and extent of the impact of biotechnology"
(Nightingale and Martin, 2004: 546). For example, the US Federal Drug
Administration (2004) White Paper states that:
"Today's revolution in biomedical science has raised new hope
for the prevention, treatment, and cure of serious illnesses.
However, there is growing concern that many of the new basic
science discoveries that have been made in recent years may
not quickly yield more effective, more affordable and safe
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medical products for patients. This is because the current
medical product development path is becoming increasingly
challenging, inefficient, and costly. During the last several
years, the number of new drug and biologic applications
submitted to FDA has declined significantly; the number of
innovative medical device applications has also decreased.
The costs of product development have soared over the last
decade {FDA,2004: i)".
Thus, there appears to be a mismatch between expectations of the capacity
of biotechnology to revolutionise health care on the one hand, and the
impacts of biomedical research in clinical practice on the other. This pattern
seems to be reproduced in India in the caseof stem cells.
However, by contrast with the sentiments expressed in the FDAWhite Paper,
a representative of firm in India suggeststhat their basic research will help in
bringing down the cost of stem cell based treatments and in the long term
enable them to provide affordable products and services to common people
in India. He argues that:
"A normal man in India can't afford it, even if you look at the
high middle class person, he also can't afford the treatment
because it is beyond his reach and it does not come under the
insurance and all. So I want to make this entire procedure very
affordable. Now there are two ways to go, one is to make
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official products, which basically people can use, and the other
is services" (Firm's representative, 7).
In this context, the representative of firm is invoking the spectre of
unaffordability of high-tech medicine for the majority of the population in
India to suggest that stem cell work can go some way towards addressing
current levels of health inequality. Stem cells are portrayed as the great
equalizer, a mechanism for bringing biomedical progress to the massesand, in
turn,social justice. However, it is instructive that this future is envisioned by a
firm representative, as it implies that the state is not capable of transforming
the social relations of the technology in a way that would be possible in a
market-based system. The representative of firm here is trying to create a
future where, through his 'particular' basic research, it would be possible to
provide affordable stem cell based products or services. In India, it is
estimated that day by day the costs of medical facilities are increasing. In a
recent survey, conducted by the Indian Institutes of Populations Sciencesand
WHO in six states of India, it was observed that Indians spend 70% of their
income to accessbasic health care facilities and medicine (Zee News, 2011).
Increasing health care expenditures are viewed as one of the reasons for
poverty in India (Reddy et al., 2011). It appears that, against this backdrop, a
firm representative in India makes an effort to justify his basic research and
create a scenario where his thigh-tech' research can provide affordable
medical services.
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Similar to the stem cell scientists and the representative of firm, policymakers
in India, as highlighted earlier, who are associated with stem cell
development, believe that stem cell research is a promising area and it has
many applications. An official of the DBT stated that:
"It is promising area ... has different applications for basic
research there is a lot of things that can be done can use
these stem cells for drug development, for in-vitro studies
with upcoming nanotechnology; I think that stem cell and
nanotechnology have good prospects. Gene therapy always
has an issue with viral vectors to carry the gene; I think stem
cell can replace those" (Policymaker, 2).
The narrative of the policymaker reflects a largely peculiar feature of
biotechnology where there is a tendency of changing expectations over time
(Brown and Michael, 2003). It appears that, if a particular expectation fails to
achieve desired results, then another expectation is created to sustain a
particular area of science and technology. For instance, gene therapy was
once heralded as a potential cure for various disease conditions and there
were high expectations of gene therapy in the 1990s. However, it failed to
achieve those futures which were once created and now focus is turned to
emerging areas such as stem cells and nanotechnology (Brown and Michael,
2003; Selin, 2007; Wilson, 2009). Similarly, many proponents of
xenotransplantation are now shifting their attentions to stem cells (Brown
and Michael, 2003). The shifting focus from gene therapy to stem cells at
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government level in India is very interesting in the sense that a nation-state is
largely playing a leading role in the creation and maintenance of expectations
over time. This is the reason the Indian state is often highlighted as "India
Inc." in the Indian press (Sunder Rajan, 2006).
These kinds of expectations coupled with high levels of support from the
government have helped in the construction of a favourable environment for
the basic research in stem cells. In India, almost every leading government
agency, Le. the Department of Biotechnology (DBT), the Department of
Science and Technology (DST), the Indian Council of Medical Research (ICMR)
and the Council of Scientific and Industrial Research (CSIR), are supporting
various stem cell programmes in different institutes. The government of India
has invested US $500 million for stem cell R& D during the period 2004-2007.
The private players have also made significant investments (Dey, 2007). As
highlighted in the previous chapter, the DBT is supporting around 55
programmes in stem cells. Similarly, the ICMR has also funded around 40
extramural research projects in different areas of stem cell research.
The expectations of scientists and firms in India of stem cells and
consequently the greater support from the different agencies could be seen
as a step to exploit basic research. Here the assumption is to diffuse or
translate knowledge from basic research to the clinic, which is similar to the
US and the UK (MRC, 2007; Wainwright et al., 200Gb). The development of a
translation focus for stem cell research in India is close to what Martin et al.
(2008a) have observed in the case of haematopoietic stem cells development
1G2
in the West. They argued that "great emphasis is now placed on the
exploitation of basic research and creating new policies and institutions to
ensure that scientific findings can be applied in the clinic" (Martin et al.,
2008a: 29).
On similar lines, recently, inStem has been established in India with the
mandate to exploit basic research for clinical applications as highlighted in the
previous chapter. Some of the research institutes/medical colleges in India
have now started research fellowships for graduate students for conducting
research in the different areas of stem cells. It is clear that expectations of
stem cells in India have been able to generate resources at various levels,
whether at the level of establishing new institutes or starting new
programmes for stem cells.
In a study conducted by Alan Cribb and his colleagues, it was observed that
the stem cell scientists in the USand the UK are not yet advocating a move
from the lab to the clinic on the grounds that more rigorous research is
required before doing so (Cribb et al., 2008). Likewise, some of the Indian
stem cell scientists' interviews reveal that at the moment their hope with
stem cells is confined within the boundary of the laboratory, which is similar
to the scientists of Western countries such as the USand the UK.A scientist in
India argued that:
"I would think that in the normal case scenario, you would go
step by step...where it is that you figure out the basic
questions, try to figure out some answers...go into animal
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models ...and say from animal to primates and many more"
(Scientist, 2).
The narration of this scientist infers that only after addressing certain
questions through basic research should one go to the clinical stage.
The analysis of expectations of stem cell basic research informs that key
players such as scientists and a policymaker including a representative of firms
believe that stem cells hold great promises for health care and they have
potential to treat various degenerative diseases and can restore damaged
cells, tissues and organs. The interviewed scientists create a promising future
of stem cell basic research on the basis that it can provide a solution to on-
going organ shortage problems and it will help in understanding stress. In
addition, one of the representative of firms creates expectations for his
particular basic research by highlighting that his basic research will help in
bringing down the costs of various treatments so that stem cell based therapy
can be affordable to common people in India.
The discussion also highlighted the role of the state in creating and sustaining
expectations as a policymaker in India portrayed that stem cells can have
applications in drug developments and also argued that they have potential to
replace shortcomings of gene therapy. It shows the active role of the Indian
state in maintaining the expectations of the overall field of biomedical
research in the country.
It can be argued that these kinds of expectations over the years have helped
in the proliferation of stem cell basic research in India. However,
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simultaneously various hospitals, clinics and some firms came up with a claim
to treat various chronic diseases using stem cells. It would be interesting to
know how these players are creating expectations of stem cell clinical
applications in India.
5.2.2 Expectations of stem cell clinical applications
Most of the clinicians interviewed "in India are expecting stem cells to cure
various chronic diseases for which there are no existing treatment options
available or, more specifically, where all treatment options for a particular
disease have been exhausted. The clinicians in India are creating a vision of a
future where all debilitating diseases can be cured using stem cells. For
instance, a clinician in India argued that:
"I think the stem cell research and therapy has huge
potentials; from my own study in embryonic stem cells aswell
as my role as head of medical services and clinical research
here...1 have seen patients were improving and benefitting
from this therapy basically for disorders on which doctors
have given up, there is no treatment available and the patient
is deteriorating; we have seen improvement in the quality of
life of these patients and there have been considerable
benefits to these patients so I think the potential is large if
used properly" (Clinician, 3).
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This interview material reflected that the clinician is using embryonic stem
cells as a treatment modality. However, the website of the hospital shows
that only adult stem cells are being used to treat patients. It is pertinent to
highlight that, though the clinician has no clinical experience of embryonic
stem cells, she is creating a future for embryonic stem cells by saying that
they have a 'huge potential'. The key words 'huge potential' and 'potential'
have been used in the field of science and technology, more specifically in the
emerging area of biotechnologies, to mobilise resources (Brown and Michael,
2003; Kitzinger and Williams, 2005).
In a somewhat similar way, another clinician argues for the use of stem cells
as a main line therapy as it has regenerating powers. He recalls that:
'The treatment for these muscular dystrophies is not present
worldwide anywhere so whatever relief we are giving through
stem cells that is going to be our achievement only because in
spite of the best result in Duchenne muscular dystrophy the
child dies by the age of 19 or 20 years and all over the world
people are using only cortisol for it as its treatment and
everyone knows that cortisol has his own side-effects: water
retention, osteoporosis and so many other complications. So if
you don't use the cortisol and instead of that you use
mesenchymal stem cells, it has regenerative powers and it
regenerates the tissue, so why should it not be used - that is
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my question. It should be promoted as main line therapy"
(Clinician, 1).
The clinician emphasises that there are no treatment options available for
muscular dystrophy and on this basis he advocates that stem cell should be
use as a main line therapy. However, in India as per the guidelines for stem
cell research and therapy (2007), stem cell based therapies are considered as
experimental, except for some haematological conditions. Section 13.1 of the
guidelines clearly emphasises that liAs of date, there is no approved indication
for stem cell therapy as part of routine medical practice, other than Bone
Marrow Transplantation (BMT). Accordingly all other than BMT (for accepted
indications) shall be treated as experimental" (DBT-ICMR, 2007: 11).
Other clinicians are also creating a future for stem cells, based on their past
Iexperience':
"We have seen a lot of improvements in the case of muscular
dystrophy ...we had moderate improvement in spinal cord
injury, multiple sclerosis, stroke. All these patients, for many
years, were in very bad clinical conditions; now they are
improving, they are better" (Clinician, 2).
Here, the clinician provides particular 'evidences' that he has already treated
so many patients with stem cells for various incurable disease conditions such
as spinal cord injury, multiple sclerosis, stroke etc. and, he further claims that
stem cell will be an important tool to tackle various disease conditions in
coming decades:
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"In my opinion, it is going to be the therapy of the next era. I
expect that, after 10-15 years, for every intractable problem,
this is going to be the solution" (Clinician, 2).
These hopes, promises and expectations of stem cells by the Indian clinicians
have framed a bright future in terms of treating various incurable diseases,
and it seems that, in the next few years, most of the problems with
debilitating diseases will be solved. However, previous studies have shown
that these kinds of early expectations rarely materialise and mostly result in
disappointment (Brown, 2003; Martin, 2006).
The case of stem cells is also similar to most of the other previous
biotechnological 'revolutions'. Stem cell science is still at an early stage of its
development and mostly confined at the level of laboratories. The translation
of stem cells is long and arduous. There are many obstacles to bring stem cells
from laboratory to clinic, in terms of quality control, efficacy and patients'
safety (Crystal, 2009; Levine, 2010). However, various clinics in India are
offering stem cell therapies to patients in the anticipation of curing all the
debilitating diseasesfor which there are no existing treatments. The narration
of clinicians in India and their expectations justify the previous arguments in
this domain, where it was argued that lithe goals of clinical work are
structured around therapy i.e. around curing or benefiting patients" (Cribb et
al., 2008: 353).
The stem cell firms in India, another key player in the stem cell arena, have
more or lesssimilar expectations of stem cells to clinicians. Firms in India are
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mostly engaged in private cord blood banking as discussed in the previous
chapter. Only a few firms are conducting research in adult and embryonic
stem cells. The thrust is more on adult stem cells compared to embryonic
stem cells. Stem cell firms in India are basically involved in stem cell
transplantation with their research focusing on the development of stem cell
based products for a wide range of disease conditions. They also provide stem
cell isolation services to various hospitals and clinicians, which are being used
by some medical practitioners as discussed above in the treatment of patients
(Pandya, 2008).
Firms in India are also creating a positive future for stem cells in the country.
Indian firms promote the idea that the stem cell has an ability to cure various
degenerative diseases, as a firm's representative illustrated that:
"There are several clinical disorders for which traditional
medicine does not offer any cure. There is only a certain
amount of palliative care for the degenerative diseases.
Regenerative medicine is evolving as the new branch of
therapy to address this spectrum of disorders and a better
understanding of regenerative medicine will pave the path for
several newer therapies in the future" (Firm's representative,
4).
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On the basis of 'regenerative capacity' of stem cells, firms in India are creating
a 'hope' amongst patients:
liThe stem cell based treatment is in a unique space because
many of the diseases which we look at, or diseases which have
no treatments what so ever right now ...we are trying to use
stem cells to improve the outcome of that disease, so in that
sense we are in the unique space ...we are trying to treat
disease where these patients and doctors have lost hope for
doing anything of this sort" (Firm's representative, 5).
Firms are also promoting the similar idea like clinicians, that stem cells have
capacity to treat those diseases for which all traditional treatment options
have been exhausted.
The statement of firm's representative 4 reflects the same tone:
"Today people are going through normal standard therapy.
OK...there are still. ..standard therapies are not able to cure
many diseases ...they address the system, not the root cause
of disease; so in stem cell we are aware that the main purpose
of the stem cell is the root cause of the disease, for example in
diabetes ...can we recreate the insulin generating
cell. ..pancreatic cells ...so it is hope for the patient ...yes there
is possibility, they can hope for getting their disease cure so
we put regenerating hope ...these patients whether for spinal
cord injury or whether it is diabetes or it is liver cirrhosis, so
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for those people the current standard of treatment gives
some hope but still with a lot of restrictions ...lots of patients
not getting a cure...so for those patients I think stem cells can
be a bigger hope, it can cure those patients II (Firm's
representative,4).
The stem cell as a future hope is created on the grounds that existing
therapies are unable to serve a large number of patients since conventional
therapies have many restrictions. The representatives of firms argued that
many patients who are afflicted with diabetes, spinal cord injury and liver
cirrhosis are unable to get benefit from standard therapy. And for those
patients stem cells can be a great hope. It would be worth highlighting here
that in India more than 50% of all deaths occur due to chronic diseasesand
there are millions of the population affected with chronic illnesses such as
diabetes, cardiovascular diseases and cancers in the country (Patel et al.,
2011). For example, India has around 50 million type 2 diabetes patients
(Diamond, 2011). It can be argued therefore that some firms' representatives
are taking 'advantage' of having large numbers of patients affected with
chronic diseasesand portraying stem cells asa potential solution for the same.
It appears that these kinds of hope help in mobilising patients towards
experimental stem cell therapy. Patients in India, which include both domestic
aswell as foreign, are being charged around US$3,OOO-US$50,000 for a stem
cell experimental treatment (Chatterjee, 2011; The Times of India, 2010). It
seems that in India also 'hope' became the basisof 'trade' and 'capitalization'
171
of an unproven therapy (Martin et al., 2008b). This 'hope' in India has put
patients at health and financial risks. It has been a matter of national and
international criticisms at different platforms. The reasons for these criticisms
are: a) there is no animal data for any stem cell therapeutic applications; b)
there are no properly phased, blind and controlled clinical trials; c) there is a
lack of systematic data regarding clinical procedures; c) there is no follow-up
of a patient after the stem cell intervention; and d) moreover, some clinics
combine a stem cell transplantation procedure with traditional medicines like
Ayurveda and Acupuncture (Murdoch and Scott, 2010; Sipp, 2011). The
combination of biomedicine with traditional medicines or alternative
medicines is not entirely a new approach, and which is being provided with
stem cells in India. It is recognised by many medical systems even in Western
countries to use a combination of modern medicines with traditional
medicines. For instance, the alternative medicines such as acupuncture,
hypnotherapy, aromatherapy, Reiki, and spiritual healing are being used with
biomedicine in the UK through some National Health Service (NHS)hospitals
and NHSaffiliated hospices to treat cancer patients. However, the concern in
the Indian case is that still there are no scientific evidences regarding the
efficacy and safety of stem cells and there is a suspicion as to whether
clinicians in India are using authentic 'stem cells' for treatments (Broom and
Tovey, 2007; Sipp, 2011).
Similar to some firms and clinicians, some of the policymakers in India also
feel that India can lead in the clinical applications of stem cells. An ex-official
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of the ICMR who has been involved in the policy-making process of
biomedicine in India for many years, stated that:
"When we had discussion [in 2002] of course everyone agreed
to one thing, that stem cell has a lot of promises and so India
should not shy away from stem cell research. India should
actively participate in the different types of stem cell
research ...the reason is of course that we have able scientists
in this country who can take up this challenge and do
something and also we have a lot of needy patients who will
be there so, once the research gets translated into practical
applications, many will benefit; and we have also clinicians
who are very capable of doing clinical trials and clinical
research and so India should take a lead role in this and we
should support and promote stem cell research" (Ex-
policymaker).
Here again the argument is that India has lots of needy or desperate patients
that can benefit from stem cell clinical applications. However, the above
narration reflects that, at the moment at government level, India is not
advocating direct use of stem cells in clinics. No doubt there is an aim to use
stem cells for therapeutic applications but only after going through a step by
step process, Le. from basic research to clinical trials.
The expectations of stem cell regarding its therapeutic applications are being
created on the basis that India has lots of needy or desperate patients who are
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afflicted with various chronic diseases, and the existing therapies are unable
to cure those patients. Clinicians and firms in India are playing a leading role in
this direction. It appears that clinicians are comparatively more excited
compared to firms since they argued to use stem cells as a main line therapy.
In contrast, policymakers believe that only after having rigorous basic research
stem cell should be used for various therapeutic purposes.
In India, in addition to stem cell basic research and clinical use of stem cells,
the excitement towards stem cell cord blood banking has escalated over the
years, given the mushrooming of cord blood banks in recent years. Similar to
therapeutic applications of stem cells, cord blood banking, especially those
being private in nature, raised legitimate concerns. Firms in India have made
several efforts to attract expectant parents to store their child's cord blood.
The next section discusses how and on what basis various firms are creating
expectations of cord blood banking in India.
5.2.3 Expectations of cord blood banking
Cord blood banking is one of the important constituents of stem cell research
and therapy. Umbilical cord blood is viewed as one of the good sources of
stem cells. In recent years, various cord blood banking firms have been
established with the concept of preserving cord blood. The idea behind it is
that, from preserved cord blood, stem cell can be retrieved whenever a
patient needs stem cell intervention. There are basically two types of cord
blood banking: a) public cord blood banking, which can be used by anyone,
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i.e. analogous, and there are no storage fees; and b) private cord blood
banking where the purpose of banking is only for the self, i.e. autologous,
though it can also be used by siblings or other family members, and for this
service banking firms charge expectant parents to preserve their child's cord
blood. The various studies in the West have critically examined the role of
expectations in cord blood banking (Brown and Kraft, 2006; Martin et al.,
2008b). These studies have shown the importance of cord blood banking in
the construction of stem cell expectations over the years.
Since most of the leading firms in India are multinational, their strategies are
more or lesssimilar to what they adopt to create positive expectations in the
West. These firms advertised directly their banking services to the expectant
parents through various workshops, seminars or via clinicians and the
lnternet". Expectant parents are being encouraged to 'invest' their money for
a 'healthy and happy future' of their child in the name of 'biological
insurance'. The advertisement leaflets of companies are making big promises
of the benefits of stored cord blood such as "your child and families can
[have] access to potential treatments for over 75 serious ailments such as
leukaemia, thalassemia, brain injury, juvenile diabetes and many more"
(Srinivasan, 2010). Not only firms but the government of India also seems to
be very positive towards cord blood banking, given the high birth rate per
year in India. An ex-policymaker argued that:
17 http://www.lifecellinternational.com/expertise-tips-on-pregnancy.aspx [AccessedFeb 12,
2011].
175
"That was the time [in 2002] having the slow development of
cord blood banks in India and it is also suggested that, yes,
cord blood stem cell is a good source, and a country like India
where you produce combined Australia and New Zealand
every year ...OK...that's our annual population is 25 million
which is more than the combined population of Australia and
New Zealand ...Australia is 22 million, New Zealand is 2
million ...24 million but we produced more than 25 million per
year ...so we have enough source material and if we effectively
use it probably we can do lot of wonders" (Ex-policymaker).
However, compared to firms, the government of India appears to be more
aligned towards public cord blood banking. An official of the ICMR illustrated
that:
"I belong to the lobby that nobody should store their cord
blood for future use...unless family, where siblings are
suffering or can be used for those siblings ...but otherwise it is
very important to have public banking" (Policymaker 2).
Despite having criticism of private banking and limited use for the self, private
cord blood banking firms have been able to collect a significant sample of
cord blood units over the years. The representative of a leading banking firm
during a field work visit informed that:
"Today we have more than 25,000 clients; we have their
child's cord blood stored with us" (Firm's representative, 1).
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The cord blood banking firms in India are creating expectations on the basis
that, if parents can afford it, then they should preserve their child's cord
blood, and also some of the banking firms stressed that people themselves
want to go for private cord blood banking. A firm's representative illustrated
that:
"There is a lot of hope and hype in the cord blood banking
business;there is something which is good about it...there are
people who have money who say why not ...my child is
precious I want to save it; whether it is 100% proven or not
there is some justification in saving a child's cord blood and I
can afford it, then why shouldn't I do it ...people want it ...they
come up to us and say I want to store it" (Firm's
representative,5).
Over the years, cord blood banking firms have been able to influence
expectant parents through their claims to treat large numbers of ailments and
have created a (demand' amongst expectant parents, where affordable
parents do not even question the legitimacy of private cord blood banking.
They also take (advantage' of the largely joint family system in India while
putting their claims in favour of private cord blood banking. As a firm's
representative argued:
"If there is an indication in the family it is a very good
option ...it is a very good option ...you never know when it
might come in handy" (Firm's representative, 4).
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It is also reflected from the above statement that not only 'certain future' but
'uncertain future' can also have the capacity to mobilise individuals in a
particular direction. 'You never know when it might come in handy' is
somewhat speaking about a 'speculative future'. The representative of firm
argues that, at the moment, there might be no benefit from cord blood
banking but in future we can take advantage from it. However, the firm's
representative is not sure about the future prospects of private cord blood
banking.
The other private cord blood banking firms argue that cord blood stem cells
have potential to replace bone marrow transplantation and on this basis they
are attracting expectant parents. A firms' representative of cord blood
banking opined that:
"We are of the opinion that cord blood banking is useful in
terms of regenerative medicine...there is a lot of debate as to
how useful cord blood banking is...whether it is worth
spending that money for saving your child's cord blood ...the
opinion we have is that, if you can use these cells for a
particular use...cord blood banking originally started as a
replacement for bone marrow transplantation ...it's very
difficult to get bone marrow and to store bone marrow and to
source bone marrow is difficult because we need
donors...cord blood itself could be a useful alternative for
bone marrow" (Firm's representative, 5).
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The idea here is similar to what I discussed in the previous section, that stem
cells are viewed as a novel form of therapy having the capability to replace
those existing therapies which are unable to tackle various debilitating disease
conditions. In sum, the expectations around private cord blood banking are
created on two key ways. First, if there is an indication in any members of the
family of any untreatable disease than cord blood is useful and second it can
be used as a replacement for bone marrow.
In these preceding contexts, where there are great expectations associated
with stem cells in terms of their potential use in basic research, clinical
applications and cord blood banking, India is portrayed as a global player in
the stem cell sector.
5.2.4 Expecting India as a global player
The narration of policymakers resonate the fact that the proliferation of stem
cells will be able to firmly place India in the global stem cell arena. One of the
officials of the ICMR, who is involved in the policy-making process of stem
cells over the years, believes that India is not far behind other developed
countries, such as the US and the UK, and in the next few years, India will be
able to produce some significant results in stem cells:
"Definitely we are moving at same pace with other developed
countries, probably now with Obama saying yes for stem cell
research, probably may increase funding in the US but we are
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at a par with them and definitely India at least has some
results in the next few years" (Policymaker, 1).
It is clear from the overall narration of different key players of stem cells that
in India there are positive expectations of stem cell in terms of its capability in
basic and translational research as well as in cord blood banking. In spite of
the absence of any legitimate products or services, the stem cell sector in
India has raised a significant amount of funds and attracted many patients,
not only from India but from different parts of the world as well. Drawing
from the notion of Biocapital (Sunder Rajan, 2006), I would argue that, at
least in the case of stem cell, India is more close to commercial capitalism
rather than commodity capitalism. It could be seen as a departure from its
initial mode of commodity capitalism, which was highlighted in the case of
drug development in India by Sunder Rajan (2006). It appears that the Indian
stem cell sector is now embracing the corporate culture of Western economy
such as the US where vision, hope, hype etc. dominate the bio-economy
rather than tangible products and services (Sunder Rajan, 2006). The
narration of a policymaker regarding the potential of cord blood banking in
India elucidates that India is on the path of speculative capitalism. It can be
argued that post-liberal (1991) India has cast off its largely socialist character
and now endorses the corporate culture of the West, especially after it
became the signatory of the TRIPSpatent regime in 2005. For instance, India
has recently introduced, the "Protection and Utilization of Public Funded
Intellectual Property (PUPFIP)Bill, 2008", similar to the Bayh-DoleAct 1980 of
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the US. This bill allows universities and autonomous research institutions to
patent publicly-funded research. This exercise of the Indian state reflects that
now India has also flexed its arms to commercialise its research. There is an
apprehension that the Indian version of the Bayh-Dole Act will have a drastic
effect in the health sector of India, leading to denial of basic health care to
millions by increasing the cost of medicine (Prakash and Abraham, 2009).
However, it would be premature to draw a conclusion that India has started
to fully imitate the corporate culture of US science since, in the same year Le.
in 2008, India adopted the Open Source Drug Discovery (OSDD) model, which
discourages the property rights for neglected tropical diseases. The motto of
OSDD is to make a balance between health as a right and health as a business
and to provide "affordable health care for all".
The PUPFIP and OSDD approach together elucidates that currently India is at
the crossroads of bio-politlcs, which embraces both contrasting and opposite
natures of bio-economy together and hence it can be inferred that India has
geared up for a strong market-centric approach to capture the global market
of knowledge-based economy with strong social backing.
Though at government level India is projected as a global player, some of the
key players believe that it is too early to expect India as a global player.
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5.3 Negative expectations of stem cells
Though, the majority of key players have a very positive attitude towards
stem cells as per their institutional settings, some of the key players, such as
scientists, believe that, it is very early to move from lab to clinic. A scientist
argues that:
"[I think] we are giving hope too soon; maybe it is going to be
good but 1 think we need to watch and be little more
cautious...we don't know if there are going to be any other
side-effects so 1think, unless it is going to be followed with
first of all experiments on animals then translate to human
beings then followed in human beings for at least 4 to 5 years
to ensure that there are no side-effects, only then we should
really be offering it as treatment in my opinion" (Scientist, 3).
Another scientist expressed his concerns during an interview about the
possible side-effects of stem cell intervention in human beings:
"In my opinion, because it is a caseof human subject and you
are intervening in the normal system by putting some
cells...there is a possibility that those cells may behave
abnormally on another side; or in other words there is the
possibility of some tumour formation" (Scientist, 1).
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The side-effects of stem cells are already reported in some cases at the
international level, which questions the legitimacy of high expectations in this
area (MacReady, 2009).
Against the policy makers (section 5.2), some scientists in India argue that
there is only hype of stem cells, and they do not believe that India is as strong
as the West:
"I don't think we are that strong. There is lot of hype
associated with this. I think we are starting okay. We got some
people and some good ideas and fortunately we are getting
better funding so it looks like we'll do well in future. At this
point, if you see how we are in terms of other countries, that
we are at the forefront of research, I don't agree with that"
(Scientist, 1).
Another scientist stated that:
"I find this a very hyped statement; nobody can say that India
will not be a global player in anything, whether it be car
manufacture or information technology or stem cells, but
realistically speaking in terms of how much stem cell research
is going on in the country, while there are some pockets
where there is very good research, which is world-class going
on, by and large we still have not reached the stage in many
areas where we can say that we are going to be a global
player" (Scientist, 2).
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It can be argued with the help of the above interview materials, that in India,
as far as the future of stem cell clinical applications is concerned, it is highly
contested. However, in terms of application of stem cell in understanding
basic biology and to enrich their basic knowledge, scientists in India feel that
stem cell can be a good source. The narration of Indian scientists, which is
similar to the scientists of the USand the UK, at least in the caseof stem cell
science, reflects the normative structure of scientists across the world where
the main aim is to enrich 'basic' or 'fundamental' knowledge (Cribb et al.,
2008).
The narration of key players in the Indian stem cell sector shows that the
'future depiction' of stem cell in India is similar amongst different stakeholders
in terms of its promises. However, there is a difference of opinion on how to
achieve that 'future'. The difference of opinion is more explicit between
scientists and clinicians. While clinicians are ready to use stem cell as a main
line therapy, in contrast scientists feel that more rigorous research is required
before offering stem cell basedtreatments to patients.
5.4 Creating expectations through media and internet
In addition to key players associated with stem cell development, the media
are playing a major role in the creation of high expectations of stem cell
amongst the general public in India. In the area of science communication the
role of the media has been given foremost importance. It was observed that
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the media act as a broker between science and the public and play a
fundamental role in shaping the public views for a particular scientific
endeavour (Caulfield, 2004; Nelkin, 2001). The science news coverage in the
media largely influences the attitudes of the public towards science, which
helps in setting the agenda for public policy (Nelkin, 2001). In addition, it
creates high expectations amongst the general public of emerging new
research areas,which not only help marshal resources for an early investment
but also assist in building public trust. It was believed that public trust is very
crucial for controversial technologies such as human genetics and stem cell
research (Caulfield, 2005). However, at the same time, the growing body of
literature in this domain has criticised the role of the media in raising
'unrealistic expectations' of genetics and stem cell research, which have
several social, ethical and commercial implications (Caulfield, 2004; Wilson,
2009). In addition to media coverage, especially in the case of stem cell, the
direct-to-consumer advertisement via the internet has played a vital role in
generating expectations regarding its 'potential' in treating various incurable
diseases(Lauet al., 2008).
In the case of India, the expectations of stem cell have been maintained since
2001 through various media coverage, internet and public statements from
different stakeholders over the years. Some of the policymakers also
portrayed positive expectations through publications in peer-reviewed
journals as well (Sharma, 2006, 2009). In the year 2001, when India's two
research laboratories drew attention at global level by getting NIH funds for
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their existing embryonic stem cell lines, the daily Washington Post highlighted
India's achievement with the headline 'India Plans to Fill Void in Stem Cell
Research' (laxmi, 2001). Subsequent years have witnessed a wide range of
cover stories and case studies in various national and international
newspapers, which portrayed India as an emerging global player in stem cells,
not only in basic research but also in clinical applications. From journalistic
points of view these news items attempted to balance the story by
highlighting various concerns of safety and social issues. However, catchy
headlines and a few quoted statements largely draw the attention of common
people towards stem cells. For instance, one of the leading news agencies in
India under the headline 'Stem cells: a new hope for diabetic patients'
depicted that "India's stem cell research can change the way health care is
practiced" (United News of India, 2009). Similarly, recently a story was
published in The Hindu with the headline, 'Delhi doctors save Pak boy with
stem cell transplant' (The Hindu, 2010).
Furthermore, various news items published the statements of leading
policymakers full of hope, such as "Once we achieve success, around 58
million cardiovascular disease patients and 10 million cancer patients, among
others, can benefit from it" (Indo-Asia News Service, 2006). Some of the
leading Indian science magazines in their coverage represented stem cells as
'miracle cells', where it was highlighted that stem cells not only have the
capacity to treat large numbers of incurable diseasesbut also they can offer
possibilities of endless life (Dey, 2007). It appears that 'strategically' there is a
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projection of various disease burden and simultaneously stem cells as a
possible 'miracle' to tackle these diseases through the media in order to
mobilise patients towards stem cell intervention.
Not only the Indian media but also the international media either directly or
indirectly are also engaged in creating high expectations of stem cells in India.
The Global Post, an online USnews agency, recently published a story about
the controversial clinician Dr Geeta Shroff, based in New Delhi with the
captivating headline, 'Unfettered by regulation, India pulls ahead on stem cell
treatments' (Khullar, 2009). This story was based on interview materials with
different experts. The quote of a US-basedphysician, who visited Dr Shroff's
clinic in 2007, illustrated that "India is at the forefront of emerging stem-cell
treatments in many ways." Further he argued that "convinced of their
superiority, American scientists hate the notion that the hottest
breakthroughs may be happening in other parts of the world and vociferously
denigrate them" (Khullar, 2009).
However, it is not often the case that the news coverage portrayed only
positive stories; it also highlighted concerns and warnings of stem cell
policymakers about the possible harm and potential risks with headlines such
as 'Patients beware: Stem cells won't cure it all' (Vora, 2011), 'Misuse of
miracle cure feared' (Perappadan, 2005), 'Fortis uses stem cell shot, medical
body calls it "il/egal, unethical" (Chatterjee, 2011).
Despite concerns, it seems that patients are highly influenced by the largely
positive coverage of the media, given the fact that thousands of patients have
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received stem cell interventions over the years at different hospitals and
clinics in India (Harachand and Brahiwal, 2011). Similarly, the expectant
parents are luring towards private cord blood banking. It was estimated that
on average, per year 30,000 Indians opt for cord blood banking (Vora, 2011).
In addition to the media, the websites of various stem cell hospitals, clinics
and firms, which are heavily loaded with promises of stem cells and various
claims to treat/cure patients, are creating expectations of stem cell based
treatments. Thesewebsites are also using patients' testimonials and stem cell
related promotional videos to support their claims181920.
Generally, the media coverage on biotechnology is seen as an exercise to draw
attention towards research activities of a particular institute, which helps in
attracting funds and in raising the research profile of that particular
institution. These efforts are basically confined in the developed countries
where research is largely viewed as a commercial enterprise. However, it was
argued that 'hype' through the media might generate unrealistic expectations
about the potential benefits of a technological intervention and consequently
there is apprehension that, if the given expectations are somehow unable to
materialise, then it will not only erode the public trust but also the credibility
of a particular research stream will be mooted (Caulfield, 2004). The
discussion of media coverage and advertisement through the internet about
18 http://www.chaitanyastemcell.com [Accessed Dec 17, 2011].
19 http://drrajput.co.in [Accessed Sept 14, 2011].
20 http://www.lifecellinternational.com [Accessed Dec 13, 2010].
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the potential benefits of stem cells in India shows that now the developing
world has also begun to imitate the research culture of the developed world
at least in the area of stem cell.
5.5 Summary and discussion
This chapter has discussed the real-time current expectations of stem cells in
India under the theoretical framework offered by the sociology of
expectations. The previous studies in this domain, which were largely
confined in Western settings, have highlighted that high expectations of a
particular technology are used as an effective tool for mobilising resources
and to establish various socia-technical networks. My discussion in this
chapter also reflects a similar occurrence in a non-Western setting. Over the
years the great expectations of stem cells have been able to mobilise
substantial investments for both the public and the private sector in India and
also established a close network of different key players. While analysing the
expectations of different players, it was observed that clinicians are more
excited about the therapeutic applications of stem cells in comparison to
other players such as scientists, firms and policymakers since they advocate
using stem cells as a main line therapy. If we compare the narration of
scientists and clinicians in India, it can be argued that the professional norms
across the world are the same, at least in the case of stem cells, Le. scientists
are more interested in basic research while clinicians are more interested in
clinical applications (Cribb et al., 2008).
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The analysis in this Chapter depicts that in India expectations of stem cells are
being created mainly on the basis that stem cells have the capacity to
understand the many problems of basic research and to address various
intractable diseases including the problem of organ shortage. In addition, it
was portrayed that India have many desperate patients and expectant
parents and for them stem cell is necessitate. It was also stressed that stem
cells can provide affordable medical services to a large number of poor
people in India. To attract expectant parents for the private cord blood
banking, it is emphasised that it is not only useful for the self but also for the
other family members and it has the capacity to replace bone marrow blood
cells.
Furthermore, there is a projection that India will be able to establish herself
at the international level by the promotion of stem cell in the area of science
and technology. This could be one of the reasons behind the major
government support and funding for various stem cell research programmes
in the country and the involvement of government in the creation of hope for
the potential benefits of stem cells.
The government of India is now also interested in capitalising on its research
investment. The introduction of the PUPFIPbill could be seen as an effort in
this direction. However, the presence of the OSDD model simultaneously
informs that India is still not ready to fully shed its socialist character.
Nevertheless, the expectations of stem cells reverberate that, at least in this
emerging area, India is preparing herself to adopt the corporate culture of the
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West, especially of the US. It can be argued that, under the current
environment of the TRIPS regime, India is gradually adopting the corporate
culture of the US, at least in the kind of technological development where
there is a competition for intellectual property rights. To sustain the current
global regime, a country needs substantial investments in R&D programmes
and it can only be possible under a favourable and acceptable environment
within a particular national regime. The support of a wider section of society
thus becomes necessary to justify investment in an emerging area of research
and it can only be achieved when a particular research area promises to solve
many existing problems. The articulation of vision, hope and hype with
respect to a particular technology is viewed as an effective tool to attract
public support and consequently investment. However, expectation studies
and other related discourse in this domain argued that, if given expectations
were unable to materialise or more specifically the expectations were unmet,
this might result in damaging the public trust and hence the proliferation of
technology. The case of gene therapy is widely cited to support this claim
(Wilson, 2009).
Though expectation studies speak about the possible damage of a particular
technology because of unrealistic or high expectations, they do not explicitly
pay attention to the ethical implications of high expectations, especially in the
area of biomedical research where technologies such as gene therapy and
stem cells potentially have several risks. In the past, it was argued the high
expectations of gene therapy led to the death of an 18-year-old, Jesse
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Gelsinger, during a clinical trial (Wilson, 2009) and recently, it was allegedly
reported that an Israeli boy has developed a tumour after several stem cell
interventions in a clinic based in Moscow (Amariglio et al., 2009).
In the Indian scenario high expectations of stem cells have been able to
attract many native as well as foreign patients towards unproven stem cell
serviceswhich raise legitimate ethical and governance concerns.
It was argued that the convergence of hype, hope and promises of medical
potential creates the demand for stem cell treatments for which the science
of stem cells is not mature enough (Murdoch and Scott, 2010). The immature
stem cell treatments have put patients at health and financial risk (Pandya,
2008). The high expectations of stem cells in India help in creating a
favourable environment for its proliferation, more specifically in a range of
clinical applications. These unproven stem cell applications raise the issuesof
patient safety and efficacy. Previous studies have highlighted that many
patients are also not fully informed about the pros and cons of the various
stem cell interventions (Pandya,2008).
The next chapter of the thesis has analysed the ethical issues in the
background of high expectations including the ethical perception of key
players and how are these player draw ethical boundaries as a way of
legitimising their stem cell activities.
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Chapter 6: The Ethics of Stem Cell Research and Therapy
in India
6.1lntroduction
The previous chapter has analysed the expectations of stem cells in India. I
argued that high expectations pinned on the therapeutic applications of stem
cells as well as an underlying desire of the Indian state to capture the global
market of stem cells have raised several ethical and consequently governance
issues. In this chapter, I will discuss those ethical issues which have been
associated with the proliferation of stem cells in India over the years.
If we closely analyse the debates in the area of stem cells, it can be argued
that, the use of human embryo in stem cell research emerged as the main
ethical issue in the West (Gottweis et al., 2009). In contrast, in Asian countries
such as China, India and Singapore, the use of stem cells in clinics has raised
more controversies than the source of stem cells (Bharadwaj and Glasner,
2009; Cohen and Cohen, 2010; Gottweis, 2009; Patra and Sleeboom-Faulkner,
2010; Sleeboom-Faulkner, 2011).
In this chapter, an attempt is made to discuss the various ethical issues which
have emerged with the proliferation of stem cells in India. This chapter is
closer to empirical bioethics (Borry et al., 2005; Petersen, 2011). Over the past
few years, the empirical studies of bioethics have attracted great attention
amongst the social science scholarship. The scholarship in this domain claims
that the social and cultural factors are largely ignored by the traditional
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philosophical bioethics while assessing the ethics of new technologies
(DeVries, 2003; Hedgecoe, 2004; Petersen, 2011). It was argued that
normative principles of bioethics such as autonomy, beneficence, non-
malfeasance and justice do not account for social and cultural factors and
they are highly universal and mechanical in its approach (Petersen, 2011).
Therefore, there is a need to take into account various social and cultural
factors aswell, while ensuring normative bioethics. For instance, in normative
bioethics principles there is a great emphasis on informant consent procedure
which is highly contentious in different social and cultural environments
(Zwart, 2008). Although this chapter discussesraised ethical issuesagainst the
framework provided by the principles of normative ethics, it also highlights
the limitations of such principles in different cross-cultural settings.
The aim of this chapter is to analyse various ethical issuesassociated with the
high expectation created around stem cells in India. It examines the issues
related to: a) the use of human embryos in stem cells; b) unproven therapies;
and c) the proliferation of cord blood banking. Furthermore, it analyses the
extent to which procedures of informed consent are capable of handling
some of these problems in India. It also aims to examine how different key
players legitimate or, alternatively, challenge various activities of stem cells,
Le. the construction of ethics by various key players. Specifically it draws from
the notion of 'ethical boundary-work' (Frith et al., 2011; Hobson-West, 2012;
Wainwright et al., 2006a) to examine how the boundaries between legitimate
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and illegitimate (or ethical and unethical) activity are drawn by the actors
themselves.
In doing so, this chapter focuses on the debates in India regarding the use of
human embryo in research and clinical applications of stem cells in section
6.2. Section 6.3 explores the tension amongst key players with respect to
stem cell based treatments. The stem cell treatment is widely conceptualised
as a 'business' rather than a therapy, so this aspect is discussed in section 6.4
with respect to the India stem cell sector. In addition to stem cell treatments,
cord blood banking also emerged as a potential area of 'business', which
raises a legitimate ethical concern. The ethical aspect of cord blood banking is
examined in section 6.5. In biomedicine informed consent is seen as an
important procedure to safeguard human research subjects and patients
during a clinical setting by various national and international bodies. In terms
of stem cell treatments in India, section 6.6 explores the functioning of
informed consent. The final section deals with the summary and discussion.
6.2 The use of human embryo
The use of human embryo in biomedical research has been a controversial
issue for a long time, especially, following the use of in vitro Fertilization (IVF)
techniques in the late 1970s (Hauskeller, 2004; Walters, 2004). However, their
use in stem cell research comparatively generated more heat and raised
intense debates on ethical grounds worldwide in the late 1990s, following the
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creation of human embryonic stem cells in 1998, since it requires killing of an
embryo to harvest stem cells (Hauskeller, 2004; McMahan, 2007). The ethical
issues in Human Embryonic Stem Cell (hESC)basically surround two points:
the sanctity of human life at the stage of embryo versus the promises of
human embryonic stem cells in the alleviation of suffering and to cure
diseases (Reichhardt et al., 2004). However, in addition, other issues were
highlighted which provoked intense ethical debates (Gottweis et al., 2009),
for instance: a) the source of human embryo, Le. aborted, IVFsupernumerary,
non-IVF donated, cloned; b) embryo creation date; c) embryo age; d) hESC
line origin; e) hESCline creation date; and f) hESCline research purpose.
In the West, it has been observed that the ethical debates are mainly
restricted to the use of human embryo in research and therapy, more
specifically to the moral status of human embryo and its acceptability
(Gottweis et al., 2009; Haimes et al., 2008). However, within the West itself
there are different approaches for human embryo, which results in a different
regulatory framework in terms of using human embryo in stem cells. For
example, Germany, Italy and Ireland do not allow the derivation of hESClines
from surplus IVFembryos, while the policy of the UKand Denmark is that it is
permissible to derive hESClines from these embryos (Caulfield et al., 2009;
Gottweis et al., 2009). It was argued that, "embryos are not fixed, universal
biological entities but are defined by, and acted upon relation to, their social
context" (Haimes et al., 2008: 124). It can be inferred, therefore, that there
are different ethical approaches on the same issuesacrossdifferent countries,
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and accordingly policies are made to regulate stem cell research and therapy.
It was observed that, "policies range from the complete prohibition of hESC
research (as in Ireland, Austria, Lithuania, Poland and Slovakia) through an
array of regulatory configurations that allow certain kinds of research to
policies that permit the creation of embryos for research and therapeutic
cloning (as in Belgium, India, Israel, Sweden, China, Singapore, South Korea,
and the United Kingdom)" (Gottweis et al., 2009: 5). The variations across
different nation-states provide the opportunity to negotiate ethical and legal
regimes in the global market of stem cells and it also sets the level and
direction of research in particular nation-states (Bharadwaj and Glasner,
2009).
In the case of India, it was observed that both the regulatory and cultural
environments are favourable for stem cells since the Indian government is
highly supportive and India does not carry the same kind of 'ethical baggage'
compared to most Western countries, especially with respect to eggs and
embryos (Bharadwaj and Glasner, 2009; Gottweis et al., 2009). However, the
proliferation of stem cells in India is perceived as a departure from 'an
imagined normative global order' (in principle, Euro-American order) in terms
of 'ethical and moral standards' (Bharadwaj and Glasner, 2009). This
departure results in a phenomenon, termed 'bio-crossing'. A 'bio-crossing' is
visualised as a passage across geo-political, ethical and moral borders which is
not always governed. This passage can exist independently of local and global
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normative principles and is characterised by competing and contested ethical
and moral frames (Bharadwaj and Glasner, 2009).
These competing and contested ethical frames could be seen while
comparing the ethical discourses within India with respect to the West. It was
illustrated that the human embryo does not accord that kind of significance in
India, as in the West (Bharadwaj and Glasner, 2009; Gupta, 2011); for
example, during a public consultation meeting in India, which was organised
by the ICMR, it was observed that, there was more concern about the clinical
applications of stem cells rather than using human embryo in research and
therapy. The organiser of the public consultation stated that:
"We know ethical issues in stem cell research revolved around
embryonic stem cell so we thought, because there is such a
huge diversity in India plus we are having different religions in
the country, we thought let us have consensus of all religious
bodies ...Only in one of the public consultations did they raise
the issue about embryo, that was probably representing the
Christian community' so it's quite natural they are against killing
embryo ...they say that embryo has life" (Policymaker, 1).
The provisional data of India's census 2011 shows that Christians belong to
only 2.3% population of India. The majority of India's population are Hindus
(80.5%) followed by Muslims (13.4%) and other religions such as Sikhs (1.9%),
198
Buddhists (O.8%),and Jains {O.4%)21.It can be, therefore, argued that there is
a small voice against the killing of an embryo in India at the moment.
However, Hinduism, which is the dominant religion in India, has pluralities of
views regarding the moral status and killing of an embryo. The killing of an
embryo is seen as an evil act. Artificial insemination, test tube babies and
abortion are not acceptable and considered as sinful acts (Lakshmi, 2001). In
the epic, The Mahabharata, it is stated that life begins at conception, as
Mishra pointed that:
"The ancient system of Indian medicine known as Ayurveda
assumes that fetuses are alive and conscious when it
prescribes a particular mental and spiritual regimen to
pregnant women. This same assumption is implicit in the
Mahabharata, the Hindu epic about a fratricidal war
apparently fought in the first millennium BC. In one of its
famous stories, the warrior Arjuna describes to his pregnant
wife a seven-stage military strategy. His yet-to-be-born son
Abhimanyu is listening, too. But as Arjuna describes the
seventh and last stage, his wife falls asleep, presumably out of
boredom. Years later, while fighting his father's cousins, the
hundred Kaurava brothers, Abhimanyu uses well the military
21 http://censusindia.gov.in/Ad_Campaign/drop_in_articies/O4-Distribution_by_Religion.pdf
[Accessed Jan 04, 2012].
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training he had learned in his mother's womb, until the
seventh stage,where he falters and is killed" (Mishra, 2005).
It was argued that in Hinduism there is more support for 'the personhood of
an embryo' than in Christianity (Mishra, 2005). However, in contrast, in the
same epic another narration reflected different views, which indirectly
support the use embryo in stem cell research.
There is a story about the birth of the hundred Kaurava brothers in the
beginning of The Mahabharata epic where lilt is mentioned that after two
years of pregnancy their [Kaurava's] mother had produced a massof flesh and
then a sage divided the flesh into 100 parts, which were treated with herbs
and ghee, and kept in pots for two years - from which the Kaurava brothers
emerged" (Mishra, 2005). By highlighting this piece of story, the proponents
of stem cell research in India argued that this is an early evidence of human
cloning through stem cells (Mishra, 2005) and stated that stem cell
technology was in fact one of the lost sciencesof India (Thambisetty, 2003).
In Hinduism, therefore, it can be argued that on the one hand there is respect
for human embryo, while on the other hand the killing of a human embryo is
permissible under certain circumstances. Hinduism is perceived as less
monolithic and more diverse than any other religion such as Christianity and
Islam (Mishra, 2005). The Hindu tradition has flexibility to accommodate
pluralities of views and it allows a more pragmatic approach to achieving the
desired goal and in doing so morality is devalued sometimes (Varma, 2006).
lannoy (1971) illustrated that, "Hindu ethics has its public face - Dharma, or
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normative, rules - and its private wisdom, or pragmatic rules, to distinguish
between the principles men espouse and the tactics they adopt" (quoted in
Varma, 2006: 28). Although in India, it is believed that life begins at
conception, the destruction of an embryo is justified in extraordinary
unavoidable circumstances and when it is done for a greater cause
(Reichhardt et al., 2004). For instance, abortion is permitted, if there is a
direct threat to the life of the mother (Walters, 2004).
Islam, the second major religion in India, also does not have any opposition
for embryonic stem cell research since they do not respect early embryo as a
human being (Reichhardt et al., 2004).
In Buddhism, there is no ethical problem with the therapeutic application of
adult stem cells. However, they are against the intentional destruction of
human embryo. Their views on conception are similar to Hindu traditions as
the followers of Buddhism believe in the beginning of life at the time of
conception (Keown, 2004).
In India, there is no consensuson the moral status of the human embryo. It is
often argued that, "different philosophical, religious and ideological
persuasions define and debate life in an eclectic and open-ended way"
(Bharadwaj, 2009: 246).
In India, it seems that there is a common voice in the favour of embryonic
stem cell research, if it is for therapeutic purposes, as a scientist expressed in
his opinion:
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"lf they [researchers] will use for therapeutic application and
not for any other purpose then I don't think there should be
any problem of ethical clearance" (Scientist, 1).
The opinion of this scientist echoes the earlier discussion of Hinduism's views
where ethical issues are diluted for a greater cause in terms of curing disease
and alleviating suffering. This view is also adopted in the Indian guidelines for
stem cell research and therapy (2007), where therapeutic cloning is
permitted, which is similar to some of the Western countries such as the UK,
Belgium and Sweden (Gottweis et al., 2009).
The development of embryonic stem cells in India is closely linked with IVF
clinics. It is illustrated that, the proliferation of various IVF clinics in India
largely weakened the issue of the moral status of a human embryo
(Bharadwaj and Glasner, 2009; Gupta, 2011).
6.2.1 Stem cell and IVF clinics
IVF clinics in India are seen as the potential suppliers of raw materials (e.g.
ova and embryos) for stem cell research (Gupta, 2011). In India, where
infertility is stigmatised, couples are offered free IVF in return for donating
embryos for [stem cell] research (Salter and Waldby, 2007; Bharadwaj and
Glasner, 2009; Bharadwaj, 2003). As a result, private IVF clinics have
flourished without any stringent oversight (Gupta, 2011; Widge, 2002) as
highlighted in Chapter 1.
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In India, there are only guidelines for IVF clinics and hence any violation
cannot be punished in the absence of a law. In a recent study, Bharadwaj and
Glasner (2009) observed that IVF clinics in India, in general, generate more
than a dozen embryos in a cycle and, even after three or four cycles of
embryo transfer, IVF clinics are still able to keep half of the spare embryos for
stem cell research. In exchange for free IVF, the expectant parents do not
generally have any concerns about the future 'exploitation' of their 'left over'
embryos (Bharadwaj and Glasner, 2009) and the procedure of informed
consent also becomes a ritual exercise in order to avail 'free IVF treatments'.
It appears that, against this backdrop, there is a general acceptance of using
'spare embryos' in stem cell research in India. A stem cell research scientist in
India believes that:
"To my mind there is no ethical problem in using spare
embryo because I think that in any case ART clinics are
generating these embryos and, if the donors have no problem
with it, to my mind this is not an issue. I think those are a good
source for human embryonic stem cells because, to me, they
don't represent an independent life form, they are a
dependent life form, so I think this is the perfectly good
source for embryonic stem cells" (Scientist, 3).
The representative of a firm also expressed his opinion in favour of 'spare
embryos' by citing the DBT-ICMR guidelines, 2007:
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"I think there are well-defined guidelines by the ICMR. We can
take an embryo from IVFwith the consent of the donors and it
should be a spare embryo" (Firm's representative, 4).
As per the DBT-ICMR guidelines, 2007, the use of spare, surplus and
supernumerary eggs in stem cell is permitted after informed consent (Gupta,
2011).
In the preceding context, it can be argued that, in India, both cultural and
regulatory environments undermine the larger philosophical issues of the
moral status of a human embryo. The use of spare embryos is seen as
permissible. There is no stringent law to limit the generation of numbers of
embryos in a cycle. In exchange for the free IVF facility the morality attached
with embryos is diluted. As a result, the use of embryos in research and
therapeutic applications of stem cells has proliferated over the years
(Bharadwaj and Glasner, 2009; Gupta, 2011). However, the larger issue in
India is the use of stem cells in clinics, since it is still in an experimental stage
and largely unproven. However, some of the clinicians in India are offering it
as a standard therapy for a large number of incurable diseases. This has raised
several ethical issues in terms of efficacy of the treatments and safety of the
patients.
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6.3 Experimental vs. standard therapy
The clinical applications of stem cells is a rapidly emerging field in India
(Sleebom-Faulkner and Patra, 2011), given the mushrooming of
hospitals/clinics across the country. Both public and private sector hospitals
are offering therapies for a wide range of untreatable diseases, such as spinal
cord injury, muscular dystrophy, myocardial infarction, Alzheimer's disease
and many more, using mainly adult stem cells (Patra and Sleeboom-Faulkner,
2010; Sleeboom-Faulkner and Patra, 2011). The majority of clinicians are
using autologous stem cells for treatments, except a few, who are using
embryonic stem cells (Bharadwaj and Glasner, 2009; Patra and Sleeboom-
Faulkner, 2011). India has become one of the favourable destinations of stem
cell based therapies, both for domestic as well as for foreign patients (Cohen
and Cohen, 2010). However, the clinical development of stem cells in India is
not validated by a wider medical and scientific community in the absence of
scientific evidence in terms of basic research and clinical trials (Blakely, 2009;
Patra and Sleeboom-Faulkner, 2010).
A scientist in India expressed his concern regarding the unproven stem cell
clinical development by saying that:
"There are lots of clinics in India, I mean doctors in India who
offered treatments which is not clear. I mean they are not
clear about the process, the procedures and they also charge
patients so it's gone from being an experimental therapy to
almost a standard therapy. I think it is wrong" (Scientist, 2).
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He further argues that:
III don't think they have been doing it ...if you have not done
proper trials ...it is not clearly established as a therapy ...this
should not be done" (Scientist, 2).
Another clinician of a public hospital stated that:
"So far as practically proving the utility of a stem cell is
concerned, the only situation where it has been proved to be
useful and it can be recommended in haematological
disorders...certain haematological disorders. Other than that
everywhere else it is experimental and should do as a part of
clinical trial. There is no justification for offering routine
treatment with stem cell basedtherapies" (Clinician, 4).
The clinician believes that stem cells should be used only in certain blood-
related disorders, and in other conditions it should only be offered as a
clinical trial and not as a standard form of therapy. The recently constituted
NAC-SCRTemphasises that "given the current state of knowledge and
evidence, only hematopoietic stem cell transplants for blood diseases and
limbal stem cell transplants for corneal diseases can be performed as
standard therapy outside of clinical trials in India. All other forms of stem cell
transplants, including those with blood or marrow derived stem cell, cord
blood stem cells, mesenchymal stem cells and any embryonic stem cell
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derived tissue should only be used within an appropriately reviewed and
monitored clinical trial"22
As discussed in Chapter 4, only by 2009 did the regulatory authority of India
approve the first true stem cell clinical trials in the country (Jayaraman,2009).
However, before that, several caseswere reported to treat/cure a significant
number of patients from different parts of the world as well as patients from
India, using stem cells. It infers that all of these patients, before 2009, had
received stem cell intervention without having clinical trials. It is a matter of
concern that India's premier research intensive public hospital, the All India
Institute of Medical Science(AIIMS), New Delhi had already conducted clinical
trials on 750 patients during the period 2003-2006 for diseases including
myocardial infarction, cardiomyopathy, muscular dystrophy, cerebral palsy,
diabetes, retinal pigmentosa, and spinal cord injury (Patra and Sleeboom-
Faulkner, 2010). In 2005, there was a report published in national newspapers
claiming the 'success' of AIIMS to treat cardiac disease using stem cells.
However, there were no publications found in terms of basic research, or
Phases1 or 2 clinical trials prior to use of this stem cell based treatment. The
ICMRofficially raised concerns over AIIMS' work since it had not taken prior
approval from a regulatory authority (Pandya,2008; Singh, 2005).
During field work, it was found that those who are involved in clinical
applications of stem cells in India are not following the mandate of existing
guidelines, asa scientist comments:
22 http://www.icmr.nic.in/icmrnews/NAC.htm [Accessed Oct 18, 2012].
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"Research people take permission no problem but question
is...Permission is most important for those who use those cells
in clinic that is most important but the idea is to make their
hand tied but actually they are not going to ethical committee
or other apex committee to prove or to accept their
proposals ...They don't bother ...They keep on using that"
(Scientist, 1).
The narration of scientists in India not only raises ethical issues but also draws
a clear line between 'bench' and 'bedside' and reflects the tension between
basic and translation research. Salter and Qui (2009: 47) perhaps correctly
argued that, "for novel fields of biomedicine, the knowledge production
process from the basic science, through clinical experimentation and trials, to
the therapeutic product is long, arduous and uncertain." Drawing on ideas of
boundary work, it can be argued that clinicians in India are unable to
understand the scientific underpinning of laboratory research particularly in
the case of stem cell translation (Wainwright et al., 2006a). However, the
proponents of 'bedside' claim that scientists lack the ability to understand the
problems of research on human subjects (Wainwright et al., 2006a). It can be
argued therefore that there is a tension between 'two cultures' in India
similar to that which has been observed in the West.
Though, the tension is clearly visible here, the narration of clinician 4 who is
working in a research-intensive public hospital and involved in various stem
cell projects, suggests that it would be hard to draw any clear conclusion that,
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at a professional level, scientists and clinicians are on different poles. The
clinician illustrated that:
"There are a number of people who are offering stem cell...so-
called stem cell therapy out in the local market which is
completely unproven (Clinician, 4).
Another clinician of a corporate private hospital who is conducting stem cell
clinical research argued that:
"Stem cell therapy as of now is research-based therapy and
used in modalities or in situations in which treatment is
advised...there is no way we could allow a clinical practice of
therapy which is not yet approved" (Clinician, 11).
The statements of clinicians indicate that not only scientists but also some
clinicians, whether they are practising in private hospitals or public hospitals,
have concerns over experimental stem cell based treatments. It can be
argued therefore that the boundary between scientists and clinicians is
blurred in the case of stem cell science in India, at least on the issue of its
clinical applications.
In addition to concern over unproven therapy, it was highlighted that, no
record is maintained in terms of safety and efficacy of the stem cell
interventions, by the stem clinicians, and hence, the evaluation of their work
done becomesa daunting task. An ex-policymaker of the ICMRasserted that:
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"They [clinicians] continue to do this therapy and people are
going to them for therapy but we have no documented proof
of how well they are doing the proper clinical trial or
maintaining records where you can systemically evaluate the
work done and see the outcome but we don't have ...but they
[clinicians] claim and these all are claims and we don't accept
them as a standard treatment at the moment" (Ex-
policymaker).
It was also highlighted in various academic studies as well as in the media that
Indian clinicians are unable to provide the treatment procedures and protocol
of their study (Blakely, 2009; Cohen and Cohen, 2010). The ex-official of the
ICMR, who is very critical about the overall stem cell clinical development in
India, again stated that:
"The hype is more, and the hope is definitely there but at the
moment proof is still not there ...because of hype patients are
willing to go to any extent to spend money to get the
treatment done ...naturally ...they are suffering' they want
some cure so they are willing to go ...but we don't have any
proof to say that, yes, it is really working ...it is going to take
some more time" (Ex-policymaker).
In the absence of any proof and documentation, it is very hard to know, what,
exactly, stem cell clinicians are using for the treatments. Furthermore, it was
argued that most of the clinicians in India do not even know about stem cell;
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instead they are using it for different treatment modalities. The
representative of a firm stated that:
"They [clinicians] don't know really what they are using...1
know of instances where a doctor claims that I am using stem
cells and where I have seen that actually it is not stem cells to
begin it...it is something ...it is something which he has been
told that this is the stem cells, you use this and this is going to
help" (Firm's representative, 5).
In general, biomedical research is subject to peer review to ensure scientific
rationale and transparency, amongst other things (Hyun et al., 2008).
However, in the caseof stem cell in India it appears that both peer review and
transparency are not ensured. For instance, the controversial clinician Dr
Shroff always refused to publish her work or allow the inspection of her clinic
(Sinha, 2008).
In spite of all these above highlighted concerns, those clinicians who are
offering unproven stem cell therapy have their own justifications for their
stem cell treatments. Some of the clinicians in India are trying to defend their
act by citing the Helsinki Declaration. A clinician of a public hospital in India
expressed his opinion in the favour of an unproven therapy and questions the
criteria of a proven treatment:
"See there is a very clear-cut international guideline for
research on human subjects, called the Helsinki Declaration.
The Helsinki Declaration, I think paragraph some 31 or 33
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clearly states that the condition for which there is no cure or
for which all treatment options have been exhausted, a
physician has a right to use unproven therapy ...our ethical
guidelines are very clear we only treat those patients, we
found there is no other hope and we are getting good
improvement...what is proven treatment? ...what is the
criteria of proven treatment? ...when does something become
proven?...so that itself is a question mark...and then a
physician has a right to use an unproven therapy. There are
enough publications now...clinical papers which are showing
improvements" (Clinician, 2).
The main argument made by clinicians is that, if all treatment options have
been exhausted for a particular disease,then a physician has a right to usean
unproven therapy. The Helsinki Declaration (1964 amended in 2008) in its
article 32 stated that lithe benefits, risks, burdens and effectiveness of a new
intervention must be tested against those of the best current proven
intervention, except in the following circumstances: a) the use of placebo, or,
no treatment, is acceptable in studies where no current proven intervention
exists." Further, article 35 of the Helsinki Declaration illustrated that, "in the
treatment of a patient, where proven interventions do not exist or have been
ineffective, the physician, after seeking expert advice, with informed consent
from the patient or a legally authorized representative, may use an unproven
intervention if in the physician's judgement it offers hope of saving life, re-
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establishing health or alleviating suffering. Where possible, this intervention
should be made the object of research, designed to evaluate its safety and
efficacy. In all cases, new information should be recorded and, where
appropriate, made publicly available."
The Helsinki Declaration does allow using experimental therapy. It is subject
to informed consent and transparency, however. In the Indian case it can be
argued that stem cell clinicians are following the mandate partly, not
holistically. The clinician 4 has argued against the way, the Helsinki
Declaration is being used to justify unproven stem cell therapy in India:
"I don't think those people really fully understand what the
Helsinki Declaration is all about and it is very unfair to invoke
the Helsinki Declaration in doing all these kind of things
becausethen there is no end to justifying whatever they want
to do; this is all I can say, they have their points of view. I
don't think, the Helsinki Declaration saysthat you can go and
do whatever you want to do. It's not like all these so-called
therapies are completely harmless. They have potential for
causing definite harm to patients, so looking at the Helsinki
Declaration here is actually very misleading"(Clinician, 4).
The above contrasting narration of clinicians reflects that the use of
experimental therapy for terminally ill patients is highly complex since at
international level also there is no clear cut framework to address this issueas
highlighted in Chapter 2. This is the reason for several campaigns from
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patients worldwide in the past and most recently, Abigail Alliance Vs Von
Eschenbach, for the right to access experimental drugs/therapy (Falit and
Gross, 2008). It is argued that it is unfair to wait for long in the case of life
threatening conditions (King, 1995). In this situation the act of some clinicians
in India could be justified that they are providing treatments to terminally ill
patients. At international level in many countries there are mechanisms in
place dealing with access to experimental drugs/therapy under
'compassionate use' with certain safeguards and prior approval from
regulatory bodies. However, these mechanisms are not uniform and across
the countries it is highly varied asdiscussedin Chapter 2.
In Indian conditions as per information provided by a clinician, there is no
policy document with respect to 'compassionate use'. This means that the
Indian clinicians are using stem cell intervention in the name of helping
terminally ill patients without any safeguards. These therapies are being
offered directly to the patients without having any pre-clinical studies and
clinical trials, aswas reflected by the statement of a clinician:
"There is a new thought among clinicians and groups which
are currently involved in autologous, that is something known
as practice-based evidence; till now we were thinking only in
terms of evidence-based medicine for which clinical trials are
required. Here clinical trials, I would say one thing would be
practically or realistically for follow-up of 10 years or 15 years
is not feasible as of now, when we know that it is safe. See
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what we are doing is not a clinical trial or a randomised
control, what we are doing is a clinical study" (Clinician, 3).
This 'clinical study' is against the national and international norms (DBT-ICMR,
2007; ISSCR,2008). These guidelines in principle advocate that the stem cell
based treatments should be conducted only under clinical trials except for
certain conditions such as bone marrow transplantation, and they should
proceed through rigorous pre-clinical and clinical studies before
administration in humans (DBT-ICMR, 2007; ISSCR,2008). The international
Society for Stem Cell Research (ISSCR) in its guidelines, "condemn[s] the
administration and unproven use of stem cells or their direct derivatives
outside of a clinical trial" (ISSCR, 2008: 4-5, quoted in Murdoch and Scott,
2010).
During field work, it was also found that most of the clinicians in India believe
that they are using adult stem cells, which are safe and therefore there is no
need to go through a pre-clinical study on an animal model or clinical trials on
human beings. Clinician 2 who is very active in stem cell translation expressed
his opinion that:
"We don't have any problem; we are using autologous bone
marrow derived stem cells. The autologous stem cells have
been going for many years for treating blood disorders and
everything so it is a safe treatment. We got no side effect
whatsoever with stem cells per se...so I think there is no safety
issue at all" (Clinician, 2).
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Apart from invoking the 'Helsinki Declaration' and 'adult stem cells' to justify
the clinical activities, the 'desperation of patients' is also being quoted to
legitimatise the use of stem cells in clinics. The representative of a firm who
provides stem cell isolation services to various hospitals and clinicians in the
support of stem cell therapy quoted the argument made by a patient:
"If you saywhatever you are doing is only for research, do you
think I have to live my life like all this until death? Can't you try
whatever you know is possible?" (Firm's representative, 2).
Drawing on the notion of ethical boundary-work, the above opinions of
different clinicians reflect that the 'Helsinki Declaration', 'adult stem cells' and
the 'desperation of patients' are used to justify the therapies based on stem
cells. In doing so, the Helsinki Declaration is being used as a justification for
experimental therapy, and adult stem cells are often portrayed as safe
therapy to address the safety concerns. In addition, it is argued that the
patients are desperate to go for stem cell based therapies since existing
therapies are unable to address their particular disease conditions. As far as
the use of adult stem cells is concerned, some other key players suggest that
there is a need for follow-up for many years to ensure that the adult stem
cells are safe. The representative of a public cord blood banking firm opined
that:
liAs of now, we know that adult stem cells are safe but we
don't know if there are going to be any other side effects, so I
think unless it is going to be followed with first of all
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experiment on animals then translate to human beings then
followed in human beings for at least 4 to 5 years to ensure
that there are no side effects, only then we should really be
offering as treatment in my opinion" (Firm's representative,
1).
Some of the clinicians, who are working in public hospitals, believe that it is
very early for various Indian centres to use stem cells in clinics:
lilt is true that we have to go for phase 1 study for another 2-
3-4 years for all the stem cell applications then only you can
utilise them for proper clinical studies ...lt is very premature
for Indian institutes to utilise stem cells" (Clinician, 6).
A scientist of a public research laboratory claims that there is a possibility of
tumour formation, even in the case of autologous stem cell intervention.
Further, he advocated for all possible tests before moving to translational
level:
"In my opinion, because it is a case of human subjects and you
are intervening in the normal system by putting in some cells,
those cells are patient-derived such as autologous, there is the
possibility that those cells may behave abnormally on the
other side or in other words there is the possibility of some
tumour formation OK...so for me all possible testing should be
done before it goes to phase 1 clinical trial" (Scientist, 1).
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The adverse outcome of an unproven adult stem cell is already reported in
the Feb 17, 2009 issue of PLoSMedicine, where an Israeli boy had developed
a tumour after getting an adult stem cell treatment in a clinic in Russia
(MacReady,2009).
The above discussion depicts that the majority of the clinicians in India are
offering various stem cell interventions as a main line therapy, though both
the scientific community and regulators in India, including a few clinicians and
the representative of a firm, believe that it is still an experimental therapy
and it should not be used as a standard therapy. There is need to follow up
stem cell therapies for some years to ensure safety.
However, clinicians who are offering stem cell therapy in India legitimatise
their activities by citing the Helsinki Declaration. In doing so, they also insist
that using adult stem cells is safe, despite them having no evidence in the
form of clinical trials. In addition, they invoke that patients themselves want
to go for stem cell basedtreatments.
The willingness of patients has a direct link with the expectation rhetoric, as
policymakers are of the view that, because of hype, patients are attracted
towards unproven therapy. It can be argued that in India patients are being
used as one of the necessary resources for the development of stem cell
science (see Chapter 5), which paves the way for the application of an
unproven therapy.
The use of experimental stem cell therapy has raised safety issues for the
patients asthere is evidence of tumour formation by using adult stem cells. In
218
addition, one of the main worries, apart from safety issues, is that patients
are being charged a hefty amount for risky treatments. In the Indian case the
high expectations attached to stem cells not only poses possible health risks
for patients but also financial risks.
6.4 Therapy or 'business'
The International Society for Stem Cell Research (ISSCR) Guidelines for the
Clinical Translation of Stem Cells condemns the charging of patients for an
unproven use of stem cells, and argued that, these activities are against the
norms of professional ethics (ISSCR,200B). It is observed that patients in India
are paying a hefty price for an unproven therapy (Blakely, 2009). An official of
the ICMR is clearly against this money-making endeavour, as she illustrated:
"For all these unproven therapies you are not supposed to
charge them. These are in the form of clinical trials. These are
not a therapy" (Policymaker, 2).
Some of the clinicians also support the view of ICMR's official, as a clinician
argued that:
"Basically it is a money-making endeavour for all these people
who are doing it, so obviously there are lot of ethical issues in
this situation"(Clinician, 5}.
However, the other clinicians in India have their own justification for charging
the patients. A clinician of a leading corporate hospital, who was recently in a
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controversy for the same (Chatterjee, 2011), made a statement in the favour
of charging the patients.
"Nowhere in the guidelines, is it mentioned that money would
not be charged. Especially, what we are doing with these stem
cells which we retrieved from the bone marrow, there are
centrifuge and now that equipment is costing something, that
is FDA approved equipment, nobody will provide you free of
cost so who will bear the cost?"(Clinician, 10).
The above clinician justifies charging patients by highlighting that DBT-ICMR
guidelines do not prevent this happening. However, he ignores the key point
that stem cell should not be used as a standard form of therapy. Similar to the
Helsinki Declaration, the national guidelines are also being cited to justify the
'business' of stem cell. In addition to stem cell treatment 'business', the cord
blood banking 'business' is also growing in India, which raises various concerns
similar to stem cell transplantation as described in the following section.
6.5 The ethics of private cord blood banking
In addition to therapeutic application of stem cells, in recent years the
mushrooming of private cord blood banking firms could be seen in India.
Chapter 4 has described in detail the overview of the stem cell sector in India,
which depicts that the majority of firms are engaged in the 'business' of cord
blood banking. They are mostly of foreign origin and private in nature. The
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various studies, in both the science and social science domains, have shown
that it is rarely used for the self and is basically based on 'future promises'
and 'capitalising hope' (Kaimal et al., 2009; Martin et al., 2008b). The chances
that a particular child will develop a condition requiring cord blood
transplantation are very slim. It has been observed that 0.04% (1/2,500) of
cord blood units stored would ever be used for autologous transplantation.
The reason is that the occurrence of diseases currently treated with cord
blood is small, and many patients would not be eligible for autologous cord
blood, including those with genetic disorders and leukaemia (Kaimal et al.,
2009).
The data from the interviews in India have shown that the mushrooming of
private cord blood banking potentially exploited expecting parents. The
representative of a hybrid (both public and private in nature) cord blood
banking firm in India clearly stated that:
"Private banking is rarely used for the self. It is very often .
this is something that people are being kind of promoting .
saying ... it can be used for the child from whom it is collected
and this is rarely the case at all because, if the child has got
the genetic problem and it has not been known at birth, the
stem cells collected from the child would also be affected with
the same problem and, unlessyou get involved in some sort of
manipulation of those stem cells and then try to introduce
them, only then will it be useful to the child from whom it has
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been taken. The only instance when it can be used for the
child from whom it's taken is if it is an acquired illness of some
kind or something which is not genetic, in those instances yes
... when you talk about private banking it is more likely to be
used only by somebody else in the family ... maybe an older
sibling or maybe somebody else" (Firm's representative, 1).
A scientist who is involved in research using cord blood stem cells opined that
it is more useful in the case of allogenic transplantation (Le. a patient receives
stem cells from his own blood) in contrast to autologous transplantation (Le.
a patient receives stem cells from a donor).
tiThe cord blood cells if at all, it can be used in an allogenic set
up, it will be wonderful cells but for somebody used for
autologous and the boy will be or kid will be grown and then
he or she will have some problem and then the cell will be
transplanted in that way it has no impact ... impact will be less
than .0001%, but if it is allogenic it will have tremendous
potential" (SCientist, 1).
In spite of, the rare chance of self-use, cord blood banking firms in India are
attracting patients in the name of 'biological insurance' (Mascarenhas, 2009),
Le. "an insurance for their child's future wellbeing" (Sullivan et al., 2005).
However, a scientist feels that it is a kind of insurance where one will not get
anything and it is only a money-making endeavour:
222
"This is a short- time businessstrategy that some people have
decided...1don't want to sound too harsh but in some way I
really feel that this is a yuppie phenomenon okay...somebody
has one lakhs (""US$2,000) to spend and they decide that
wow! nothing is too good for my child so I am going to spend
the lakhs, essentially on liquid nitrogen charges for preserving
something. It sounds like a good idea but actually speaking
there is not that much benefit to cord blood banking. It's like
an insurance policy except in the caseof an insurance you are
going to use it at some point of time ...whereas in cord
blood ...you know after the age of 21 you can give an
autologus bone marrow transplant, why you need to have
cord blood" (Scientist, 3).
The main criticism here is that private cord blood banking has a very limited
use for the self. It is already documented through various studies that there
are very low chances that a child will need his/her cord blood in the future
(Hollands and McCauley, 2009). Furthermore, cord blood banking firms at the
moment only preserve cord blood till the age of 21; then the question arises,
what would happen if a child needed any transplantation after that age?The
scientist argued that there is not much clinical benefit of preserving cord
blood. Patients are being charged for only preserving materials such as liquid
nitrogen. It does not deliver what it promises in the name of 'biological
insurance'. Similar opinion has been also expressed by some other study in
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the West, as Nelson argued that "insurance provides a certain benefit for an
uncertain future"; however, in the case of stem cell banking, there is "an
uncertain benefit combined with uncertain future" {Nelson, 2008b: March
13}.
The scientist 3 is of the view that the cord blood banking is more beneficial for
firms themselves rather than the child of expectant parents. She stated that:
"To charge people for a low probability event sounds more
like a business plan than a necessity" {Scientist, 3}.
The private cord blood banking is even criticised by the representative of a
firm, who, himself engaged in the 'cord blood banking business', He
expressed his opinion against the preservation of cord blood, if a child is
affected by any genetic disease:
/tThe problem is that you can't use your own cord blood if you
have a genetic disease. If you have a blood disorder later in
life then you can't use your own cord blood because the stem
cells in the cord blood may also have the same genetic disease
or the same problem which you have now, so that really
makes life difficult for cord blood banking companies because
how do you justify this?" {Firm's representative,S}.
The European Commission's Group on Ethics in Science and New
Technologies' {EGE} report on the ethics of private cord blood banking also
questions the legitimacy of private cord blood banks for self-use. This report
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argues that, "they [private cord blood banks] promise more than they can
deliver" (Puigdomench-Rosell and Virt, 2004:20). The representative of a
hybrid cord blood banking firm argues along the same lines:
"They do give a lot of false claims. There is a long list of 70
diseasesthat everybody keeps counting ...1think, there needs
to be more serious studies that go on before one can actually
say it can be used for late year illness...their tall claims really
frightened me...if you go to the website you feel that every
disease under the sun can be cured" (Firm's representative,
1).
It is argued that, the cord blood banking firms are playing with the emotion of
parents. An !CMRofficial stated that:
"Private banking, ! find playing with the emotions of people
who are donating or storing their cord blood ...after 18...21
years its maintaining them for so long is of no use...! don't
think so...Unless and until in family you need somebody
requires then definitely one should store that"(Policymaker,
2).
The statement of the policymaker echoes the similar observation highlighted
by Brown and Kraft whilst studying the role of expectations in the proliferation
of cord blood banking in the UKwhere emotion playsan important role. It was
reflected by this study that, at the time of birth, mothers are more emotional
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and also quite vulnerable and they can be easily influenced by any promises if
it is for the future of their child (Brown and Kraft, 2006).
The other main ethical concern is that most of the firms in India do not
possess enough scientific expertise to retrieve the stored cord blood. A stem
cell clinician raised this issue during the field visit:
"My experience with one of the cord blood banking was, they
have saved it but they don't know how to retrieve it. They
don't know a standardised way to remove [that] preservative
and in a patient who had an autologous cord blood store we
could not use her stem cell because the company did not
know how to use it" (Clinician, 3).
In recent years, apart from umbilical cord blood banking, firms in India have
started offering storage of other 'potentials sources' of stem cells; for
instance, umbilical cord blood tissues, menstrual blood, milk teeth and dental
pulp, similar to other banking firms in the Western countries (Dasgupta, 2010;
Nelson, 2008b). The representative of a leading cord blood bank in India
provided the following information during the field visit:
"The last couple of years we have set up research operations
where we have launched the umbilical cord tissue bank that's
a complimentary service to the cord blood banking service;
now expecting parents have the opportunity of having the
children's cord blood and tissue stem cell stored at birth. We
also now license the technology from CryoCell, i.e. menstrual
226
blood service ...we are planning to roll out in the next few
months in India" (Firm's representative, 3).
However, the representative of another firm argues that, it is practically
impossible to retrieve stem cells from frozen cord tissue.
"Some companies are saying okay ...you pay us a small amount
more and we will save the tissue for you. We will take the
umbilical cord tissue and we will save it for you; whenever you
need cells, we will remove it and we will derive cells from it
and we will give it to you, which is hoggish because if you see
the umbilical cord it is the complex tissue, it is thick
sometimes and the thickness makes it difficult to freeze it ... if
you take cord tissue and just freeze it you will kill all the cells
which are there in the cord; you can't derive any cell from it
later on but it is a marketing gimmick" (Firm's representative,
5).
It is clear from the above discussion that private cord blood banking firms in
India are primarily a business venture. This business is based on promises
rather than any tangible products or services. Expectant parents are being
mobilised on 'emotional grounds'. The notion of 'biological insurance' is also
playing a major role in attracting expectant parents. However, there are very
slim chances that a child would ever use her/his preserved cord blood in the
future. Furthermore, some firms claim to treat various genetic disorders by
using a child's own cord blood, which is again not valid since stem cells in the
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cord blood may contain same genetic defects. It was argued by some of the
informants that firms do not even know how to retrieve stem cells from the
preserved cord blood, which raises concerns in terms of the legitimacy of
banking firms.
The development of private cord blood banking in India, which is similar to
the development in the West, reflects the universal nature of bio-economies
which "depend on a promissory future economic value and potential rather
than present use" (Martin et al., 2008b: 128).
It is argued that, in a medical condition where the main motive is to make
money, it becomes very difficult to obtain informed consent and, moreover,
when clinicians do not disclose their treatment procedures for an untested
therapy (Cohen and Cohen 2010). In India, the informed consent procedure,
in general, always has been a debatable issue given medical paternalism and
the problem of patients without basic literacy (Kalantri, 2004; Rajkumar et al.,
2007). The stem cell research and its clinical application can be seen as a
further addition into this.
6.6 Stem cell translation and informed consent
Informed consent is seen as one of the key aspects in biomedical research and
therapy for the safety and autonomy of patients. It is recognised as the main
bioethical principle "to protect the individual patient or healthy volunteer
subject from possible exploitation and harm" (Corrigan, 2003: 771). There is a
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great emphasis on informed consent all over the world, at least on paper,
through various national and international guidelines (Kalantri, 2004). As per
the Helsinki Declaration, 'informed consent' refers to:
"In any research on human beings, each potential subject
must be adequately informed of the aims, methods, sources
of funding, any possible conflicts of interest, institutional
affiliations of the researcher, the anticipated benefits and
potential risks of the study and the discomfort it may entail.
The subject should be informed of the right to abstain from
participation in the study or to withdraw consent to
participate at any time without reprisal. After ensuring that
the subject has understood the information, the physician
should then obtain the subject's freely-given informed
consent, preferably in writing. If the consent cannot be
obtained in writing the non-written consent must be formally
documented and witnessed" (World Medical Association
Declaration of Helsinki, 2008).
However, various studies have shown that 'consent' is hardly 'informed' in
most of the cases (Doyal, 2004). The international universal procedure of
informed consent, more specifically the principle of autonomy, largely ignores
the importance of culture, language and levels of education (Corrigan, 2003;
Hoeyer, 2009; McCabe et al., 2005; Schenker et al., 2007). For example, in
India, where most of the decisions are taken collectively at the level of family
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(Bharadwaj and Glasner, 2009), it is very hard to adhere to the principle of
autonomy. Furthermore, the content of the consent form is usually written in
English and it is much harder for the majority of the illiterate population to
fully understand the informed consent documents. An attempt has been
made to translate these documents in vernacular languages. However, exact
translation of English words and phrases often leads to confusion (Padhy et
al., 2011). It is also observed that, "consent forms in most hospitals in India
are either too brief or sketchy or full of incomprehensible medical and legal
jargon (emphasis added)" (Kalantri, 2000).
In the case of stem cell intervention in India, it was documented that the
patients undergoing stem cell treatments are not fully informed about the
possible side-effects of an experimental therapy (Cohen and Cohen, 2010;
Pandya, 2008; Patra and Sleeboom- Faulkner, 2010). A clinician in India
argued that patients are not informed that these treatments are unproven:
"There are many desperate patients who have no hope
practically with conventional therapy and are not told that
these treatments are unproven" (Clinician, 4).
The regulatory bodies in India through various mechanisms try to ensure that
the ethical guidelines should be followed. The procedure of informed
consent, however, is diluted in the Indian condition, since patients have great
trust in clinicians and they regard them as next to God (Sanwal et al., 1996),
and generally patients do not question the mode of treatments/procedures
offered by clinicians. The representative of a firm arguesthat:
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"He [patient] just relies on the doctors basically and it is
normal practice in India...whatever doctors say, you go for
that" (Firm's representative, 7).
Trust is often viewed as a defining element in the patient-clinician
relationship, especially for patients since they generally encounter clinicians at
a vulnerable stage and at that time patients highly depend on clinicians
(Goold, 2001). In general, patients have placed a high level of trust in the
medical system not only in India but more or less in every part of the world
(Rowe and Calnan, 2006). Trust is especially important for health care, as it
allows patients to reveal personal information and to follow various treatment
procedures. However, increasingly in the corporate nature of medical care,
particularly in India where more than 80% of health care services are being
provided by the private sector, the trust relationship between patients and
clinicians could be vulnerable. Clinicians might take unfair advantage of this
trust. Various studies and media reports in the stem cell domain have already
highlighted that, in desperation to cure, significant numbers of patients are
spending large sums of money without questioning the largely unproven
treatment procedures (Chatterjee, 2011; The Times of India, 2010; Zarzeczny
et al., 2010).
Furthermore, it is argued that patients are incapable of making their own
choice as they are not strong enough intellectually as well as psychologically
(Kallivayalil and Chadda, 2011; Ravindra, 1994), as a stem cell scientist
pointed out:
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liVery often people who are terminally ill, they are not in a position to
give informed consent" (Scientist, 3).
In addition, particularly in the caseof stem cell, Indian scientists believe that
those who offer therapy, are not fully informed themselves of the pros and
cons of stem cell therapeutic applications. As a scientist 3 argues:
"I don't think that these people are really giving a full picture
because very frankly people who are offering don't have the
full picture because...lf you look at the websites of people who
are offering this kind of therapy and in some of the caseswe
came to know about ...for example, a doctor is giving
autologous bone marrow cells to a patient ...say...who has
muscular dystrophy; now muscular dystrophy is a genetic
disease, so there is no point in giving autologous cells, as they
still have the same genetic defect so what would be the
point?"(Scientist, 3).
The above discussion revealed that the patients in India who are undergoing
stem cell therapy are not only receiving untested therapy, but far worse they
are not fully informed about the possible side-effects of stem cells. The
universal informed consent procedure in the Indian state of affairs is largely
diluted, given the different cultural and socio-economic conditions.
In the whole process we cannot ignore the influence of high expectations on
the functioning of informed consent. The previous chapter has discussed in
great detail the role of high expectations in the proliferation of stem cell
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research and therapy. The high expectations put pressure on both
researchers/clinicians and patients for 'breakthroughs' and the desire to cure,
respectively, and this leads to the dilution of informed consent (Churchill et
al., 1998). Even policymakers/regulators in India are very excited for a
'breakthrough' in order to emerge as a global player, as discussed in a
previous chapter. The statement of an ex-policymaker indirectly reflects how
the procedure of informed consent can be ignored or compromised in the
background of high expectations. She illustrated that:
"Because of the hype, patients are willing to go to any
extent ...when you have patients suffering from a particular
illness, the family is willing to go to any extent to get them
treated and people do come and get treatment" (Ex-
policymaker 1).
Against this backdrop, it can be argued that the procedure of informed
consent is not only subject to various socio-cultural conditions but also to high
expectations associated with a new 'revolutionary medical advancement'.
However, in various ethical documents such as the Helsinki Declaration or
ClaMS guidelines, there is no provision to address this important issue, as
discussed in Chapter 2.
233
6.7 Summary and discussion
The proliferation of stem cells has raised intense debates worldwide with
respect to the use of human embryo in research and the applications of stem
cells in curing a wide range of debilitating diseases. In the West, the debates
are mainly concentrated around the use of human embryo as a raw material
in research. However, in India, the main ethical issues surround the clinical
applications of stem cells, which are largely unproven. The human embryo in
India does not raise those kinds of ethical issues as in the West. One of the
reasons might be that the dominant religion of Hinduism in India is less
monolithic than Christianity. In addition, there is no consensus on the moral
status of human embryo in Hinduism. Hindus' ethics are flexible and they vary
as per 'demand' of a particular situation. There are no stringent rules and
regulations in terms of using human embryo in biomedical research. Both the
cultural and regulatory environments, therefore, have diluted the issue of
human embryo in stem cell research in India.
However, the therapeutic applications of stem cell have raised several ethical
issues, such as the safety of patients and efficacy of the treatments and,
furthermore, the financial exploitation of the patients. The narrations of key
players in stem cells, Le. scientists, firms' representatives and policymakers
have expressed their concern over the unethical clinical development of stem
cells. Among clinicians, differences in opinion could be observed. Some of the
clinicians are in favour of unproven treatment in a condition when all
treatment options for a particular disease have been exhausted. However,
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other clinicians are against the applications of unproven stem cells in clinical
settings. During field work, it was observed that the clinicians who are
working in private hospitals are mostly engaged in unproven stem cell
treatments. However, in some cases, it was also found that some of the
clinicians of public hospitals are also offering questionable stem cell therapy.
It can be argued, therefore, that the professional norms in India, more
specifically in the case of clinicians, vary from person to person and they are
independent of their institutional affiliations.
The national and international guidelines, particularly the DBT-ICMR
guidelines and the Helsinki Declaration, were cited to justify the questionable
clinical activities of stem cells by the clinicians. In addition it is argued that no
safety issues are attached with adult stem cells and, moreover, it is also
stressed that there are significant numbers of needy patients who are
desperate for the stem cell intervention.
In sum, if we see these justifications in the background of ethical boundary-
work (Frith et al., 2011; Hobson-West, 2012; Wainwright et al., 2006a), it
clearly reflects that there are three key ways to legitimatise the application of
stem cells at clinical level. First, the Helsinki Declaration allows it to happen;
second, desperate patients; and the third, the useof adult stem cells is safe.
India started its stem cell programmes in the very beginning of the last
decade with the support of both public and private research institutes. Later,
several public and private hospitals and clinics started offering various
treatments using stem cells. However, none of the treatments has gone
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through clinical trials and in the absence of any documented evidence of
various stem cells clinical interventions it is very hard to examine the
treatment modality. Furthermore, patients are being charged for these
unproven therapies. The proliferation of stem cell in India is seen asa money-
making business rather than to alleviate suffering of the so- called 'desperate'
patients.
The 'mushrooming' of private blood banking has also emerged as another
money-making endeavour. It is argued by the different key players such as
scientists, clinicians, policymakers and a few representatives of firms that, in
the name 'biological insurance', expectant parents are being exploited since
there is a rare chance for a child to use its own cord blood in the future.
In the whole process, key issues such as informed consent procedures are
largely ignored. Generally, patients go for stem cell intervention when they
are at the terminal stage. They have exhausted all existing treatment options
when they encounter stem cell clinicians. It was observed that, at this stage,
patients are incapable of giving informed consent, as reflected by the
narration of some of the key players. It appears that terminally-ill patients will
continue to be the subject of exploitation given that various international
guidelines do not effectively address the issue of terminally-ill patients. In
addition, the role of high expectations in the functioning of informed consent
hasalso not been given attention.
Though this chapter investigated the significant ethical issues and the way
these are framed by key players to justify research and clinical activities, the
236
larger question remains as to why some of the clinicians continue to offer a
treatment which is perceived as unethical? The interesting thing is that these
therapies continue to flourish, despite concerns expressed by the
policymakers. It suggests that either India has no stringent mechanisms in
place to govern stem cells or there are well-developed mechanisms for the
same but the implementation of these established mechanisms is poor. The
next chapter of the thesis therefore examines the existing governance
framework related to stem cells.
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Chapter 7: Governance of Stem Cell Research and
Therapy in India
7.1lntroduction
The previous data chapters have discussed the proliferation of stem cell
research and therapy and raised ethical issues in the backdrop of high
expectations and promises to solve various problems of basic research and to
cure a wide range of debilitating diseases.
The prominent ethical issue in the Indian stem cell sector is the clinical
applications of stem cells, given that it is still considered as an experimental
therapy. Despite concerns expressed at the regulatory level from time to
time, some clinicians continue to offer treatments that could be described as
unethical, given that they have not been subject to a process of testing and
are not offered as part of a regime of a clinical trial. Regulatory agencies
appear to be helpless to restrain unproven stem cell clinical development and
this raises the fundamental questions - 'what are the formal mechanisms that
govern stem cell research and therapy in the country?' and 'how do these
mechanisms work in practice?'
In recent years the Indian regulatory authorities have introduced several
changes in response to concerns about lack of oversight in this area. For
example, the much awaited National Apex Committee for Stem Cell Research
and Therapy (NAC-SCRT) has been constituted. The mandate of this
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committee is to examine the scientific, technical, ethical, legal and social
issues in the area of stem cell based research and therapy. Regulatory
agencies have also taken a step to provide a legal backup to the existing
guidelines, with the Indian Council for Medical Research(ICMR) introducing a
public consultation in different parts of the country. In addition, since the use
of stem cells in clinics is linked with general medical practices, the
government has also introduced some changes to strengthen the governance
of medical practice in the country. This chapter analyses these changes in
more detail and aims to investigate why they seem to be not effective in
practice.
Against this backdrop, this chapter aims to understand the governance
mechanisms dealing with biomedical research and therapy in general and
stem cells in particular. The chapter is informed by the conceptual framework
provided by Pierre and Peters (2000) (see Chapter 2) to understand the
different modes of governance Le. governance as hierarchy, governance as
networks, governance as community and governance as market. In doing so,
Section 7.2 explores the role of different agencies in biomedical research
governance as a whole. Section 7.3 investigates the governance of medical
practices and highlights the recent changes in this governance system, which
has been prompted by concerns raised about clinical practices including the
use of stem cells in clinics. Section 7.4 draws on interview data to explore the
existing stem cell governance framework in India. Section 7.5 examines the
motives behind the 2011 public consultation on stem cells held in different
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Indian cities by the ICMR and investigates its contribution towards the goal of
strengthening stem cell governance.
7.2 Biomedical research governance: Governance by hierarchy
The institutionalisation of biomedical research in post-independent India can
be traced back to 1949 when the Indian Research Fund Association (IRFA) was
re-designed into the Indian Council of Medical Research (ICMR). The IRFAwas
constituted by the British government in 1911 in response to the plague
epidemic of the late is" and early zo"century in India. The ICMR acts as the
apex body for planning, promoting and co-ordinating biomedical research in
the country (Muthuswamy, 2010), under the Ministry of Health & Family
Welfare. Over the years, ICMR has developed its institutional network by
establishing permanent institutes and regional centres in the different parts
of the country focusing on specific diseases (ICMR website). Since 2007, ICMR
has been supervised by the newly constituted Department of Health Research
under the same ministry. Apart from ICMR, other government agencies, i.e.
Department of Biotechnology, Department of Science & Technology and
Council of Scientific & Industrial Research, are also involved in the promotion
of biomedical research through various research and development
programmes.
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7.2.1 Department of Health Research
The Department of Health Research (DHR) was launched on s" October,
2007, though it officially started functioning in November 2008. The DHR is
headed by a secretary who is also the director-general of the Indian Council of
Medical Research (ICMR). The DHR is constituted to promote and co-ordinate
basic, applied and clinical research as well as clinical trials and operational
research in areas related to medicine and health. It is also assigned to
promote and provide guidance on research governance and ethical issues in
medical and health research. The supervision of the DHR and the ICMR by the
same person suggests that the DHR is just a new name for the ICMR on paper
and it is very hard to accept in this situation that the DHR will entirely act as a
new agency with fresh ideas to govern biomedical research in India.
Moreover, as per the information provided at the DHR website, the ICMR will
now be supervised by the DHR. Since both departments are working under
the same leadership, it can be argued that the constitution of the DHR does
not make any sense.
7.2.2Indian Council of Medical Research
The Indian Council of Medical Research promotes biomedical research
through intramural as well as extramural research. "Intramural research is
conducted through the Council's 30 Research Institutes/Centres/Units. These
include (a) nineteen mission-oriented national institutes located in different
parts of India that address themselves to research on specific areas such as
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tuberculosis, leprosy, cholera and diarrhoeal diseases,viral diseasesincluding
AIDS, malaria, kala-azar, vector control, nutrition, reproduction,
immunohaematology, oncology, medical statistics, etc; (b) six Regional
Medical Research Centres that address regional health problems, and also
aim to strengthen or generate research capabilities in different geographic
areas of the country; and (c) five Unit/Centres dealing with food & drug
toxicology, viral diseases, handling microorganisms of a highly infectious
nature, prenatal diagnosis for neonatal retardation etc, and supply of various
animal models and feeds for experimental purposes" (ICMRwebsite)23.
Similarly, "extramural research is promoted by ICMR through (a) setting up
Centres for Advanced Research in different research areas around existing
expertise and infrastructure in selected departments of medical colleges,
universities and other non-ICMR Research Institutes; (b) task force studies
which emphasise a time-bound, goal-oriented approach with clearly-defined
targets, specific time frames, standardised and uniform methodologies, and
often a multi-centric structure; and (c) open-ended research on the basis of
applications for grants-in-aid received from scientists in non-ICMR research
institutes, medical colleges, universities etc located in the different parts of
the country" (ICMRwebsite)24.
One of the major roles of ICMR is to advise government on various ethical
issues raised by biomedical developments. The ICMRacts as an apex advisory
23http://www.icmr.in [Accessed Sept 20,2011].
24 http://www.icmr.in [Accessed Sept 20,2011).
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body by formulating ethical guidelines for studies involving human and animal
subjects. A policy document on ethical issues involving research on human
subjects was first released by ICMR in 1980; later, with the new advances in
biomedical science, it was revised in 2000 as "Ethical Guidelines for
Biomedical Research Involving Human Subjects"; again, in 2006, keeping pace
with the development of stem cell science, bio-banking and growing
worldwide interest in clinical trials in India, these guidelines are revised as
"Ethical Guidelines for Biomedical Research on Human Participants". These
guidelines can be viewed as a fundamental document in terms of biomedical
research ethics in India, though it is not directly legally binding. However, the
amendment of the Drugs and Cosmetics Act of 2002 and the Medical Council
of India Act of 2002, the compliance to ICMR ethical guidelines was made
mandatory for clinical trials and research by clinicians (Muthuswamy, 2010).
These guidelines lay emphasis on the constitution of an Institutional Ethics
Committee (lEe) at institute level, which is equivalent to Institutional Review
Boards, the Ethics Review Board and Research Ethics Boards of other
countries. It is expected that every research proposal involving human
participants should have approval from lEe. Ethical guidelines highlighted
that, "it is mandatory that all proposals on biomedical research involving
human participants should be clear by an appropriately constituted
Institutional Ethics Committee." In addition to IEC, in India, there is also a
provision of an Independent Ethics Committee which is not a part of any
institution and, as its name indicates, it works independently. This ethics
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committee works for those researchers who are not affiliated to any
institution or institution where there is no ethics committee. Independent
Ethics Committees have been functioning at places like Delhi, Mumbai,
Bangalore, Hyderabad,Ahmedabad etc. (Dent and Krishan, 2007).
Although the ICMRethical guidelines place significant emphasis on the need
for independent ethics committees, various reports have questioned the
extent to which this objective is achieved in practice. In various institutions,
either there is no ethics committee or, where one exists, the extent to which
it functions in practice or might be considered independent is questionable. In
a report published in 2008 in the Bulletin of the World Health Organisation, it
was mentioned that "Fewer than 40 ethics committees in India are properly
constituted and functioning" (Chatterjee, 2008). To investigate this problem
further, the ICMRconducted a survey in 71 institutions where ICMR-funded
research projects were going on. Only 36 institutions responded to the ICMR,
out of which only 23 had standard procedures for ethical review and only 14
had trained members in research bioethics (Jesani,2009; Kumar, 2006). It was
alleged that the members of various ECsare not well trained (Bhan, 2012). In
addition, there is concern over the conflict of interest in ECssince, in some
cases, members of ECsare themselves involved in conducting clinical trials
(Sreelata, 2012).
The Drug Controller General of India (DCGI) who approves and monitors
clinical trials is entirely dependent on ECsfor maintaining ethical standards,
though it has no linkagesof any kind with ECs.More specifically, the DCGIhas
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no control over the functioning and supervision of ECs. It is entirely up to the
institutions how they manage ECs, where the trials are being conducted
(Jesani, 2009). It therefore can be argued that, in maintaining ethical
standards in biomedical research in India, the role of ECsis questionable.
Efforts are underway to legalise ICMR ethical guidelines and there is a
proposal to establish a Biomedical Research Authority. In the proposed Bill,
every IEC should register with this authority. The authority would evaluate
and monitor functioning of the IECs. There is also a proposal to rename the
Central Ethics Committee on Human Research (CECHR)as the National Ethics
Committee in the proposed Bill. The CECHRwas set up by the ICMR in 1996 to
monitor clinical research in the country. This committee examines various
proposals related to biomedical research as well as ethical issues which are
brought to its notice (Muthuswamy, 2010).
7.2.3 Department of Biotechnology
The Department of Biotechnology (DBT) under the Ministry of Science and
Technology is playing a major role in the promotion of various programmes in
the area of medical research. It is basically a funding agency which was set up
in 1986 to support research programmes in agriculture and health sectors.
India's s" five-year plan (1980-85) was viewed as a first policy document
which initiated the development of biotechnology in the country. In 1982, an
apex official agency, viz. the National Biotechnology Board (NBTB), was
established to initiate and promote R&D in various areas of biotechnology.
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The NBTBformulated the "Long-term Planfor Biotechnology in India" in 1983.
This plan identified priority areas for the development of biotechnology in
view of national needs. Later, in 1986, NBTBwas re-designated to a fully-
fledged government body called the Department of Biotechnology. Since its
inception, DBT is playing a major role in the development of biotechnology
(Salter et al., 2007). From the s" five-year plan (1992-97) to the 11th five-year
plan (2007-12), the DBTbudget has increased by 16 times. In the year 2008,
DBT in partnership with the Wellcome Trust (UK) launched the Biomedical
ResearchFellowship Programme, worth US$130 million. The major thrust of
the Wellcome Trust/DBT India Alliance is to capacity build the Indian scientific
community. In the area of stem cells, DBT has constituted a separate task
force to promote stem cell R&D in the country. It is also involved in
formulating stem cell guidelines with the ICMR.
7.2.4 Department of Scienceand Technology
The Department of Science and Technology (DST)was established in 1971,
with the mandate to promote new areas of Science& Technology (S&T) and
to play the role of a nodal department for organising, coordinating and
promoting S&T activities in the country. It involves formulation of policies
relating to S&T, co-ordination of areas of S&T in which a number of
institutions and departments have interests and capabilities, and to support
basic and applied research in national institutions. DSTis supporting various
programmes in stem cells aswe" (PadmaSrivastava,2009).
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7.2.5 Council of Scientific and Industrial Research
The Council of Scientific and Industrial Research (CSIR), an autonomous but
government-funded body registered under the Societies Registration Act
1860, was established in 1942. It is viewed as India's largest Research and
Development (R&D) organisation, with 39 laboratories and 50 extension
centres (CSIRwebsite). Over the years since its establishment CSIR has been
able to provide affordable health care for the common man by the
development of cheap life-saving drugs. The CSIRwebsite claims that "eleven
out of the fourteen new drugs developed in India are from CSIR."
7.2.6 Central Drugs Standard Control Organization (Drugs Controller General
of India)
The Central Drugs Standard Control Organization, Le. the Drugs Controller
General of India (DCGI) has the responsibility to lay down the standards of
drugs, cosmetics, diagnostics and devices and to approve licences to
manufacture certain categories of drugs as the Central license Approving
Authority. It regulates market authorisation of drugs and clinical
research/trials in the country. In sum, it is similar to the US Food and Drug
Administration.
In the previous chapter, one of the main concerns raised by some of the
informants was that stem cell treatments are being offered without having
clinical trials. However, in India the procedure of clinical trials itself raises
serious concern. The DCGI is supposed to monitor clinical trials in the country;
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however, over the years several studies and media reports reflect that the
DCGI is unable to curb unethical clinical trials (Jayaraman, 2012; The Indian
Express, 2012; Vee, 2012). There are allegations that large numbers of poor
and vulnerable people have developed serious adverse side-effects during
clinical trials in India. The death of several research participants is also
reported (The Hindu, 2011). Recently, the procedures of clinical trials in a
public hospital in Indore inform us about the growing violations of ethics and
problems with the biomedical research governance in India (Vee, 2012). It was
alleged that, in Indore, Ita total of 81 patients, including 18 children, had
serious adverse effects and even death during clinical trials" (Vee, 2012: 397).
However, the matter is still under investigation. There are also allegations
that clinicians have received millions of dollars from pharmaceutical
companies to conduct these trials (Vee, 2012). Furthermore, it was also
reported that the survivors of the Bhopal gas disaster have been used as
'guinea pigs' without informed consent. The clinical trials on gas victims also
question the validity of clinical trials data since the long-term exposure to
leaked mythyl isocyanate (MIC) is yet to be documented. There is no idea
about the physiological conditions of those gas victims and this might have an
effect on the results of clinical trials (Ghosh, 2011; lakhani, 2011).
7.2.7 Summarising biomedical research governance
The above description shows that there are multiple agencies in place to
govern biomedical research in India. These agencies are promoting
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biomedical research through funding and also providing guidance to
researchers to conduct research in an ethical manner, especially for
contentious areas such as genomics and stem cells. Some of the agencies act
as a monitoring and licensing authority with respect to clinical research and
biological products. All these agencies work under different ministries, for
instance the OBT functions under the Ministry of Science and Technology and
the ICMR is under the Ministry of Health and Family Welfare, which is seen as
problematic in a governance mechanism with respect to co-ordination while
dealing with the same area such as stem cells (Bharadwaj and Glasner, 2009;
Salter et al., 2007). However, the ICMR is the main agency for preparing policy
documents. Over the years it has played a leading role in the formulation of
various policies, guidelines and preparing bills. Basically, ICMR sets the
direction of biomedical research in the country. The Indian FDA, Le. the OCGI,
also makes decisions based on ICMR guidelines.
It appears that, in India, there are well-developed state-led mechanisms
(what Pierre and Peters (2000) call governance as hierarchy) in place for the
governance of biomedical research. However, serious questions have been
raised over the functioning and independence of ECs, and the legitimacy of
clinical trials suggests that this governance framework is weak and ineffective
in practice. This suggests that the system for governing stem cells as an area
of research is likely to be found wanting. Before discussing stem cell
governance in more detail, it is important to put it in the context of the
governance of medical practices in India since the intervention of stem cells in
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clinics emerged as a main ethical issue, and the governance framework in
dealing with clinicians has a profound impact on the clinical practices of stem
cells.
7.3 Governance of medical practices
As described in Chapter 2, there are multiple systems of medicine in India.
Ayurveda is recognised as the principal system of medicine. Siddha, Unani,
Homoepathy and folk medicines are also considered as a part of the Indian
System of Medicine (ISM). In the first half of the zo" century biomedicine
began to interact with traditional medicine (Khan, 2006).
After independence, with government support, biomedicine has become a
well-established system of medicine in India. It is accessible through both
public and private players. This section aims to explore the different modes of
governance with respect to medical practices in India. It also analyses to what
extent different modes of governance are effective in practice. As far as
governance of medical practices is concerned, it basically governs through
various legislative measures as well as through a state-sanctioned self-
regulatory body. In addition, governance in the form of the association of
medical professionals and civil society are also visible. But, how they work in
practice is a different matter.
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7.3.1 Statutory governance: Governance by hierarchy
The quality and structure of health care delivery systems in India has always
been a matter of concern. And, in response to various concerns, the
government of India has taken several initiatives over the years. India has
formulated nearly 41 Acts which directly or indirectly regulate the hospitals
and clinicians (Phadke, 2010). Health is a state subject, and different states
are free to formulate different laws according to their needs. This is the
reason for so many laws in the country. It is pertinent to highlight here that
the Indian Constitution does allow central government to make any laws on
state subjects with the consent of state legislative assembly.
Recently, the government of India has passed the Clinical Establishments
(Registration and Regulation) Bill, 2010. The statement of this Act highlighted
the dismal state ofthe health care sector. It is stated in this Act that:
"At present the supervision and regulation of the quality of
services provided by the health care delivery system to the
people by both public and private sectors has largely
remained a contentious and, therefore, unresolved issue. The
current structure of the health care delivery system does not
provide enough incentives for improvement in efficiency. The
private health care delivery system in India has remained
largely unregulated and uncontrolled. Problems range from
inadequate and inappropriate treatment, excessive use of
higher technologies and wasting of scarce resources to serious
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problems of medical malpractice and negligence" (Phadke,
2010: 232).
It is believed that this Act will be able to streamline the medical facilities in
India. Before going on to analyse the main features of this Act, it would be
pertinent to highlight some other important Acts which directly or indirectly
govern biomedicine in India (multi-layered structure of governance).
7.3.1.1Indian Medical Council Act of 1956
The Indian Medical Council Act was enacted in 1933 and, according to the
mandate of this Act, a Medical Council of India was established in 1934. After
independence, this Act was repealed and a new one enacted in 1956 with the
main functions of establishing and maintaining uniform standards of medical
education and recognition of medical qualifications through a state-
sanctioned self-regulatory body named the Medical Council of India (MCI).
This Act also aimed to regulate the practice of medicine by introducing an
ethical code of conduct for registered medical practitioners in 2002.
7.3.1.2 Drugs and CosmeticsAct 1940
This Act regulates the import, manufacture, distribution and sales of drugs
(and cosmetics). It also oversees the clinical trials in the country. In terms of
clinical trials, this Act is perceived as very weak since, in the case of any
transgression, the violator cannot be punished as there is no provision for
this. Under this Act, the DCGIcan only suspend or stop the trial. The Ministry
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of Health and Family Welfare intends to amend this Act to make violation of
medical ethics a punishable crime. At present, medical ethics violations are
dealt with indirectly under various sections of the Indian Penal Code (Dhar,
2010).
7.3.1.3Indian Penal Code
The Indian Penal Code is meant to define criminal acts and related
punishments. In the case of medicine in India, Section 304-A deals with
complaints against medical practitioners for alleged medical negligence
(Nayak, 2004). The violation of medical ethics in India is treated as a medical
negligence (Dhar, 2010). However, to prove a doctor has been negligent is
complicated given that, according to a recent order of the Indian Supreme
Court, an opinion of an expert or panel of doctors is necessary to begin a case
of negligence against alleged clinicians (Kamath, 2010). Furthermore, the law
related to medical negligence has been subject to judicial interpretation. It is
alleged that the Supreme Court in India has provided protection to medical
practitioners through its own interpretation of the law. During a hearing a
case of medical negligence the apex court stated that, " ... it is the bounden
duty of civil society to ensure that the medical professionals are not
unnecessarily harassed by complainants who use the criminal process as a
tool for pressurising the medical professionals and hospitals for extracting
uncalled for compensation. It would not be conducive to the efficiency of the
medical profession, if a doctor is to administer medicine with a halter around
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his neck" (Menon, 2010: 96). The analysis here reflects that the success of a
statutory mode of governance is subject to other modes of governance as
well, at least in the case of Indian medical governance.
7.3.1.4Indian Contract Act of 1872
This is basically the Law of Contract and provides legal protection to the
agreements between the parties. However, it has hardly been used for health
issues in India (Peters and Murleedharan, 2008).
7.3.1.5 Law of Torts
This law is viewed as a most important law in terms of governing the medical
malpractices in India. It applies to all health professionals, whether in the
public or the private sector. This law can be useful in a circumstance when a
clinician treats a patient without informed consent (Nandi math, 2009). Tort is
a civil law and under which an aggrieved party can claim for compensation to
another party in the case of any wrong act.
The Indian Penal Code, Indian Contract Act of 1872 and Law of Torts appear
to be competent enough to govern medical practices in India. However, they
are subject to judicial interpretation and, furthermore, the delay in disposal of
court cases poses limitations on the real benefit of these laws. Till 2010, more
than 30 million cases were pending in various courts of India and there is
estimation that, within the existing judiciary system, it will take 320 years to
clear all cases (The Times of India, 2010). Moreover, a large section of the
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population in India struggles for basic necessities such as food and water, and
they do not have enough money and other resources to fight for several years
for justice. Legal services in India are not only lengthy but also expensive.
Given the situation, it is hard for an aggrieved patient to go court against any
clinician. It appears that, to address these concerns, medical services were
incorporated into a new piece of legislation discussedbelow.
7.3.1.6 Consumer Protection Act 1986
The Consumer Protection Act was enacted in 1986 to protect the interests of
consumers from poor products/services. The intention was to provide speedy
disposal of consumers' disputes. The medical services were included in this
Act by the year 1995 after a Supreme Court ruling. The Supreme Court ruled
that "patients aggrieved by deficiencies in medical services rendered for
payment can claim damages under the Act. The court said, however, that the
Act would not cover doctors and hospitals providing free services to all their
patients" (Mudur, 1995: 1385). It means that this Act governs only private
medical practitioners. There is provision to set up a commission at the district,
state and national level in this Act; collectively they are called the Consumer
Forum. The Consumer Forum is a quasi-judicial body. The mandate of this Act
is basically to provide inexpensive and speedy legal services to consumers.
However, the organisational structure of the Consumer Forum has been
always a matter of criticism (Peters and Muraleedharan, 2008). It is viewed
that a heavy workload coupled with an insufficient work force and poorly
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developed infrastructure leads to the ineffectiveness of the Consumer Forum.
Furthermore, in terms of medical practices, the requirement of expert advice
from other doctors to begin a case of alleged malpractice against a doctor
makes it less effective. It is argued that "almost all cases of medical
negligence under the Consumer Protection Act fail because it is impossible to
get a doctor to testify against another doctor. They fear being ostracised"
(Joshi, 2011).
7.3.1.7 Right to Information Act 2005
The mandate of this Act is to "provide for setting out the practical regime of
right to information for citizens to secure access to information under the
control of public authorities, in order to promote transparency and
accountability in the working of every public authority, the constitution of a
Central Information Commission and State Information Commissions and for
matters connected therewith or incidental thereto" (Right to Information Act,
2005). Over the years this Act has been used to seek information regarding
the functioning of clinical trials by various activists and it has exposed several
unethical trials in the public domain (Paliwal, 2011). However, mere exposure
does not guarantee that the alleged will get stringent punishment. In one of
the poor states, Madhya Pradesh, through clinical trials government doctors
made millions of dollars of money; in contrast the concerned authority fined
alleged doctors a mere US $100 for their violations (Vee, 2012). Furthermore,
this Act is only applicable to public authorities; therefore it poses a limitation
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on the capacity to obtain information from private bodies such as private
hospitals and private clinicians in the case of medical services. It is pertinent
to highlight here that the private sector contributes nearly 80%of health care
services in India.
7.3.1.8 The Clinical Establishments Act 2010
This Act is seen as a comprehensive Act to streamline the functioning of all
the systems of medicine in India, which covers a wide range of public and
private health facilities (Phadke, 2010). There is a provision to constitute a
National Council to determine the standards and regulation of the clinical
establishments. The National Council shall consist of the Director-General of
Health Services,Ministry of Health and FamilyWelfare, the representatives of
the Medical Council of India, Dental Council of India, Nursing Council of India,
and PharmacyCouncil of India, including other representatives from different
systems of medicine. At state level, the State Council will monitor the
activities of clinical establishments and their registration process.
However, the Indian Medical Association (IMA) expressed their concern over
the composition of the National Council, especially the inclusion of the
members of different systems of medicine (Le. Siddha, Unani etc.) and
persons from pharmacy and nursing in the Council. The IMA feels that these
persons are not competent enough to oversee the practices of biomedicine
(Phadke, 2010). Since this Act made it mandatory to have a minimum
infrastructure for a hospital or nursing home in order to operate, the IMA
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believes that it will unnecessarily raise the cost of health care services. The
IMA alleged that this Act basically serves the purpose of corporate hospitals
(Sinha, 20l2). In addition, there is concern that this Act will be an added
bureaucratic exercise to control the medical practitioners in India, which are
already regulated by a significant numbers of legislations (Phadke, 20l0).
There is an apprehension that this Act will only promote 'inspector raj' (The
Times of India, 2011). In India, bureaucratic organisations were seen as a
stumbling block rather than being effective and efficient in the progress of
science (Bagla, 2003); that is why 'red tape' is often used for Indian
bureaucracy (SciDevNet, 2006). Whether this Act will streamline the health
care delivery system or work as 'red tape' is still uncertain since, even after
two years, only a few states ratify this Act (The Hindu, 20l2). Recently, the
Minister for State for Health in India has held responsible 'red-tapism' for the
delay in the implementation of various projects (DNA, 20lD).
The above analysis highlights that India has both civil and criminal laws in
place to regulate medical practices. However, these laws are subject to
certain limitations and hence their effectiveness is questionable. In this
situation, therefore, one can ask about other modes of governance.
7.3.2 State-sanctioned self-regulation and professional governance:
Governance by networks
The Medical Council of India (MCI) is a state-sanctioned self-regulatory body
to govern biomedicine in the country holistically, as it oversees both medical
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education and clinical practices (cf. Salter, 1999). Through the Indian Medical
Council Act, as highlighted in Section 7.3.1.1, government has provided
statutory power to the MCI. The board of governors of the MCI consists of
India's leading medical professionals and its main objectives are: a)
maintenance of uniform standards of medical education, both undergraduate
and postgraduate; b) recommendation for recognition/de-recognition of
medical qualifications of medical institutions of India or foreign countries; c)
permanent registration/provisional registration of doctors with recognised
medical qualifications; and d) reciprocity with foreign countries in the matter
of mutual recognition of medical quallflcatlons".
One of the main roles of the MCI is to register medical practitioners to ensure
a proper standard of medical practices. The MCI acts at central level, while at
state level there is a provision of State Councils.All medical practitioners have
to register through State Medical Councils. To ensure ethical conduct of
clinicians, the MCI has put forward Indian Medical Council (Professional
Conduct, Etiquette and Ethics) Regulations, 2002. However, its various
provisions have been violated over the years by some of the clinicians. For
instance, Indian clinicians and corporate hospitals advertise their medical
services either through media interviews or hoardings at public places.
Advertising is considered asan unethical act as per the medical code of ethics.
However, the principles of this code are often violated by some of the medical
professionals and also been challenged in the background of a highly market-
25 http://www.mciindia.org/AboutMCl/lntroduction.aspx [Accessed Nov 12, 2011]
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driven health care sector (Balasubramanian, 2008). The MCI, at both central
and state levels, is perceived ineffective in ensuring ethical conduct of
medical professionals. It was observed that "they have not bothered to
exercise the powers given to check unethical medical practice" (Pandya, 2007:
2). The MCI and its counterpart the State Medical Council have been plagued
with corruption charges over the years (Pandya, 2007; The Times of India,
2010). It is not surprising, therefore, that there is a lack of proper
implementation of existing oversight mechanisms dealing with medical
practices. It was argued by some of the medical practitioners in India that "it
is important to have ethical guidelines. But the profession should enforce
them. We need to develop mechanisms so that a variety of transgressions are
regulated and penalised" (Jain, 2010).
In addition to state-sanctioned self-regulation, there is the presence of
another network in the form of medical professionals, Le. the Indian Medical
Association (IMA). The main objectives of the IMA are: a) promotion and
advancement of medical and allied sciences in all other different branches; b)
the improvement of public health and medical education in India; and c) the
maintenance of honour and dignity of the medical profession. The official
website of the IMA highlighted that "[IMA] looks after the interest of doctors
as well as the well-being of the community at large.',26 However, critiques
argued that the IMA works more as an interest group for doctors rather than
working for the society. The opposition of the Clinical Establishment Act 2010
26 http://www.ima-india.org/IMA.html[Accessed Sept 24, 2011).
260
by the IMA reflects that the medical professionals are basically concerned
about themselves rather than society at large. Moreover, it is alleged that,
unlike in the West where similar medical associations playa vital role in
shaping health policies of a nation-state, the IMA never made any
contribution in the medical policy of India (Thomas,2011).
In addition to statutory and professional governance, it would be interesting
to analyse whether in India there is any contribution from the public in
governance of biomedicine.
7.3.3 Civil society: Governance by community
India has witnessed several civil society movements after independence
related to the environment (Chipko movement in the 1970s), development
(Narmada BachaoAndolan in the 1980s), agriculture (anti-GM movement in
the late 1990s) and, more recently, the anti-nuclear power movement
(Bhattacharya et al., 2008; Scoones, 2008; Srikant, 2009; The Economist,
2010). These movements have made a contribution to some extent in the
governance of respective sectors. For instance, recently, protest against Bt
Brinjal, a genetically modified crop, forced the Indian government to
postpone the approval of commercial releaseof this technology. If we analyse
the nature of various massmovements in India, it reflects that the issuessuch
as livelihood and displacement were more prominent in these movements.
The anti-GM crop movement revolves around the issueof livelihood, unlike in
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the West where health issuesare more prominent than livelihood (Srikanth,
2009; Swaminathan, 2000).
By contrast, the health sector in India has hardly witnessed any public debate
or civil society movements in terms of the role of biotechnology or
pharmaceuticals. The exploitation of poor people during clinical trials and
surrogacy or issues related to organ trade, human tissues, body parts and
placenta do not seem to attract ordinary people (Bhattacharya et al., 2008).
Though various health issues do not attract a mass movement, there have
been some individual efforts in the form of campaigns or petitions to raise
legitimate health issues, which has forced the government to act. For
instance, the proper implementation of The Pre-conception and Pre-natal
Diagnostic Techniques (PCPNDT)Act, 1994 is made possible because of the
petition filed by some of the non-government organisations and activists in
the Supreme Court in 2000. The Supreme Court then gave direction to state
governments for the proper implementation of the PCPNDTAct (Kurup,
2011). However, its implementation is still questionable (Ghosal, 2012).
Recently, on the issue of unethical clinical trials, gradually common people in
India have now started lobbying (Rajalakshmi, 2012; Shukla and Phadke,
1999). For example, in Feb 2011, a protest movement was organised against
the unethical clinical trials on Bhopal gas victims. This movement compelled
the government of India to take action against the clinicians who were
involved in the clinical trials. However, various health activists are not
satisfied with the government action (Rajalaksmi, 2012) as the penalty
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imposed on alleged doctors was a token (Vee, 2012). It can be argued
therefore that, although, the public are getting sensitised with health-related
issues, their contribution in the governance framework is not adequate.
According to Pierre and Peters' (2000) framework of governance, in India
three modes of governance in the form of hierarchies, networks and
community are visible. As far as the market mode of governance is concerned,
even though there is a growing market of stem cells in India, it is seen as
exploitative rather than empowering for patients as reflected from the
analysis in previous chapters. Therefore, the market mode of governance can
be ruled out. The discussion in this chapter suggests that medical practices in
India are governed through multiple actors ranging from the government, a
state-sanctioned self-regulatory body, medical professionals and individual
health activists. The legal framework appears to be a more dominant mode of
governance compared to others. It appears that there are well-developed
legislative measures in place and also, in response to various concerns, the
government of India from time to time either revised the existing laws or
came up with new measures. However, the system in place is unable to check
the growing numbers of violations. Despite enormous power vested in the
MCI, it rarely takes action against those clinicians who violated the code of
medical ethics (Vashishtha, 2010). Similarly the DCGI is unable to prevent
transgression during clinical trials.
Various legislations which are in place to govern clinicians appear to be very
strong on paper but not in practice. The Clinical Establishments Act 2010,
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which is supposed to standardise the health care delivery system in the
country, is still waiting ratification from the majority of the states. This Act is
not binding on states, given that health is a state subject. Furthermore,
medical professionals are also opposing this Act on various grounds. The State
Medical Associations of some states have already requested to their
respective state government not to ratify the centrally imposed legislation
(Sinha, 2012). In this situation, the implementation of this Act across the
country is questionable.
The governance through the medical community also seems to be weak as
medical professionals are not involved in any policy-making process and,
furthermore, there are allegations that the medical associations work more
for their own interest rather than for society. Some individuals have now
started questioning the medical authority using the Right to Information Act.
However, these individuals' efforts are unable to take shape of a mass
movement at the moment.
Against this backdrop, it can be argued that, in India, statutory measuresare a
dominant mode of governance. However, these have failed to prevent various
transgressions, and serious doubts remain over their capacity to govern in
practice. It appears that there are significant difficulties in ensuring
implementation of statutes in the health sector, and existing monitoring
mechanisms are weak. Stem cell work in India has proliferated in this context,
directly or indirectly governed by the various government agencies and
medical Acts discussed in preceding sections. The next section analyses the
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governance of stem cells, which is directly governed by the DBT-ICMR
guidelines.
7.4 Stem cell governance
The main document to govern stem cell research and therapy in India is the
DBT-ICMR 'Guidelines for Stem Cell Research and Therapy' 2007. This policy
document was jointly prepared by the DBT and the ICMR in 2007. Because of
the involvement of the DBT and the ICMR in preparing this policy document,
it was assumed that these two agencies are regulating stem cells in the
country. However, for any clinical trials and pharmaceutical products based
on stem cells and umbilical cord blood banks, the monitoring and licensing
authority is the DCGI. Nevertheless, India has always been accused of having
various agencies to govern stem cell development (Bharadwaj and Glasner,
2009; Salter et al., 2007).
7.4.1 Multiple agencies
The formulation of 'Guidelines for Stem Cell Research and Therapy' 2007
jointly by the DBT and ICMR shows that, in India, these are the two main
agencies which regulate stem cell science in the country (Bharadwaj and
Glasner, 2009; Salter et al., 2007). However, the DBT-ICMR guidelines clearly
establish that the DCGI is the main regulatory agency to approve stem cell
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marketable products and to provide licences to cord blood banking firms. A
firm representative stated that:
"OBT is a funding agency. ICMR is an advisory body; the only
regulatory agency is OCGI" (Firm's representative, 5).
However, the OCGI has no expertise in the area of stem cells; more
specifically they have no experts to internally evaluate the stem cell
proposals. An ex-policymaker argued that:
"At present we have an expert committee on stem cell
research both in the OBT and in the ICMR ... at the moment
DCGI has no such expertise" (Ex- policymaker).
The OCGI is perceived as equivalent to the US FOA; however it is argued that it
is not competent enough to deal with biological materials such as stem cells.
A policymaker argued that:
"Actually OCGI does not have their framework to evaluate
these [stem cells] proposals. Initially, OCGI thought that stem
cell does not fall as a biological entity so they say that it does
not come under their purview so they started forwarding, I
mean all these applications to ICMR but later on they realise
that it is part of schedule V, it comes under biological cell or
vaccine or recombinant; everything comes under biological
and on the basis of that probably they now started building up
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framework, they are also stabilising committee" (Policymaker,
1).
At the moment it seems that the ICMR is working as an Indian FDA, though as
per the mandate it is a funding-cum-advisory body to the health ministry. The
actual Indian FDA, Le. the DCGI, might therefore be seen as just a licensing
authority for 'rubber-stamping' drugs and clinical research, since it makes its
decisions solely on the recommendation of the ICMR, at least in the case of
stem cells. In addition, all the policy documents relating to biomedical
research in India are formulated by the ICMR, and the so-called Indian FDA
has little influence over the policy-making process relating to biomedical
research and therapy in India. A policymaker in India stated that:
"ICMR is not a regulatory body, actually it is a funding agency
and being an advisory to the health ministry as you know our
FDA is not that strong. It is still building up so Indian FDA
requested ICMR to help them with ... so all the policy
documents ICMR is involved with ethical guidelines for
biomedical research ... Guidelines for AR ... Guidelines for
foods derived from GM crops so these all were made by
ICMR" (Policymaker 2).
The active role played by the ICMR reflects that it is a regulatory agency for
biomedical research and therapy in India and this also creates confusion
amongst other stakeholders such as clinicians. For instance, a clinician, on the
issue of multiple agencies in India to govern stem cell science, argued that:
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"The Ministry of Health appointed ICMR as a regulatory body
so they are the apex body. All stem cell work has to go with
ICMR. OBT has no regulatory role at all. OBT only gets funding,
OST gets funding but all the regulations are done by ICMR,
that is very clear. In India, the Ministry of Health clearly puts
stem cell in the area of ICMR" (Clinician, 2).
The narration of a clinician who believed that the ICMR is the regulatory
authority for stem cells instead of the OCGIclearly elucidated the weakness of
the 'Indian FDA and also reflects confusion over jurisdiction. The involvement
of different agencies in the governance of stem cells has been a major issue in
India, and there have been institutional and bureaucratic disputes in the past
between the OBT and the ICMR to ascertain their own guidelines before a
final agreement on a combined set of guidelines in 2007 (Bharadwaj and
Glasner, 2009; Salter et al., 2007). The involvement of the OBT in the
formulation of guidelines also raises a fundamental issue about its role in the
governance of stem cell science in India. Though, the OBT is a part of stem cell
policy in India, it does not monitor those stem cell activities which are not
funded by the OBT.A OBTofficial stated that:
"Unless it is funded by the OBT we are not concerned at all
because we are not the controlling body as such for the
therapy. It is OCGI, Ministry of Health and Family Welfare. So
OBT is basically an agency to promote stem cell research R&D,
pre-clinical and clinical" (Policymaker, 2).
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The DBT only monitors those stem cell research activities which are financially
supported by its various R&D programmes. The DBT has a separate stem cell
task force for the same and different committees to oversee stem cell
research. However, for marketable stem cell products and clinical trials the
approval of the DCGI is required.
Apart from the ICMR, the DBT and the DCGI, who are involved in the
governance of stem cells, the government of India has recently constituted a
long-awaited National Apex Committee for Stem Cell Research and Therapy
(NAC-SCRT), which was proposed in the DBT-ICMR guidelines 2007. The NAC-
SCRTwill oversee and monitor the activities in the field of stem cell research
and therapy. However, the NAC-SCRThas no statutory power, as a member of
NAC-SCRTon the issue of legislative power stated:
"This is something we talked about in the last two meetings.
NAC-SCRTdoes not want a policeman role but it is mandatory
for the institutions to follow NAC-SCRTotherwise the licence
of the institution will be cancelled. Our members can't go
from one institute to other" (a member of NAC-SCRT).
Though the member of the NAC-SCRT stresses that the violation of the
mandate of NAC-SCRTwill lead to the cancellation of licences, it is not clear
who will be the designing authority to cancel the licence since NAC-SCRTstill
has no statutory power to cancel any licence. In the past, the DCGI has
warned the New Delhi-based clinician Dr Geeta Shroff for offering unproven
269
embryonic stem cell treatments. Nevertheless she still continues with her
work (Pandeya, 2010).
After the constitution of NAC-SCRT,the question was raised as to how it will
co-ordinate with the Indian FDA. At the moment this important aspect
appears to be not clear. A firm representative argued that:
"Once the NAC formed, we need to get more clarity in terms
of the roles and responsibilities of NAC, whether NAC will only
focus on basic research and will focus on the clinical side
which we need to get clarity and how NAC will internally
interact with OCGI, so also we need to have some more clarity
from ICMR" (Firm's representative, 4).
The concern over co-ordination between the NAC-SCRT and the OCGI is
largely diluted, if we closely analyse the composition of NAC-SCRT. The
policymakers who are in charge of the stem cell division in the ICMR and the
OBTare also members of NAC-SCRT.A member of NAC-SCRTstated that:
'The NAC-SCRT is body which is created jointly by the ICMR
and the OBT. Geeta Jotwani from ICMR and Alka Sharma from
OBT are also members of NAC-SCRT" (a member of NAC-
SCRT).
Though the long awaited NAC-SCRTis now in place, the question remains, as
to whether the NAC-SCRTwill be able to regulate unproven treatments with
stem cells in India. A scientist who is also the member of the OBT stem cell
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task force questioned the capacity of NAC-SCRTto regulate clinical activities
of stem cells:
"Once NAC-SCRT is in place it is going to be still difficult to
regulate people who don't come to government for funding"
(Scientist, 3).
The narration of different stakeholders clearly depicts that there are multiple
agencies in the governance of stem cells in India. However, their jurisdiction is
limited at the level of research, marketable products and banking services.
Moreover, these agencies can only regulate that research which is being
funded by public money as they do not have any jurisdiction over privately-
funded research programmes. However, in the case of marketable products
and banking services, the approval of the OCGI is essential for both, whether
it is public or private.
The presence of various agencies has been a matter of criticism, since it often
results in a lack of co-ordination (Bharadwaj and Glasner, 2009; Salter et al.,
2007). However, if we closely analyse, it is the ICMR who is playing a leading
role in stem cell governance at the moment. In the past there was a great
thrust to have a NAC-SCRT.Now the NAC-SCRTis in place. The constitution of
this committee is seen as a new step to oversee stem cells in the country but
if we see the composition of NAC-SCRT,mostly the same 'elite persons' are
members of this committee who are the programme officer of stem cells in
the OBT and the ICMR. Moreover, there is no member from the so-called
Indian FDA, Le. the OCGI in the NAC-SCRT. It clearly depicts that the Indian
271
FDA has no expertise to oversee stem cells. Recently, the DCGI has
constituted a special division for stem cells in response to criticisms of not
having any internal evaluation mechanism (BioSpectrum, 2012). Now it looks
as if the DCGI can deal with violations independently without the assistance
of the ICMR. However, the appointment of Director General of ICMR as a
chairman of this stem cell division reflects that the DCGI is still not competent
to supervise the proliferation of stem cells.
These 'various agencies' basically govern the research part of stem cells. The
larger question of how to regulate stem cell medical practices still remains.
During my field work, I encountered different key players arguing for a
stringent mechanism to be put in place and for more clear and efficient
guidelines to prevent unethical stem cell intervention.
7.4.2 Guidelines and a law
The DBT-ICMR stem cell guidelines (2007) group research into three
categories: a) prohibited; b) restrictive; and c) permissive. In this framework,
although reproductive cloning is prohibited, therapeutic cloning and research
on hESCand Chimera are encouraged. In various academic discourses, these
guidelines are seen as permissive for the development of stem cells in India
(Bharadwaj and Glasner, 2009). During field visit, it was observed that
different key players express different opinions on the mandate of existing
guidelines with respect to its capacity to regulate the stem cell clinical
development.
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A clinician opined that:
'The guidelines are very progressive as compared to the world
guidelines. They are very clear, they put things in three
categories, prohibited, restricted and permissive, like cloning
and other thing is prohibited ...embryonic stem cell is
restricted where as adult stem cell and umbilical cord cell is
permissive. Only country in the world which is divided things
among these lines. We divided stem cell work in different
categories so I think we are very progressive" [Cllnlclan, 2).
However, some other stakeholders such as scientists and some other
clinicians including a few representative of firm feel that guidelines should be
clearer and updated, in keeping with recent development of stem cells. A
scientist, who is working in a government-funded research laboratory,
expressed his opinion that:
"The DBT-ICMR guidelines are pretty old ...they are not yet
modified ...they are in the process of upgrading it but the
guidelines are mostly forecast on how to use embryonic stem
cells as such, but the question is that if I am a policeman and I
say that you should not dacoit or steal anybody's items, that is
perfectly fine ...others are honest, you should not do that but if
somebody does that, one had to act as police but there is no
policing agent so far ...they just make some policy ...Now it has
to pass through parliament as a rule and once it is made as a
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rule then probably those malpractices will be stopped,
otherwise it will not stop ...1think UK, US and Europe it is not
possible, nobody do that, the licence will be totally cancelled"
(Scientist, 1).
Here, the scientist argues for a stringent punishment for those who violate the
mandate of existing guidelines. In India, even after several concerns of
unethical practices were expressed in some newspapers and magazines
(Indian Express, 2011; Sachan, 2011), no clinician been punished. In contrast,
in the UK, recently a doctor's licence to practise was struck off by the General
Medical Council (GMC) for offering unproven stem cell treatments (BBC,
2010).
A private medical practitioner, who himself offers experimental stem cell
therapy for muscular dystrophy, lamented on the policy of the government
and argued that everyone is free in India to offer experimental stem cell
therapy at the moment:
"[The] government of India has policies but I think they are
sluggish ...the legislation in India does not have any teeth on
the stem cell therapy providers because they are still in the
making of law and as I heard they don't come by the first
quarter of the next year but till that time everyone is free, it is
as good as any alternative medicine suppose you give
Ayurvedic, Homeopathic nobody bothers you it is like same
but definitely there should be some legal code for that
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guidelines, if you don't follow the guidelines you should be
penalised. There should be law and there should be
punishment. Currently there is no law for that; just a guideline
if you violated nobody is bothered. Even if you go to the Drug
Controller of India he says, what can I do ...when I don't have
powers to crash you, even you don't follow the guidelines
then why should I bother you?" (Clinician, 1).
The narration of this clinician informs us that the agencies who are involved in
stem cell governance have no power to punish anyone who violates the
existing guidelines and therefore everyone is free to use stem cells in clinics.
A representative of a cord blood banking firm stated the guidelines have been
in place for many years, and there is a need to have a strict mechanism to
deal with violations:
"See there are only guidelines still after so many years of
debate it has been starting in 2004. From 2004 to 2010 there
are only guidelines still there is no policy that this is what has
to be followed so unless it becomes a mandate and it
becomes strict and enforcement everywhere across the
country, you can't prevent this from happening" (Firm's
representative, 1).
However, even if these guidelines become law, it will be hard to regulate
stem cell clinicians with their existing mandate unless and until they cover the
clinical part as well; at the moment they are essentially focused on basic
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research, although they clearly mentioned that stem cell therapy is still
experimental, except in bone marrow transplantation. In addition, although
the Ethical Guidelines for Biomedical Researchon Human Participants 2006
are legally binding through various Acts, they only deal with clinical trials and
basic research. An ex-policymaker explains the problem within the existing
governance framework, which allows clinicians to offer unproven stem cell
therapies:
"[The] Drugs and Cosmetics Act, which regulates all clinical
trials ...this was amended in 2002 and it saysall clinical trials in
this country, ICMRguidelines should be followed so according
to that if anybody gets permission from the Drug Controller
for doing a clinical trial they have to follow ICMRguidelines
and if they don't follow them, under the Drugs and Cosmetics
Act one can punish...similarly the other act is Medical Council
of India Act which regulates doctors in this
country ...physicians...this was also amended in 2002 and it
says that all the research being done by the doctors in this
country, they have to follow the ICMRguidelines...so this also
you can say indirectly mandate on the doctors whatever they
do in the name of research they should follow the ICMR
guidelines but the problem with the stem cell therapy is that
those who are offering therapy don't consider it as
research...OK...they think that it is therapeutic ...patients are
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given...it is a treatment who are giving treatment...any doctor
has the right to give treatment ...so they are doing their
practice...it not comes under research...so there is no need for
any permission and there is no need to follow any
guidelines...you really can't punish them" (Ex-policymaker).
The above narration clearly suggests that there is a lacuna in the existing
regulatory mechanism dealing with clinicians. Within the mandate of existing
regulations, the regulatory authority can take action only in the case of
research activities. However, if a clinician is offering a therapy, the regulatory
authority cannot take any action. Therefore, the question arises as to how an
unethical activity of a clinician can be regulated. The narration of an ex-
policymaker reflects that various legislative measures described in Section
7.3.1 are ineffective. The ex-policymaker further clarifies that:
"For punishing you should have a strong mechanism so that
you know...somebody has to complain ...the complaint has to
be seen by somebody and then you can take it to human
rights or anything for the punishment ...otherwise you can't do
anything at the moment" (Ex-policymaker).
It is clear that there is no measure to control treatment procedures of the
stem cell clinicians or clinicians in general, unless somebody specifically
lodges a complaint against the said clinicians under various Acts described in
Section 7.3.1. This oversight mechanism is not unique to India: in countries
such as the UK, as per information provided on the GMCwebsite, it appears
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that GMC also takes action only after receiving a complaint, either from
patients or from any aggrieved body. However, given that, especially in the
health sector, as highlighted in Section 7.3.3, the public in India are not much
empowered, so it is very hard to expect that they will lodge a complaint
against any clinician.
Although in the Indian scenario there is a significant voice in the favour of a
strong legislation, several studies have argued that a legislative measure
alone is not sufficient to ensure ethical conduct (Brein, 1998; Montgomery
and Oliver, 2009). The unethical practice of stem cell clinical application in
India, I would argue, has nothing to do with specific legislation in this area;
rather it is associated with the larger issue of medical malpractices in India.
Medical practices in India are governed by nearly 41 Acts (Phadke, 2010). The
compliance to ICMR ethical guidelines is mandatory through the Medical
Council Act 2002 and the Drugs and Cosmetics Act 2002. In spite of this, from
time to time several instances have been reported in the media where a
patient was either misdiagnosed or mistreated, leading to further
complications and even death (Indian Express, 2011, John, 2005).
In India the major problem is implementation of the existing laws and
monitoring. An ex-policymaker argued that:
"You may have guidelines ...you may have a law ...but
implementation is a major problem ...we already have so many
laws in this country but the problem has been implementation
and monitoring" (Ex-policymaker).
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The problem of implementation and monitoring has been a longstanding
problem in India. In the backdrop of the recent anti-graft movement, it has
been argued that there is an age-old governance and ethical deficit in India
(The Times of India, 2011). In these circumstances it is very hard to rely solely
on legislative measures to regulate unethical behaviour. If we argue for a self-
regulatory mechanism, then it also makes the situation more complex since
the ethical behaviour of the medical profession in India is largely vulnerable
against the backdrop of commercialisation of modern medicine (Bal, 2001;
Pandya, 2007). In a recent study related to 'scientific research conduct' in the
US context, it was observed that in the initial years 'scientific research' was
governed largely by a normative mechanism when most of the research was
supported by public funds. Later, especially after the 1970s, with the
increasing research on human subjects; and consequently the exploitation of
human subjects led to the formulation of guidelines and forced regulation.
However, it was observed that the coercive pressure was only effective in
federal government-funded research. It was ineffective to ensure ethical
conduct in privately-funded research projects. Further, it was felt that both
normative and coercive pressure requires scientific research to be conducted
in an ethical manner (Montgomery and Oliver, 2009).
The decreasing child sex ratio (0-6 years) in India reflects that having a
stringent law does not always guarantee a solution to the existing problems.
The Pre- Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act is
seen as one of the most stringent laws in India to prevent foeticide, which was
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enacted in 1994. Despite this Act being in place, the child sex ratio in India has
declined from 927 in 2001 to 914 in 2011 (Ghosal, 2012). The reason for this
decline is partly due to poor implementation of this Act, and partly becauseof
various socio-economic and cultural factors. It is argued that in general there
is a strong preference for a son in India, which is one of the reasons for the
declining child sex ratio (Singariya,2012). In addition, it was observed that for
some of the medical professional female foeticide is a lucrative business
(Rahman, 2010). Against this back drop it can be argued that ethical behaviour
is subject to various factors. For individuals or society to act ethically there is a
need for holistic approach. Only having a law will not always ensure ethical
conduct. In India, there are so many laws to regulate medical professionals.
However, regulatory authority fails to curb various transgressions.
As far as stem cell governance in India is concerned, it is still in the
development stage, as reflected from the interviews of different stakeholders.
Various key players feel that the existing stem cell guidelines need to be
updated. And there is a concern that it essentially addresses basic research
and not clinical applications of stem cells. It appears that, in response to these
concerns, the government of India has geared up to revise the existing
guidelines and, in doing so under the leadership of the I(MR, the public
consultations were conducted in different parts of India. The next section has
attempted to evaluate the process of public consultations. It also tries to
analyse the contribution of public consultations in developing the stem cell
governance framework.
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7.4.3 Public consultation
The initiative of public consultation could be viewed as a 'new' mode of
[scientific] governance in India, especially in the stem cell sector (Irwin, 2006;
Pierre and Peters, 2000). The ICMR has conducted four public consultations
on stem cell research in different parts of the country. Though it was
organised in only four places, in principle it has covered the entire country as
it was based on the four regions. The first consultation for the western region
was held in Mumbai on February 20, 2010 and the second one was held in
Bangalore for the southern region on April 10, 2010, followed by a third at
Dibrugarh for the north-east on May 14, 2010, and the last at New Delhi for
northern regions on December 17, 2011. When I started my field work, three
public consultations had been completed. Though the detailed outcome of
the public consultation is still to be analysed, during the field work visit I got
mixed opinions about the way the public consultation was conducted. It was
seen asa good step by the ICMR.An ex-policymaker stated that:
"The initiative of ICMRpublic consultation was very good. At
some places the response was very good and at some places
the response was slow...still people think that it is a highly
scientific area and there is nothing for them to come in this
debate the common people representation was very
limited and mostly scientists are coming...ethics committee
members do come...However in some places like Bombay and
even in the north-east we had lot of patient representatives
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who were keen to know what the conditions were in which
stem cells are applicable...what is the success rate...what is
the hope that very soon this therapy will be available" (Ex-
policymaker).
In the area of science and technology, especially after the 1980s, public
consultation on controversial issues is viewed as essential in the decision-
making process; in countries such as the US, the UK and across much of
Western Europe and in the Asia-Pacific region, there is a great thrust on
consulting the public on controversial issues such as GM crops, radioactive
waste, stem cell research etc. (Irwin, 2001; Leroux et al., 1998; POST,2002).
However, there are concerns over the process of public consultations; for
instance, questions arise over the representation of the wider public in a
particular consultation process (Irwin, 2006). It was observed in the case of
the stem cell public consultation in India that it was not able to take a wider
public opinion. A clinician stated that:
"See the public forum was expected more than what it
actually did...it was supposed to be a public forum where
people should be able to ask questions and debate over it but
that did not occur" (Clinician, 3).
The public consultation was largely focused on the scientists, clinicians, and
firms' representatives rather than on the public. A scientist-cum-member of
the DBTstem cell task force illustrated that:
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"I think the notion of having a public consultation was a very
good one but unfortunately the way it is played out that most
of the people who come are either scientists or doctors who
are already involved in these things and so the group who
gathers essentially already know what's going on so you are
preaching to the converted so there is no real debate as such"
(Scientist,3).
It is very hard to understand whether the way the public consultation was
organised was for the public or for the scientists, clinicians, and firms'
representatives who are already involved in stem cell development. One of
the firms' representatives observed that, during the meeting, the public were
not able to express their opinions or concerns:
"In the two-hour meeting, one-and-a-half hours somebody
was talking ...some lectures; 15 minutes for the public, it is not
adequate see clinicians should not be the designing
authority basic scientists should not be the designing
authority the society for which we all are working, the
society should take a consensus on any and every issue"
(Firm's representative, 2).
Similarly, another scientist argued that:
lilt was good but it has not a good impact actually, the reason
being because they have not really taken the public per se"
(Scientist, 2).
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In principle it is always acknowledged that public consultation should take
account of as many different opinions as possible and it can only be achieved
through the representation of a large section of the society; however,
sometimes it becomes a daunting task to accommodate each and every
opinion in the policy-making process. For instance, the UK government is still
struggling to accommodate the output of public consultation on GM crops in
decision making (Doward, 2011; POST, 2002). In one way public consultation
can be seen as a more democratic approach, on other side the process of
consulting the public and its credibility is often disputed, which questions its
underlying democratic approach. It can be argued that consulting people on
controversial issues is just a ritual exercise and it is difficult to solely make any
decision on the basis of public consultation. The UK GM crops public
consultation was criticised on two accounts: that it was too short, and it was
poorly publicised. The consulting team acknowledge that it was difficult to get
the public involved because of limited funding (BBC, 2003). It means,
therefore, that it was not represented by the large section of the population.
In contrast, supporters of GM crops question the public attitudes by arguing
that it is basically based on 'emotion' rather than 'reason' and the public was
accused of being 'anti-science' (Bingham, 2009; Gill, 2010). Furthermore, the
'pre-framing' of the consultation agenda and the issue of patronising the
public often leads to the politicisation of public consultation (Durodie, 2003;
Gill, 2010) and therefore the whole process of public consultation is
questionable.
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The stem cell public consultation in India was solely a government initiative;
there were no issues or debates as such among the public. No civil society or
any religious organisations raised any social or ethical issues related to stem
cell basic research or its clinical applications. An official of the ICMR illustrated
that:
"There was not really a major issue for public consultation.
Mostly I mean as we know ethical issues in stem cell research
revolved around embryonic stem cell so we thought because
such a huge diversity in India plus we are having different
religions in the country we thought let us have a consensus of
all religious bodies"(Policymaker, 1).
The narration of scientist 3 reflects there is no opposition of stem cells in
India:
"Unlike many other countries there is a very high acceptance
of stem cell therapy so there are no philosophical and
religious issues which people raise ...saying that it is against
Islam or it is against Hinduism ...so those kinds of issues are
not being raised in India ...such a high public acceptance that
there are ...for example companies or hospitals where they are
offering unproven stem cell treatment ...people are not
questioning ...because they thought that this is a forefront
science and going to be a miracle drug" (Scientist, 3).
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Surprisingly, a country that once largely opposed biomedicine during the
colonial period (Kapila, 2010), now seems to embrace it without any
substantial resistance. Soon after independence, biomedicine proliferated
under the patronage of "elite politicians and scientists" (Krishna, 2001), while
at the same time ignoring the indigenous medical systems such as Ayurveda
and even primary health care (Banerji, 2009). Biomedicine in India basically
serves the urban elite and this concern was expressed in the National Health
Policy of 1982. It was stated in this policy document that lithe hospital based,
disease and cure oriented approach towards the establishment of medical
services has provided benefits to the upper crusts of society, specially those
residing in the urban areas" (Banerji, 2009:806).
Stem cell, which flourishes in India under its ambitious biotechnology
programme, largely attracts urban elites. These urban elites or more explicitly
middle class are influenced by the promises of stem cells made by various
scientists, clinicians, firms and policymakers at different platforms, though the
safety concerns were also highlighted simultaneously (Basu, 2005; Mathew,
2011; Prasad,2010; Somasekhar,2006). It is largely perceived that stem cell is
welcomed by the Indian middle classwho can afford its services, though it is
speculative and unproven (The Times of India, 2010). It is not unexpected;
therefore, that stem cell is flourishing without any considerable opposition
despite its potentially exploitative nature, at least in the Indian scenario.
It is not always the case that modern medicine has been accepted by Indian
society. The protest against unethical trials suggeststhat now Indian societv is
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challenging the 'exploitative' nature of biomedicine. However, this protest is
confined to the level of the poor and marginalised populations only, who are
the victims. The urban and elite populations still have not shown any
resistance towards modern medicine in India.
Against the backdrop of high acceptance of stem cells, it can be argued that
the public consultation process has no relevance. However, at the same time,
the whole exercise appears to be flawed as the representation of the wider
public was questionable. In this scenario we cannot really draw any conclusion
that stem cells are embraced by the wider population in India. The narration
of the scientist 3 implies that the public consultation process was just a ritual
exercise. She stated that:
"I am not sure that it actually achieved the goals but
procedurally you have to have this before because any
guidelines go to law, you have to have public consultations on
this type of issue so, on the one hand, you can say, you need it
because you have to be procedural but you won't go beyond
procedural is my point and is that where I think the
consultations have not reached their goal" (Scientist, 3).
This statement of the scientist, who is also involved in policymaking process,
suggests that the Indian government is interested to have a law in place,
specifically for stem cells; that is why the public consultation was conducted.
As per the above statement it can be inferred that the public consultation was
conducted only because since procedurally it was essential for the law-making
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process. In this situation it is quite obvious to have a low public participation.
After the fourth public consultation the Indian regulators have revised the
existing guidelines. The revised guidelines are available at the ICMR website as
ICMR-DBT Guidelines for Stem Cell Research 2012 (draft). The draft version of
these guidelines informs us that the government of India is now more
concerned about the unproven applications of stem cells in clinics. It
emphasises in these guidelines that, "stem cell therapy (other than HSCTand
epithelial -stem cell-based treatments for burns and corneal disorders) is
considered/deemed to be experimental therapy as of now and should be
conducted in the form of clinical trials. Those conducted outside clinical trial
are unethical and hence not permissible" (ICMR-DBT, 2012: 23). The newly
constituted NAC-SCRTalso emphasised the same.
Though the procedure of public consultation was criticised by various key
players, it has made some contributions in the governance mechanism, as
revised guidelines are more clear about unethical stem cells practices.
However, various concerns expressed by different key players during field
work regarding legislation remain, and still India has only guidelines. The
revised draft guidelines indirectly have exposed the confrontation between
the DBT and the ICMR for the leadership. The guidelines of 2007 were entitled
the DBT-ICMR Guidelines for Stem Cell Research and Therapy. The 2012 draft
guidelines are entitled the ICMR-DBT Guidelines for Stem Cell Research. The
name of the ICMR is now placed before the DBT, which suggest that these two
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agencies are competing with each other for the leadership in the stem cell
arena.
7.5 Summary and discussion
For the governance of biomedicine, there are multiple government agencies
and legislations in place with different mandates. Some agencies are involved
specifically in the promotion of basic research while some are engaged in the
policy-making process as well. The analysis in this chapter shows that for the
governance of stem cell research there are multiple agencies in place, namely
the ICMR, the DBT and the DCGI. In addition, a committee, the NAC-SCRT is
recently constituted with the mandate to govern stem cell in a more efficient
way. Amongst these agencies, the DCGI acts as the main approval and
licensing authority for stem cell clinical trials and products. The nature of the
DCGI is equivalent to the US FDA. However, the DCGI does not take its
decision independently as it has no internal evaluation mechanism for stem
cell clinical trials and products. For this it is entirely dependent on the
expertise of the ICMR. In the response to growing concerns, recently, the DCGI
has constituted a stem cell division. This stem cell division will work under the
leadership of the ICMR, which again reflects the co-dependency of the DCGI
with the ICMR to make any decision on stem cells. It appears that despite
having various agencies to govern stem cell, it is the ICMR, though mainly an
advisory body works as a principal regulator. Furthermore, in the NAC-SCRT,
the programme officer of stem cells of the ICMR and the DBT is appointed as a
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member. This depicts that mostly the same persons are involved in the
governance of stem cells in India under different agencies.
Although, the ICMR plays dominant role in the governance of biomedical
research in the country, in the case of stem cells, it appears that there is a
confrontation between the ICMR and the OBTon the issue of leadership in this
emerging area. The conflict between these two agencies started in the very
beginning in 2002 when India had taken the initial step to govern stem cells
(Bharadwaj and Glasner, 2009; Jayaraman, 2005; Salter et al., 2007) and it
appears that it is still continuing given the renaming of the revised draft stem
cell guidelines 2012. This reflects the lack of co-ordination between the OBT
and the ICMR and hence weakness in the governance framework, though the
OBT has no major role on the policy front and the ICMR still dominates as a
leading agency in the policymaking process.
All these agencies mainly govern the basic research and clinical trials, as
informed by a policymaker. Though basic research does not raise any
significant governance issues, the governance of clinical trials raises legitimate
concerns given the ineffectiveness of ECs and the death of various research
participants during clinical trials. Within the existing oversight mechanisms,
the trials using stem cells, therefore, might be questionable.
In India, the use of stem cells in clinics has raised various concerns related to
patient safety and their economic exploitation. To regulate medical practices
in general, there are considerable numbers of legislative measures in place.
The unregulated stem cell clinical activity, which is a part of general medical
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practice, can be checked under the existing mechanisms. However, it appears
that the state-led governance framework is not effective in practice.
Some of the legislations such as the Indian Penal Code, Indian Contract Act of
1872 and Law of Torts are very strong on paper. However, their effectiveness
is subject to the judicial interpretations and the capacity of poor patients to
use these laws against alleged clinicians. The expensive and time-consuming
judicial services make the situation more complicated. Similarly, the Consumer
Protection Act 1986 and the Right to Information Act 2005 appear to be only
effective on paper. The Consumer Protection Act is largely perceived as
meaningless, especially in the health sector since it is highly dependent on
expert advice from other doctors to begin a case against an alleged doctor.
The Right to Information Act no doubt has exposed several violations.
However, the state-sanctioned self-regulatory body, the MCI, which acts as
the licensing authority for clinicians, has enormous power to curb unethical
clinical practices, and has never taken a strong step against alleged clinicians
whose unethical activities have been exposed in the public domain.
As far as the effectiveness of other forms of governance is concerned, it
appears to be not competent enough to govern medical practices. The IMA
basically acts for the interests of clinicians rather than for patients, and civil
society movements are also not strong enough to force regulators to take
strong action against any violations. Therefore, overall different modes of the
biomedical governance mechanism with respect to clinical practices are weak
in India.
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The clinical applications of stem cells flourish within this governance
framework. Though majority of the key players in India including previous
studies as highlighted in introductory chapter argue for a stringent mechanism
to discourage the intervention of unproven therapy, I would argue that there
is no need to have a law especially for stem cells. Within the existing
framework stem cell transgression can be addressed. There is need to have a
proper implementation mechanism of existing laws. Basedon the analysis in
this chapter, it can be argued that there is a need of proper co-ordination
between different modes of governance. The state-led governance can only
be effective if the MCI also takes action against the alleged clinicians.
Simultaneously, different modes of governance need to be strong enough to
have a contribution in developing a governance process. Pierre and Peters'
(2000) model of governance argues that state-led governance is still a
dominant mode of governance across nations and Chapter 2 also highlighted
that, in the area of science and technology especially for stem cells, many
countries have this mode of governance. However, the question rises as to
whether this mode of governance is effective on grounds and whether for
effective governance other forms of governance also need to be strong. My
analvsis has shown, at least in the caseof stem cells in India, that governance
in the form of hierarchy can only be effective if other modes of governance
are also strong enough. Nevertheless, this needs further empirical analysis.
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Chapter 8: Conclusions
8.1lntroduction
The overall aim of this study was to analyse the nature of stem cell activities
in India, how key players from science, clinical practice, private firms and
government justify or challenge the need for specific activities and frame the
ethical issues they raise, and how arrangements to govern stem cell activities
work in practice. To fulfil the overall aim, this study attempted to: map the
current development of stem cells in India in terms of basic research, clinical
activities and cord blood banking; analyse the configuration of expectations
around stem cells by different key players; examine how key players construct
boundaries between ethically legitimate/illegitimate activities and investigate
the potential for different modes of governance around stem cell research
and its clinical practice, and their capacity in implementing existing oversight
mechanisms.
This chapter pulls together the empirical findings of the thesis and tries to
establish a link between expectations, ethics and governance and highlights
the policy implications of the study. It also highlights the strengths and
weaknesses of the study including possible questions for future research. The
summary of findings is as follows.
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8.2 Stem cells in India
In India, there is considerable activity in the area of stem cells both in terms
of research as well as at the translational level. In the area of basic research,
major programmes are dominated by adult stem cells. Recently Indian
scientists have succeeded in creating induced pluripotent stem cells (iPS). In
media commentary, it is heralded as a country's growing research strength in
the area of stem cells as few countries have been able to develop this
technology. However, in contrast, research in embryonic stem cells has not
yet gathered pace as shown in Chapter 4, possibly due to the failure to
develop the 'state-of-the art' technical skills which are required. The
embryonic stem cell lines, which were developed in 2001 by RLSand NCBS,
and got NIH funding for further work, are still not available for researchers.
However, recently JNASCR has developed a few stem cell lines which are
available for conducting further research through UK stem cell banks. There
are similarities here with the West; for example, Paul Martin and his
colleagues in a survey of the regenerative medicine industry have observed
that in the West most of the R&D focus is on adult stem cells (Martin et al.,
2009). In India, most of the firms are focusing on cord blood banking, but
adult stem cells are still the dominant aspect of R&D in the government-
funded research laboratories and in the clinics.
At the translation level, hospitals in both the public and private sectors are
offering stem cell therapy for a wide range of ailments. Therapies using stem
cells have attracted a significant number of patients, not only from India but
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from abroad as well: the so-called 'stem cell tourists'. Again, however, most
are using adult stem cells derived from patients' own bone marrow.
Treatments using embryonic stem cells do not appear to be widely replicated,
with the exception of Nutech Mediworld. Some hospitals are also treating
patients with cord blood stem cells. The interesting thing is that, especially
with respect to stem cell based treatments in India, international commentary
has paid more attention to embryonic stem cell therapy rather on adult stem
cell therapy, despite its frequent ethically contested application in clinics.
In terms of investment by public and private sectors in stem cells, Chapter 4
showed that basic research in stem cells is extensively supported by the
government of India as demonstrated by increasing public spending on
various programmes over the years. From the 8th five-year plan (1992-1997)
to the n" five-year plan (2007-2012), the DBI's budget has been increased
by 16 times, of which stem cells share more than 1/4th of the total budget. In
2009 a new research institute, inStem, exclusively focusing on stem cells, has
been established with government support. This is seen as a major boost for
stem cell R&D in India (Sachitanand, 2011). One of the main aims of inStem is
to bridge the gap between scientists and clinicians. For this, it has
collaborated with Christian Medical College, Vellore.
In addition, private players are also making a significant contribution to the
development of stem cells given the increasing presence of firms in this sector
over the years. A few firms such as Stempeutics have invested millions of
dollars in product development in this area.
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Despite the formal separation between public and private sectors, a closer
look indicates that there are in fact close linkages between government
hospitals/laboratories, firms and clinicians. For instance, RLShas linkage with
government hospitals such as AIIMS for clinical trials; similarly it has
collaboration with NCCS,a public research laboratory. Arguably, firms are
providing stem cell isolation servicesto clinicians aswell. There appears to be
a close linkage between firms and clinicians for unproven stem cell based
treatments. The stem cell city cluster programmes initiated by the DBTaim to
facilitate and establish links between publicly and privately-funded research.
In addition, firms have developed strong collaboration with universities for
knowledge production. Hence, boundaries between public and private are
blurred at various levels.
The increasing activity of stem cells seems to be highly linked with visions of
future market potential, which is estimated to be US $8 billion by 2015. In
2010, the market of stem cell-based treatments was projected to US $490
million. Presently, clinicians are charging patients US $3,OOO-US$30,000.
Similarly, the estimated market of cord blood banking is worth millions of
dollars, given the high birth rate (25 millions/year) in India, and firms
currently charge US$l,sOO-US$2,000 to expectant parents to preserve their
child's cord blood. It appears that the potential market of private cord blood
banking hasattracted many firms of foreign origin to India.
The growing market of different stem cell based services indicates that India
can take the edge in this area similar to medical tourism. Affordable and
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timely access to health care in India has attracted many patients from Europe,
the UK and the US for routine medical services (Turner, 2007). The medical
tourism industry in India was estimated to be US $2 billion by 2012 (Shetty,
2010). With comparatively greater restrictions on stem cells in the West and
simultaneously growing stem cell activities in India, it is not surprising that
stem cell tourism will also flourish similar to medical tourism. However, the
use of stem cells in clinics and cord blood banking raises major ethical issues
of patient safety as most of the treatment modalities lack enough scientific
evidence and are largely categorised as experimental. Moreover, these
patients are paying a large sum for the same procedure, raising further
questions about economic exploitation. These ethical issues are directly
linked to the governance framework since they raise a fundamental question
as to why various clinical applications flourish in India despite being
experimental. The blurring of boundaries between public and private players
might have some influence on the governance regime.
Before analysing the ethical and governance issues in more detail, an attempt
was made to investigate how it has become possible to attract various
resources and actors towards an immature science. To address this question,
both the role and the nature of expectations around stem cell futures were
examined.
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8.3 Expectations
Overall, future expectations constructed around stem cells in India are
overwhelmingly positive, as is evident from the interview data and the media
reports. It was observed that, in India, expectations of stem cells are being
created by different groups, mainly on the basis that: a) stem cells will help in
understanding the basic biology; b) they can solve the problem of organ
shortage; c) there is a burden of incurable diseases such as diabetes,
cardiovascular, cancer etc.; d) existing therapies have several limitations in
dealing with these diseases; and e) there are many needy or desperate
patients, and expectant parents in the case of cord blood banking. For private
cord blood banking, expectations have been created that cord blood can be
used in place of bone marrow cells and it was emphasised that it is not only
useful for the self but also for the other family members.
As one might expect, different groups have different expectations as per
their institutional and cultural setting. For instance, scientists are more
excited about basic research whilst clinicians expect that stem cells have the
potential to address a large number of incurable diseases. In contrast to the
Anglo-American and European context, some of the informants emphasised
that stem cells can provide affordable medical services to a large number of
poor people in India. Furthermore, there is a projection that stem cell
research will help India in establishing herself as a global leader in the area of
science and technology since India has comparatively a more favourable
environment than other developed countries. This seems to be one of the
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reasons that the Indian state is playing an important role in the creation of
hope for the potential benefits of stem cells, which resonates in the form of
major government funding and support in various stem cell research
programmes in the country.
These various visions in India are used as 'poles of attraction' (Stewart, 1999)
for the alignment of various actors, resources and patients towards an
experimental therapy, and helps in the creation of a 'community of promise'
for transforming the health care sector in India in a way that might bridge the
gap between the elite and the poor. The narratives of different groups reflect
that the notion of desperate patients, global leadership and affordability for
the poor all have the potential to legitimate the activity surrounding Indian
stem cells. Affordability for the poor seems to be especially appealing given
that millions of the population in India have very low incomes and they are
unable to afford expensive medical services. In this context, Chapter 2 noted
that a large number of health service providers are in the private sector and
there is no insurance cover for the majority of the population in India. There
is evidence that high medical bills are one of the reasonsfor poverty in India.
Along with widely-shared positive expectations of stem cells, there are fears
as well, which are reflected by scientists' concerns over stem cell clinical
applications on the basisthat various therapeutic applications are not backed
by enough scientific evidence. These scientists also questioned the ability of
the Indian stem cell sector to be a global player in this area at the moment.
The timeline of promises was the main issue for all scientists that were
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interviewed; while they shared the views of other players as far as promises
of stem cells are concerned, they felt that clinicians are giving hope too soon,
especially with respect to the ability of stem cells to cure various disease
conditions. The discrepancy between scientists and clinicians might be one of
the reasons behind the establishment of inStem, as highlighted in Chapter 4.
The mandate of inStem suggests that the Indian government is hopeful about
the long-term promises of stem cells to address various incurable diseases. It
can be argued that inStem has become the institutional embodiment of
expectations.
The creation of expectations around stem cells in India is similar to what has
been observed in the West where hopes, promises and visions are articulated
to shape the development of a science and technological stream such as gene
therapy, the human genome project, personalised medicine and stem cells.
Comparing the nature of expectations of stem cells between India and the
West, it was observed that in the West expectations' rhetoric mainly
circulates around the future potential uses from embryonic (and adult) stem
cell research (Kitzinger, 2008; Martin et al., 2009; Wainwright et al., 2006b;
Wilson, 2009) and the storage of cord blood (Martin et al., 2008). While there
are similarities in India, expectations are running ahead in the sense that they
have been created around the potential of adult stem cell therapy currently
offered in clinics.
Furthermore, a significant difference in the Indian case is the invocation of so-
called 'needy' or 'desperate' patients - both from India and abroad - towards
300
various clinics as a way of mobilising expectations. In addition to patients,
expectant parents are also influenced by the promises of private cord blood
banking and, despite slim chances of the autologous use of cord blood stem
cells, they are paying a hefty amount to preserve their child's cord blood in
the name of biological insurance. This has raised profound implications for
ethics as most of the treatment modalities have lacked enough scientific
evidence.
The clinical development and use of unapproved stem cell therapies in India
in the background of heightened expectations therefore informs us that there
is a need to analyse the ethical implications of expectations. In the past,
various studies in the sociology of expectations have paid little attention to
this important aspect (Petersen, 2011). For instance, technologies such as
gene therapy, personalised medicine, stem cells and private cord blood
banking have not only attempted to capitalise on hope and influence the
actions and policy decisions, they have also encouraged patients and families
to go for unproven treatments. In the caseof Indian stem cells, this has been
profoundly observed and consequently put patients and families at health
and financial risk. Arguably, the high expectations associated with gene
therapy had even led to the death of a patient in the past (Wilson, 2009).
Similarly, an Israeli boy was reported to have developed benign tumours after
receiving stem cell treatment in a clinic based in Moscow (Ryan et al., 2010).
Chapter 2 noted that, within social studies of expectations, most research has
focused on how unrealistic expectations affected the financial, political and
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public support for a given area of science and technology. These studies
largely overlook the ethical implications of expectations (Martin, 2006;
Wilson, 2009).
Furthermore, the involvement of the state in authoring expectations' rhetoric
also needs to be analysed. Whilst developing the concept of 'sociotechnical
imaginaries', Jasanoff and Kim (2009) argued that in STSresearch there is
little attention paid to analysing the role of non-scientific actors and
institutions in the promotion of science and technology. If one were to ask
why a state supports and promotes a particular area of science and
technology, the answer might vary across different nation-states which
depend on widely shared societal visions which themselves vary across
cultures. In the case of Indian stem cells it was observed that the state
policymakers are highly influenced by the promises associated with stem
cells. This finds expression in the high level of financial support from the state
to various programmes in the country. In addition, to taking maximum
advantage from the 'promise' of stem cells, the Indian government has
established various networks of public and private players including scientists
and clinicians, as highlighted in the previous chapter.
The notions of desperate patients, global leadership and affordabilltv for poor
people appear to pull heterogeneous actors together and help in the creation
of a 'community of promise'. However, some negative expectations expressed
by scientists problematise the concept of a 'community of promise'. It can be
argued that the alignment of heterogeneous actors towards a particular
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technology is subject to the nature of the technology in question and
underlying promises attached with a particular technology will not always be
helpful to pull different actors together and results in contested futures.
In sum, these findings inform us that the scholarship of sociology of
expectations needs to consider the ethical implications of expectations and
the role of the state in expectations discourse. These considerations will help
in analysing the issues of ethics and governance which arise with the
proliferation of a particular technology in the locale of heightened
expectations.
8.4 Ethics
Comparing the nature of the ethical debate in the Western context with the
Indian one, we see that, while, in the West, boundaries are mainly
constructed around the use of different sources of human embryos (Le.
around ethically preferable sources of human embryo) (Wainwright et al.,
2006a), in the Indian casethese are being drawn around the use of stem cells
in clinics (Le. whether to use stem cells as a standard therapy to treat
incurable diseases).This shows that there can be different forms of ethical
boundary-work (Ehrich et al., 2006). Unlike in the West, the use of human
embryos either in research or in clinics has not raised any major ethical issues
in India. The reason might be that there are pluralities of views on issues
related to eggsand the moral status of the human embryo and the dominant
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religion Hinduism is less monolithic compared to other religions, hence
allowing a flexible approach to accommodate different views. In contrast to
controversies around embryonic research, the major questions around stem
cell work in India are associatedwith the proliferation of unproven therapies.
This is not surprising, given that expectations created around stem cells in
terms of their therapeutic application are high, as highlighted in Chapter s.
How different stakeholders frame or respond to these ethical challengeswas
examined in depth in Chapter 6.
Therapeutic applications of stem cells have raised major ethical issues over
the safety of patients in the absenceof proven efficacy of the treatments, and
the possible financial exploitation of patients given the significant costs of
treatment. Most of the stem cell based treatments have not gone through
clinical trials, nor have they been subject to prior approval by regulatory
authorities, as was shown in Chapter 4. There is no documented evidence of
any of these clinical interventions available in order to examine the treatment
modality, Le. whether it is beneficial or harmful to the patients. In this
context, the proliferation of stem cell therapies in India might easily be
described as a money-making business rather than an activity undertaken to
alleviate the suffering of those desperate patients who are regularly invoked
in the discourse of clinicians. The 'mushrooming' of private blood banking has
also emerged as another money-making endeavour. The majority of my
informants argued that, in the name of 'biological insurance', expectant
parents are being exploited since there is a rare chance for a child to use its
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own cord blood in the future. In the whole process, the informed consent
procedures are largely ignored.
In the above context, Chapter 6 explored how key actors within the Indian
stem cell community construct and justify ethical boundaries (Hobson-West,
2012; Wainwright et al., 2006a) around their work. It was observed that there
is considerable variation in how different key players perceive the ethical
issues around growing stem cell clinical activities. Whilst comparing the
rhetoric of expectations and ethical framing of different key players, the
chapter showed that, though expectations rhetoric is highly embedded in
institutional settings, there are notable differences in how actors within a
community construct their ethical arguments. For instance, not all clinicians
are advocating the use of unproven stem cell therapies in clinics and charging
patients for the same. Furthermore, many of them also consider the business
of private cord blood banking to be unethical.
On the other hand, those who are offering stem cell interventions in clinics
justify their practice as ethical in three key ways. First, they argue that adult
stem cells are safe for use with patients without the need for clinical trials.
Second, some employ international ethical guidelines to justify experimental
therapy. Third, the figure of the desperate patient is invoked not only in the
creation of expectations about stem cell futures (as we see in Chapter 5) but
to make a case for stem cell intervention as necessary and desirable.
However, there is still considerable contestation over the interpretation of
ethical guidelines, such as the Helsinki Declaration. Some clinicians argue that
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this document allows them to use an experimental therapy if all other
treatment options for an existing disease have been exhausted. Others assert
that it is unethical to offer experimental stem cell intervention in the name of
the Helsinki Declaration and they contend that stem cells should not be used
as a standard therapy as there are still various unresolved and unknown
safety issues. Scientists and policymakers were likewise critical.
Representatives of firms expressed mixed opinions, in a way that is similar to
clinicians, with some arguing that desperate patients are looking for some
kind of help; therefore, they cannot spend time in doing research only.
The narratives of different actors suggest that the main contentious issue is
whether to use experimental therapy in clinics and this is the reason some
clinicians often invoked 'desperate patients' in their ethical boundary-work
rhetoric. The issue of experimental therapy is highly complex given the
ongoing campaign in different countries in the favour of right to access
experimental drugs for terminally-ill patients outside of clinical trials,
especially for certain incurable diseases for which existing standard
treatments have been exhausted (CBC News, 2010; Okie, 2006; Vale, 2007-
08). It is argued in some academic discourses that "technology assessment
takes too long - it isn't fair to patients or physicians - scientists to have to
wait in the face of life-threatening illness" (King, 1995: 8). Under this
circumstance, the activity of clinicians in India might be legitimised on the
grounds that they are providing some kind of treatment to terminally-ill
patients. The US FDA also allows experimental drugs under 'expended access',
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sometimes called 'compassionate use', on a case by case basis with certain
safeguards such as prior approval from the FDA before doing so. However, in
the Indian case, clinicians have not in fact gained or tried to gain this type of
special-case exemption or approval from regulators; in this respect, therapies
without any safeguards are being offered in the name of providing relief to
desperate patients. This case suggests that the national/international
biomedical governance community perhaps needs to develop a uniform
mechanism and set of guidelines for 'compassionate use', interpretation of
which is highly variable in different jurisdictions, as analysed in Chapter 2. As
far as the situation in India is concerned, there are no policy documents
related to 'compassionate use'."
The analysis of discourse around the ethical challenges of stem cells in India
informs us that 'ethical boundary-work' is flexible and subject to a particular
social and cultural context. It illuminates that 'ethics' is framed and managed
differently in different cross-cultural settings within the same area of science
and it is highly linked with existing regulatory framework or policy documents.
However, despite the differences in ethical controversy in India and the West,
there is a significant similarity in rhetorical boundary-work in that both are
centred on the health benefits of the research in question and on the capacity
of the existing governance framework to legitimise the work, as Hobson-West
(2012) and Wainwright et al. (2006a) have shown in other cases.
27 As informed by a clinician in a personal communication.
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The concept of ethical boundary-work can be very useful for guiding the
developing governance framework as it provides an opportunity to analyse
the views of key actors and accordingly a policy framework could be
developed. For instance, in the Indian case, if a governance framework in the
area of stem cells were sufficient to discourage experimental therapy (with
appropriate safeguards)then it is possible that the various ethical issuescould
be addressed. However, the scholars, who used the concept of ethical
boundary-work, have mainly concentrated on the construction of ethical
boundaries, Le. what is ethically preferable and what is not; how do certain
actors ethically legitimise their work or manage the 'ethical' in their practice
(Frith et al., 2011; Hobson-West, 2012; Wainwright et al., 2006a); and how is
non-science in the form of 'ethics' used to justify the activities of science?This
research has paid little attention to the policy implications of construction of
various boundaries, a subject that was the focus of Chapter 7.
In sum, it is clear from the above discussion that the proliferation of stem cell
activities in India could be easily described as unethical. In the Indian case, the
interesting thing is that these therapies continue to flourish, despite concerns
expressed by the policymakers. Chapter 7 examined the reasons behind this
situation.
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8.5 Governance
Informed by the governance model proposed by Pierre and Peters (2000),
Chapter 7 analysed the biomedical governance (both research and clinical
part) framework in India. This chapter investigated the extent to which a
particular mode of governance was in place, i.e. a) governance as hierarchies,
b) governance as markets, c) governance as networks, or d) governance as
communities. The aim was to investigate the potential for different modes of
governance around stem cell research and its clinical practice and their
capacity in implementing existing oversight mechanisms.
For governance of biomedical research and therapy in India, there are a
number of different government agencies and laws in place with different
mandates. Various agencies are promoting biomedical research through
funding and some agenciesare involved in the policymaking process. For stem
cells, there are multiple agencies to govern stem cell research such as the
Indian Council of Medical Research(ICMR),the Department of Biotechnology
(DBT) and the Drug Controller General of India (DCGI). In addition, the
National Apex Committee for Stem Cell Researchand Therapy (NAC-SCRT)is
also in place for the same reason. Formally, therefore, it appears that there is
fragmentation of governing capacity in the biomedical domain. The main
approval and licensing authority for stem cells is the DCGI,which is the formal
equivalent to the USFDA.However, this centralisation of authority amidst a
fragmented governing structure does not translate into implementation
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authority on the ground, as one of the policymakers also admitted that this
'Indian FDA' is not strong enough to actually deal with stem cell practices.
The governance structure as it works in practice is still more complicated since
the DCGI takes its decisions with the help of the ICMR, as it has no internal
evaluation mechanism for stem cell clinical trials and products as argued by
various key players during field work. Recently, the DCGI created a stem cell
division under the chairmanship of the ICMR, which again suggests a strong
co-dependency on the ICMR to make any decision on stem cells. It can be
argued that various agencies exist only on paper and it is the ICMR, though
mainly an advisory body, indirectly working as an 'Indian FDA' rather than the
formally authorised body, DCGI. Furthermore, in the NAC-SCRT, the
programme officer of stem cells of the ICMR and the DBT is also appointed as
a member. This shows that mostly the same persons are involved in the
governance of stem cells under different agencies.
Although the ICMR plays a dominant role in the governance of biomedical
research in the country, in the case of stem cells, it appears that there is a
confrontation between the ICMR and the DBT on the issue of leadership in this
emerging area, as highlighted in Chapter 7.
The analysis in this chapter suggests that, at one level, the form of governance
of biomedical research in India appears to be primarily hierarchical or state-
led to use the typology developed by Pierre and Peters (2000). However, in a
significant departure from the governance-as-hierarchies approach, which
strictly upholds the public-private distinction (Pierre and Peters, 2000),
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biomedical research governance in India blurs the boundary between public
and private through the City Cluster programme. The City Cluster programme
is an initiative of the government of India for the development of
biotechnology which involves private institutes/firms as we", along with
publicly-funded research institutes. This indicates the transformation of the
role of the state from a role based in hierarchy towards a role based in co-
ordination and integration of public and private players (Pierre and Peters,
2000). This may be particularly relevant to the biomedical context; similar
findings are reported by Burau and Vrangbaek (2008) in a comparative study
of medical governance in the five European countries (Britain, Denmark,
Germany, Italy and Norway). They observe that, though new medical
governance is strongly dominated by hierarchical forms of governance, it is
combined with other forms of governing. Further, they argue that in different
countries the relative balance between forms of governance varies (Burau and
Vrangbaek, 2008).
It is worth mentioning here that various agencies highlighted above only
oversee basic research and clinical trials of biomedical research in general,
including stem cells and not the clinical practice of stem cells assuch. Thiswas
noted by a policymaker during field work, suggesting that the clinical use of
stem cells remains relatively invisible within the existing governing structure
for biomedical research - or out of their formal reach - despite its visibility in
the media. In the absenceof concerns over the use of embryos, basic research
in stem cells does not appear to raise any significant governance issues.The
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governance of clinical trials in general is considerably weak, given the
ineffectiveness of Ethics Committees and the death of various research
participants during clinical trials. In the previous chapter, we saw that some of
the key players, especially scientists and policymakers, argued for the need to
have clinical trials prior to the use of stem cell in clinics. However, when the
procedure of clinical trials itself is flawed, the capacity of stem cell trials
conducted within the existing biomedical governance framework to settle
ethical concerns might be questionable.
If arrangements for governing biomedical research are ineffective in terms of
their ability to manage the use of stem cells as therapy, the question remains:
how are clinicians governed in India and what are the prospects for stem cell
therapies to be regulated directly as clinical practice as opposed to research
practice?
It was observed that there are various laws in India which directly or indirectly
oversee clinical practices such as the Indian Penal Code, Indian Contract Act of
1872 and Law of Torts. These Acts are very strong on paper. Stem cell therapy
is a part of this governance regime and any violation related to this practice
can, in principle, be addressed by using these laws. However, it is beyond the
capacity of poor patients to use these laws against alleged clinicians given the
expensive and time-consuming legal process in India. In addition, the
effectiveness of these laws is also subject to judicial interpretation. The
Consumer Protection Act 1986 appears to be effective on paper, given that
Consumer forums comparatively take less time to dispose of a case and are
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also less expensive. The Right to Information Act 2005 is also an effective tool
to expose various transgressions in the public domain. However, neither of
these Acts, similar to other legislations, is efficient in practice. The Consumer
Protection Act is largely perceived as meaningless since it requires expert
advice from other clinicians to begin a case against an alleged clinician. The
Right to Information Act no doubt has exposed several violations. However,
this Act is unable to restrict unethical behaviour of clinicians given that the
regulatory authority has never taken a rigorous step against alleged clinicians
based on information revealed by using this Act.
In addition to these laws, India has a state-sanctioned self-regulatory body, Le.
the Medical Council of Indian or MCI (cf. Salter, 1999), which is equivalent to
the General Medical Council (GMC) in the UK. The government of India has
provided enough statutory power to regulate medical professionals in the
country. This body acts as the licensing authority for clinicians, and has
enormous power to curb unethical clinical practices. For instance, under the
Code of Ethics Regulation 2002, the MCI has power to cancel the licence of
any medical practitioners who violate the code of medical ethics. However,
there are allegations that it has never taken a strong action against those
clinicians who do not follow the existing code of medical ethics and is often
itself plagued with corruption charges. In a popular television talk show
Satyamev Jayate (Truth Alone Prevails), which aired on May 27, 2012, it was
revealed that since 2008 not a single clinician's licence had been cancelled in
India, despite various incidents of alleged medical malpractices. In contrast, in
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the UK in 2010, the licences of 92 doctors had been cancelled by the GMC
because their fitness to practice was in doubt." This suggests that in India the
self-regulatory mechanism does not work in practice.
A clinician stated that at the moment everyone is free to offer experimental
therapy. An ex-official of the ICMR also admitted that India has problems with
monitoring and implementation. Similarly, a scientist argues that these types
of malpractices are not possible in the West given the strict measures for the
same reason.
Chapter 7 has shown that both the hierarchical mode of governance of
biomedical research and state-sanctioned self-regulatory structure for clinical
practice including other legislations are ineffective in terms of controlling stem
cell activity, despite their formal dominance in the existing governance
framework.
Given the peculiar nature of stem cells and the difficulties noted above, the
government of India has recently revised guidelines specifically oriented
towards discouraging the use of stem cells for therapy. Indeed, most key
players, even those who are allegedly involved in unethical practices, have
argued for a stringent mechanism to check transgressions around stem cells.
However, the new guidelines also appear to be ineffective as they do not have
the legal teeth to punish any violations. The newly constituted NAC-SCRThas
28 http://www.gmc-uk.org/news/10866.asp [Accessed Sept 12, 2012].
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also no legal power to punish anyone in the case of violations, as informed by
a member of the NAC-SCRTduring field work.
If neither governance through command and control (hierarchy) nor
governance through self-regulation is effective, what about other potential
modes of governance? Pierre and Peters identify two other forms, i.e.
governance through networks and governance through communities or civil
society; but, again, neither possibility works in the Indian case. In principle,
collaboration between the state and medical professionals, i.e. the Indian
Medical Association (IMA) or a strong civil society voice might have been
capable of exerting influence on the biomedical governance framework.
However, the IMA arguably acts for the interest of clinicians rather than for
patients, and civil society movements are not strong enough to force
regulators to take strong action against any violations. The growing market of
stem cell based therapies and cord blood banking, as described in Chapter 4,
suggests that there is a strong market influence on the developing governance
framework. Whether this empowers patients (citizens) is a separate question
- so far, evidence suggests that various services provided by different players
tend to be more exploitative rather than empowering for patients, as
reflected in Chapter 6.
In sum, different modes of biomedical governance mechanism with respect to
clinical practices are weak in India. The governance of stem cells is a part of
this existing governance framework. It is not surprising, therefore, that
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unproven therapies have flourished in India and clinicians are boldly justifying
their activities on various grounds, as described in the previous chapter.
The analysis in Chapter 7 indicates that, in India, the dominant mode of
governance in biomedical governance is hierarchical including state
sanctioned policy network, Le. professional self-regulation in the form of MCI.
Neither government-professional networks nor civil society make a significant
contribution to biomedical governance; rather, they are comparatively weak.
This might be the reason behind the ineffectiveness of a hierarchical mode of
governance in dealing with stem cell medical practices.
8.6 Policy implications
The findings of this study suggest that there is no particular need to have a law
especially for stem cells. This is distinct from the argument made in previous
studies and various key players during field work. Within the existing
biomedical governance framework, stem cell transgression could potentially
be addressed, but this would mean dealing with the major implementation
gap that exists between the formulation of laws and their translation in
practice on the ground.
Furthermore, there is a need to have more clarification with respect to using
stem cells in clinics. The use of stem cells is often considered as a part of
routine medical practices and, according to the MCI rules and regulations, it is
the fundamental right of a clinician to do medical practice as per her/his
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wisdom. It is not only the case in India; it appears that many countries in the
West also acknowledge this right of clinicians (Cyranoski, 2012; GMC, 2012). In
India, a clinician, who is accused of malpractices, can only be brought under
legal proceedings if somebody makes a complaint against her/him. Because of
the distinctive social and cultural factors such as lay deference to clinicians
combined with lengthy and expensive legal procedures, lay people in India are
generally reluctant to go against clinicians. India, therefore, needs to develop
those kinds of mechanisms through which a clinician can be brought under
legal proceedings directly by the regulators if it is observed that any clinician is
using an unproven therapy as a standard therapy. In a recent decision, a US
Court upheld the FDA claims that the use of adult stem cells should not be
considered as routine medical practice and it should be categorised as an
unapproved biological product as stem cells are manipulated before being
injected into the patients (Cyranoski, 2012). However, the Indian government
has neither taken a similar initiative nor developed any effective mechanism
with respect to 'compassionate use', similar to the US FDA, and this is one of
the reasons that various clinicians are offering stem cells in the name of
helping terminally-ill patients, as highlighted in Chapter 5. In addition, a
professional self-regulation mechanism also needs to be strong enough to
deal with medical malpractices.
To summarise, the failure of the state (even during a state-led biomedical
regime) to regulate the practice of medicine suggests that the Indian
government is not very serious about curbing unethical practices of stem
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cells. In addition, it has been unable to implement existing laws which are in
place to oversee clinicians. Furthermore, state-sanctioned professional
governance in the form of the Medical Council of India (MCI) is also not
effective in enforcing professional norms such as ethical codes of conduct.
This clearly indicates that both hierarchical and networks modes of
governance fail to prevent transgression. An important reason might be that
there are high expectations of stem cells at both state aswell as clinical level,
where there is a desire to be a global player as well as to cure various
debilitating diseases.
Furthermore, there is a high potential market in India for both stem cell based
therapies and cord blood banking. Against this backdrop, seemingly the Indian
state and the state-sanctioned self-regulatory body, Le. the MCI, allow the
unproven stem cell treatments. On the similar line of medical tourism, there
is great potential for stem cell tourism in India. It is not surprising, therefore,
that neither the state nor the MCI implements existing regulatory standards
forcefully. However, India has a long-standing problem with the
implementation of various laws and social welfare schemes (Robinson, 2011).
Chapter 7 highlighted the problems with the implementation of the Pre-
Conception and Pre-Natal Diagnostic Techniques (PCPNDT)Act, 1994. The
poor implementation of this Act is one of the reasons behind increasing
female foeticide in India. Similarly, even after 10 years, India could not
implement the mandate of the Biological Diversity Act, 2002 (Bhutani and
Kohli, 2012). It was observed that, as a result, biodiversity has been declining
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in India (Bhutani and Kohli, 2012). Furthermore, a gap was observed in the
implementation of the public health policy related to HIV testing in some
parts of India (Sheikh and Porter, 2010). It can be argued therefore that the
stem cell sector is mirroring the wider problem of implementation in India.
But the larger question remains: what reform can be introduced in the
current biomedical governance regime in order to prevent unethical clinical
practices not only in stem cells but also in general medical practices? The
analysis in Chapter 7 has shown that there is a difficulty in bringing a private
litigation or implementation policy via courts due to a structural problem
within the governance system. In this situation, this study suggeststhat there
are two key ways that reformative measurescan be introduced to strengthen
the biomedical governance system. First, India can take a lesson from the UK
GMC reforms which were introduced by the GMC in the 1980s and especially
after the Bristol case29 and the Shipman affair30 (Stacey, 2000). One of the
most notable reforms was the greater representation of lay members on its
fitness-to-practice committee. This initiative has opened up the disciplinary
proceedings against any doctors. At the moment, there are an equal number
of medical and lay members in the GMC.This suggeststhat the public has an
equally important role in regulating clinicians in the UK. In addition, recently
the GMC has implemented a long-standing proposal of revalidation of
29The Bristol case was related to deaths of 29 babies and young children at the Bristol Royal
Infirmary who had received complex cardiac surgery from 1985-1995.
30The conviction of GP Harold Shipman for murdering several of his patients in 2000.
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licensed doctors", Revalidation is the process by which practising doctors
need to demonstrate their fitness to practise, usually every five years. During
their annual appraisal and revalidation, doctors will have to provide feedback
from patients as one of the supporting pieces of information, including other
things. It can be argued that the GMC is more accountable to the general
public and its proceedings are more transparent. In contrast, in the MCI there
is no representation of lay rnernbers ". If the MCI introduced similar reforms
on the line of the GMC, then the monopoly of doctors could be reduced and
there could be a greater possibility of disciplinary actions against a clinician in
the case of any violation. Chapter 7 has shown the poor record of MCI in
taking action against any clinician. Second, there is a need to have a citizen
health advocacy network. In India, there is no truly organised group to pursue
the rights of patients (Shah and Garg, 2011). This type of network can pursue
claims against medical malpractices and negligence through both the courts
and the MCI. In the West there are some universities and groups who run
health advocacy-related courses and programmes to train people in advocacy
(Shah and Garg, 2011). A similar initiative could be taken in India. Finally, this
study concluded that, by making decision-making more transparent, changing
the balance of interests in the MCI, and empowering citizen advocates, some
real progress can be made in the biomedical governance system of India,
including stem cells.
31http://www.gmc-uk.org/doctors/revalidation.asp [Accessed Dec 12, 2012].
32http://mciindia.org/AboutMCI/BoardofGovernors.aspx [Accessed Dec 5,2012].
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8.7 Strengths and weaknesses of the study
My study has analysed the stem cell sector in India and in doing so it mapped
the different activities in basic research, clinical activities and cord blood
banking. This has provided an opportunity to understand the current status of
different areas of stem cell research and treatments in India which no
previous studies hasundertaken to date. By using the concepts of sociology of
expectations, ethical boundary-work (Wainwright et al., 2006a) and Pierre
and Peters' (2000) governance framework, my study has provided a more
nuanced understanding of generation of expectations, framing of raised
ethical issues and different modes of governance dealing with stem cell
research and its clinical applications in India. Most importantly, my study
takes account of key actors' perspectives and establishes a link between
expectations, ethics and governance. Furthermore, the highlighting of adult
stem cells and cord blood stem cells in India is noteworthy, given that many
previous studies and international media had not paid due attention to the
proliferation of adult stem cells and private cord blood banking. The use of
adult stem cells in clinics and private cord blood banking also raised important
ethical concerns, similar to embryonic stem cells, with respect to patients'
safety and possible economic exploitation of patients and expectant parents
in India. The analysis of expectations rhetoric helps to understand on what
basis key players try to attract necessary resources, patients (both local and
international) and expectant parents. Similarly, the findings of this study have
shown how key players justify or challenge various stem cell activities. The
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justification for using unproven stem cell clinical applications on terminally-ill
patients in the name of the Helsinki Declaration is instructive, as it suggests
that there is a need to have a robust framework for terminally-ill patients.
Furthermore, unlike in previous studies, which focused on the inability of the
DBT-ICMRguidelines in preventing unethical practices of stem cells, my study
found that the ineffectiveness of different modes of medical governance is
responsible for the unethical medical practices of stem cells. More
specifically, the state-sanctioned body for self-regulation of the medical
profession has never taken strict actions against those clinicians who are
offering unproven stem cell therapy. Given this system, it is unlikely that
abuses in the caseof stem cells will be regulated any better.
For the data collection, I used a survey, documentary analysis and qualitative
interviews. The survey was very useful for mapping the various stem cell-
related activities which are being conducted at various public and private
institutes, including identifying individuals to interview. The analysis of
documents, including media analysis, was helpful for understanding the
existing policy framework and the creation of expectations including ethical
and governance issues.Qualitative interviews playa vital role in uncovering
stakeholders' perspectives, which was not possible through survey and
documentary analysis. Though I identified most of the individuals and
locations for interview through carrying out a survey, I came to know about
the newly-established inStem institute during an interview with one of my
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informants. This suggests that combining various methods was really helpful
for my study.
Although my research adds to and goes beyond sociological studies that have
already been conducted around the proliferation of stem cell research and
treatment in India, it has of course also certain limitations. A more systematic
media analysis, especially the use of metaphors in press coverage and its
ethical and social implications along the lines studies in the case of other
areas of science and technology including stem cells (e.g., Hellsten and
Nerlich, 2011; Nerlich and Jaspal, 2012; Musolff, 2009) might have been
conducted. Similarly, the websites of various hospitals/individual clinics and
firms could have been analysed in depth as various websites work as 'direct-
to-consumer advertising' for stem cell treatments (Lau et al., 2008; Petersen,
2011). These websites are loaded with inflated promises and claims to cure a
wide range of disease conditions which play an important role to attract both
native as well as foreign patients. In addition, more in-depth qualitative
analysis of interviews could have been carried out (Wainwright et al., 2006a).
Research in this area might also benefit from the analysis of stem cells
development within the context of different prevalent alternative medicine
systems in India and socio-cultural differences such as the urban-rural divide,
including interviews with patients who have either already received or are
currently seeking stem cell treatments, as previous studies in this domain did.
Had I started the research today, the subject of international stem cell
323
tourism might have also been a natural focus. These issues lay the foundation
for future research that might build on my thesis work.
8.8 Future research
A research project specifically concentrating on the proliferation of private
cord blood banking could be developed with the aim of analysing what drives
expectant parents to try to preserve their child's cord blood despite its slim
chances of self-use for the child and what are the different strategies being
used by the private firms to attract expectant parents. The sociological study
of stem cell tourism could be an another exciting project, given that a global
form of governance for this emerging field is still at the nascent stage in the
context of vastly different systems around the conduct of biomedical research
and the regulation of stem cell science. The project could explore the
relationship between domestic and international law, and the extent to which
policymakers of a particular country can and should intervene to protect their
citizens from perceived exploitation in another part of the world. In addition
there is little known about the perception of patients who travel overseas for
an unproven therapy. All these aspects and many more could be explored in
the stem cell tourism project. A more in-depth analysis of the use of
metaphors on stem cell-related websites and in news coverage is also
warranted, and their ethical and governance implications could be explored.
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Appendix I: Contact letter
DearXXX
I am writing to see if you might be able to help with a research project
exploring the ethical principles governing the use of stem cells in India and
how these are 'translated' into governance regimes at national and local
level. The project aims to analyse the governance of research and clinical
practice in relation to stem cell therapies and the main barriers facing the
effective governance of the stem cell field. The findings will contribute in my
PhD, funded by the Wellcome Trust (UK). I have enclosed an information
sheet which provides further details.
I am conducting a series of interviews with leading scientists, clinicians,
companies, and policy makers in India. I would greatly appreciate the
opportunity to interview you as part of this study. The data from this research
will provide valuable evidence of the ethical issues raise by the clinical
development and use of stem cells in India and the problem with the existing
framework of governance.
The interview would last no more than one hour. The interview and all
correspondence will be treated as confidential and consistent with the best
ethical research practice.
I very much hope that you will be able to participate in this research, as I
would greatly value your contribution. Ideally, I would like to schedule a
388
meeting between ...to ...1will follow up in next weeks. Please do not hesitate
to contact me, if you would like to discuss the project or require more
information.
Thank you in advance for your time and assistance,
Yours sincerely,
Shashank S.Tiwari
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Appendix II: Information sheet
The ethics and governance of stem cell clinical research in India
Shashank S. Tiwari
E-mail;lbxst1@nottingham.ac.uk
Introduction
India is rapidly becoming established as a major player in the development of
stem cell therapies, with a significant numbers of research centres, private
clinics and companies active in this area. The current stem cell therapy market
in India is approximately US $540 million and it is expected to grow rapidly.
The country is becoming an attractive destination for global stem cell
companies and research institutes in the areas of clinical trials/clinical
research, stem cell research and contract manufacturing. However, clinical
research and the therapeutic application of stem cells are less regulated than
in many developed countries, and this has led to a number of ethical
controversies and concerns, including: the ready availability of different stem
cell-based interventions offered by a range of individuals and institutions; and
claims that these are successful in curing a number of diseases. There are calls
for more formal oversight and statutory regulation of the emerging market
for stem cell therapy, otherwise false claims and serious risks to patient safety
could destroy the sector.
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Project Aims and Research Questions
• To describe the current clinical development and use of stem cell
therapies in India and the ethical issues this raises;
• To analyse the governance of research and clinical practice in relation
to stem cell therapies, the responsibilities of the main institutions
involved and problems with the existing system of governance;
• To explore the extent to which ethical principles are being translated
into practice and how public policy might be developed to better
ensure ethical conduct and public protection in this area.
Methods
The study will combine various qualitative methods, drawing on data from
documentary and media analysis, and semi-structured interviews with
scientists, clinicians, and policy makers.
Relevance to Policy and Practice
The study will provide valuable evidence of the ethical issues raise by the
clinical development and use of stem cells in India, the ethical principles being
introduced to address these problems, the extent to which these principles
are being translated into practice and the main barriers facing the effective
governance of the stem cell field. This will be of direct relevance to scientists,
clinicians, companies, and policy makers in both India and other developing
countries.
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Appendix III: Interview guide
Basic Research
1. In which area of stem cell research you are involved? ( Scientists,
Firms)
2. What are the short term and long term potential applications of your
research? (Scientists, Firms)
Clinical Research
3. In what kinds of stem cell clinical research you are involved?
(Clinicians, Firms)
4. What are the potential applications of your clinical research?
(Clinicians, Firms)
Clinical Services
5. What kinds of stem cell therapies/services you offer to your patients?
(Clinicians, Firms)
6. What are the potential benefits of stem cell based treatments
compared with other existing treatments? (Scientists, Clinicians,
Firms, Regulators)
7. Are your patients only from India or abroad aswell? (Clinicians, Firms)
8. Havethese therapies gone through clinical trials? (Clinicians, Firms)
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9. In your opinion, at what stage, it is appropriate to move from lab to
clinic? (Scientists, Clinicians, Firms, Regulators)
10. What are your views regarding stem cell clinical development in India?
(Scientists, Clinicians, Firms, Regulators)
Linkages
11. Do you have any kind of national/international collaboration?
(Scientists, Clinicians, Firms)
12. Could you please let me know about the nature of collaboration?
(Scientists, Clinicians, Firms)
13. Do you also discuss any ethical issues? (Scientists, Clinicians, Firms)
Ethics
14. What is the source of your research material? (Scientists, Clinicians,
Firms)
15. Are there different ethical issues associated with different sources of
embryos? (Scientists, Clinicians, Firms)
16. There is national/international criticism, of the way some
clinicians/firms are practicing/offering stem cell therapies/services to
the patients. What are your views regarding that? (Scientists,
Clinicians, Firms)
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17. Every clinical trial needs approval of Institutional Ethics
Committee/Review Board. How do you see this whole process of
approval mechanism? (Clinicians, Firms, Regulators)
18. How do you recruit your participants for clinical trials? (Clinician,
Firms)
19. Are there any particular difficulties in obtaining informed consent?
(Clinicians, Firms)
20. What are your views on the process of clinical trial registration?
(Clinicians, Firms, Regulators)
21. How the ongoing clinical trials being monitored? (Clinicians, Firms,
Regulators)
22. How do you ensure maximum benefits to trial participants?
(Clinicians, Firms, Regulators)
23. India is emerging as a centre for stem cell based therapies which
attracts Indian as well as foreign patients. Which patients are making
more use of these therapies? (Clinicians, Firms)
24. Are there different ethical issues associated with different groups of
patients? (Clinicians, Firms)
25. Are there any particular ethical issues associated with those patients,
who comes India for stem cell based treatments? (Clinicians, Firms)
26. In India, the policy related to stem cell research and therapy is still
developing. Are there anything in the existing guidelines which
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addresses International audience? (Scientists, Clinicians, Firms,
Regulators)
Governance
27. How the stem cell clinical trials are regulated in India? (Scientists,
Clinicians, Firms, Regulators)
28. What are your views regarding current policy related to informed
consent? (Clinicians, Firms, Regulators)
29. How these policies are relevant in Indian condition? (Clinicians, Firms,
Regulators)
30. What is your opinion regarding stem cell research regulation in the
country? (Scientists, Clinicians, Firms, Regulators)
31. What is your opinion about the current guidelines of the DCGI
regarding stem cell marketable product? (Scientists, Clinicians, Firms)
32. Do all these regulations work in practice? (Scientists, Clinicians,
Firms, Regulators)
33. What is the role of your organisation in the development and
governance of stem cell science in India? (Regulators)
34. What is your opinion about recently established National Apex
Committee for Stem Cell Research and Therapy (NAC-SCRT)?
(Scientists, Clinicians, Firms, Regulators)
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35. How do you co-ordinate with other government bodies, who are also
involved in the governance of stem cell science in India? (Regulators)
36. How do you see the effort of ICMR regarding stem cell public
consultations? (Scientists, Clinicians, Firms)
37. What were the issues which initiated public consultations regarding
stem cell research? (Regulators)
38. How do you ensure full representation of different stakeholders in
public consultations? (Regulators)
39. As a regulatory agency what kind of challenges you are facing?
(Regulators)
40. There are some reports related to safety and risk of the research
participants during clinical trials in general? Is there any kind of issues
related to stem cell clinical trial? (Clinicians, Firms, Regulators)
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